

Revised: August, 2017

CURRICULUM VITAE

ROBERT MUNSON CAREY



Birth: August 13, 1940, Lexington, KY

Parents: Henry Ames Carey; BA, MA, University of California Berkley (Professor Alfred L. Kroeber, mentor); PhD, Columbia University (Professor Franz Boas, mentor) and Eleanor Day Munson Carey, BA, Wheaton College (Massachusetts); BS in LS, Columbia University.

Marriage: Theodora Vann Hereford (August 24, 1963); BA, Vanderbilt University

Children:

Adonice Ames (Carey) D'Atre (1968); BA, University of Virginia; MSW, Virginia Commonwealth University

Alicia Vann (Carey) Dagli (1970); BA, University of Richmond; MD, University of Virginia

Robert Josiah Hereford Carey (1985); BA with distinction, University of Virginia; MDiv *Magna cum Laude*, Covenant Theological Seminary

Education:

Lafayette High School, Lexington, KY, 1954-1958

BS - University of Kentucky, Lexington, KY, 1962

MD - Vanderbilt University School of Medicine, Nashville, TN, 1965

Present Positions:

Professor of Medicine; Dean, Emeritus, University of Virginia School of Medicine

Postal Address: Box 801414, Department of Medicine, Aurbach Medical Research Building, University of Virginia School of Medicine, Charlottesville, VA 22908-1414

Package Address: Aurbach Medical Research Building, 450 Ray C. Hunt Drive,

Charlottesville, VA 22903

Phone: 434-924-5510

Fax: 434-982-3626

E-mail: rnc4C@virginia.edu

Website: <http://www.healthsystem.virginia.edu/internet/carey/>

Church and Community Activities:

Member, Trinity Presbyterian Church, Charlottesville, Virginia

Board of Directors, Young Life (1984-87)

Honorary Chair, The Covenant School Capital Campaign (1998-2001)

Board of Directors, The Covenant School (2002-8)

Co-chair, Development Committee (2003)

Chair, Development Committee (2004-8)

Chair, Development Advisory Board (2006-8)

Honorary Council, Charlottesville Symphony Society (2006-present)

Professional Career:

1965-1966: Intern in Medicine, University of Virginia Hospital (Dr. Byrd S. Leavell), Charlottesville, VA

1968-1969: Junior Assistant Resident in Medicine, The New York Hospital-Cornell Medical Center (Dr. Alexander G. Bearn), New York, NY

1969-1970: Senior Assistant Resident in Medicine, The New York Hospital-Cornell Medical Center (Dr. Alexander G. Bearn), New York, NY

1970-1972: U.S. Public Health Service Fellow in Clinical Endocrinology and Instructor in Medicine, Department of Medicine, Vanderbilt University School of Medicine (Dr. Grant W. Liddle), Nashville, TN

1972-1973: American Heart Association Post-doctoral Fellow in Medicine (Hypertension), Medical Unit, St. Mary's Hospital Medical School, (Professor Sir W. Stanley Peart), London, England

1973-1976: Assistant Professor of Medicine (Endocrinology and Metabolism), University of Virginia School of Medicine, Charlottesville, VA

- 1973-2014:** Attending Physician, University of Virginia Medical Center, Charlottesville, VA
- 1975-1986:** Associate Director, NIH General Clinical Research Center, University of Virginia Medical Center, Charlottesville, VA
- 1976-1980:** Associate Professor of Medicine (with tenure) (Endocrinology and Metabolism), University of Virginia School of Medicine, Charlottesville, VA
- 1977-1979:** President, Clinical Staff, University of Virginia Medical Center, Charlottesville, VA
- 1978-1986:** Director, Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Medical Center, Charlottesville, VA
- 1980-2014:** Professor of Medicine (Endocrinology and Metabolism), University of Virginia School of Medicine, Charlottesville, VA
- 1986-2002:** Dean and James Carroll Flippin Professor of Medical Science, University of Virginia School of Medicine, Charlottesville, VA
- 1998-2001:** Senior Associate Vice President for Academic Affairs, University of Virginia Health System, Charlottesville, VA
- 2002-2014:** University Professor, University of Virginia, Charlottesville, VA
- 2002-present:** Dean, Emeritus, University of Virginia School of Medicine, Charlottesville, VA
- 2003-2014:** David A. Harrison III Distinguished Professor of Medicine, University of Virginia School of Medicine, Charlottesville, VA
- 2007-2014:** Non-resident faculty, Center for Public Health Genomics, University of Virginia Health System, Charlottesville, VA
- 2015- present:** Professor of Medicine (Division of Endocrinology and Metabolism), University of Virginia School of Medicine, Charlottesville, VA

Military Service:

- 1966-1968:** Surgeon (LCDR), U.S. Public Health Service assigned to Peace Corps, American Embassy, Tehran, Iran
- 1968-present:** Surgeon (LCDR), U.S. Public Health Service Inactive Reserve

Certifications:

1966: National Board of Medical Examiners

1972: American Board of Internal Medicine (General Internal Medicine)

1973: American Board of Internal Medicine (Endocrinology and Metabolism)

Radioisotope Licensure: Authorized User #153-80, University of Virginia Medical Center

Medical Licensure:

1973-present: Virginia (0101023803 issued 12/03/73)

Drug Enforcement Administration (USDJ) Registration: AC9243837

Virginia Board of Pharmacy: 0204-001803

Special Courses:

AAMC Executive Management Course for New Deans, July 17-22, 1987, Brewster, MA

University of Virginia Health Sciences Center Leadership Program, Darden Graduate School of Business Administration (1997)

Intensive Review of Internal Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA (2002)

Course in Thyroid Ultrasound, The Endocrine Society (2006)

Honors and Awards:

Alpha Omega Alpha Honor Medical Society

Fellow of the American College of Physicians (1973)

Fellow of the Council for High Blood Pressure Research, American Heart Association (1975)

Established Investigator, American Heart Association (1975-80)

President, American Heart Association Virginia Affiliate (1979-80)

Distinguished Service Award, American Heart Association/Virginia Affiliate (1980)

Elected Member, American Society for Clinical Investigation (1980)

Elected Member, American Clinical and Climatological Association (1982)

Attending Physician of the Year Award, Department of Internal Medicine, University of Virginia Medical Center (1983-84)

Elected Member, Association of American Physicians (1985)

Member, Subspecialty Board of Endocrinology and Metabolism, American Board of Internal Medicine (1985-1990)

Hall of Fame (Charter Member), Lafayette High School, Lexington, Kentucky, at Golden Anniversary Celebration of the School (1989)

President of the Symposium: Dopamine and Hypertension, International Society of Hypertension (1990)

Elected Member, Institute of Medicine, National Academy of Sciences (1992)

Distinguished Alumnus Award, Vanderbilt University School of Medicine (1994)

Walter Reed Distinguished Achievement Award, University of Virginia Medical Alumni Association (1996)

Doctor Honoris Causa, Federal University of Ceara, Fortaleza, Brazil (1998)

Co-moderator, National Center for Research Resources Scientific Planning Forum 1997 (with Louis W. Sullivan and Joshua Lederberg)

Doctoral (Ph.D.) Thesis Opponent, Ulla Holtback, Karolinska Institute, Stockholm, Sweden (1998)

Hall of Distinguished Alumni, University of Kentucky (2000)

Master of the American College of Physicians (2000)

Lifetime Achievement Award, Consortium of Southeastern Hypertension Control (2000)

Distinguished Achievement Award, The New York Hospital/Cornell Medical Center Alumni Council (2000)

Fellow of the American Physiological Society (Cardiovascular Section) (2001)

Irvine Page-Alva Bradley Lifetime Achievement Award, Council for High Blood Pressure Research, American Heart Association (2001)

Fellow of the American Heart Association (2001)

President, American Clinical and Climatological Association (2001-02)

Honorary Professor of Biomedical Ethics and Medical Humanities, University of Virginia School of Medicine (2002)

Honorary Citation by the Honorable Mark R. Warner, Governor of Virginia (2002)

Dean Robert M. Carey Award (given each year to a member of the second year class for leadership), University of Virginia School of Medicine (first award 2003)

Thomas Jefferson Award, University of Virginia (the University's highest award) (2003)

Fellow of the Royal College of Physicians of Ireland (2004)

Laureate Award, American College of Physicians (Virginia Chapter) (2004)

Chair, Council for High Blood Pressure Research, American Heart Association (2004-06)

Commendation by the General Assembly of the Commonwealth of Virginia, Joint House and Senate Joint Resolution No. 98 (2004)

Distinguished Physician Award, The Endocrine Society (2005)

Member, Faculty of 1000 Biology (2005-present)

Best Doctors in America (2005-06; 2007-08; 2009-10; 2011-12; 2013-14; 2015-16)

America's Top Physicians, Consumer's Research Council of America (2006, 2007, 2009, 2010, 2011, 2012, 2013, 2014)

Carey, Marshall and Thorner Scholar's Day, Department of Medicine, University of Virginia (2006-present)

Award of Excellence in Education, Department of Medicine, University of Virginia (2007)

American Heart Association Scientific Councils Distinguished Achievement Award (2008)

President, The Endocrine Society (2008-09)

Robert Tigerstedt Distinguished Scientist Award, American Society of Hypertension (2009)

National Institutes of Health Distinguished Editorial Board (2009)

USA Today Qforma Most Influential Doctors (2009)

Best Doctors in Virginia and Washington, DC, Virginia Living (2011-2014)

Edward H. Ahrens, Jr. Distinguished Investigator Award, Association for Clinical and Translational Science (2012)

Department of Medicine Research Award, University of Virginia (2012)

American Heart Association Research Excellence Award (sponsored by Novartis Pharmaceuticals Corporation), Council for High Blood Pressure Research (Novartis Award; 2012)

Elected Member, Virginia Academy of Science, Engineering and Medicine (2013)

Department of Medicine Mentorship Award (2014)

Outstanding Leadership in Endocrinology Award, Endocrine Society (2015)

Elected Member, National Academy of Medicine (2015)

Medical Grand Rounds, University of Virginia Health System, in honor of Robert M. Carey, MD (2015)

Endowed/Named/Plenary Lectures:

Edward Rose Lecture, University of Pennsylvania School of Medicine (1984)

Bley Stein Visiting Professor in Endocrinology, University of Southern California (1987)

State-of-the-Art Lecture, Council for High Blood Pressure Research (1999)

Richard Underwood Memorial Visiting Lecture, Harvard Medical School (2000)

Frank and Sheila Thompson Lecture, Texas A & M University College of Medicine (2005)

Emory Wilson Dean's Distinguished Lecture, University of Kentucky College of Medicine (2007)

Special Plenary Lecture, 80th Annual Congress of the Japanese Endocrine Society (2007)

Beverly Towery Lecture, Department of Medicine, University of Louisville (2008)

John and Meredith Oates Distinguished Lecture, Vanderbilt University School of Medicine (2008)

Opening Plenary Lecture, 33rd Annual Congress of the Italian Endocrine Society (2009)

Nachum and Bertha Mizney Memorial Lecture, Sir Mortimer B. Davis – Jewish General Hospital, McGill University, Montreal, Canada (2009)

Plenary Lecture, Chinese Endocrine Society, Dalian, China (2010)

Plenary Lecture (Year-in-the-Adrenal), The Endocrine Society, Boston (2011)

André Aisenstadt Memorial Lecture, McGill University (2011)

Allan F. Moore Memorial Lecture, Massachusetts General Hospital and Harvard Medical School (2012)

Plenary Lecture, International Society of Hypertension, Sydney, Australia (2012)

Robert M. Blizzard Lecture, Pediatric Endocrine Society, Washington, DC (2013)

Plenary Lecture, Japan Endocrine Society, Sendai, Japan (2013)

Inaugural Ed Schteingart Memorial Lecture, University of Michigan (2014)

E. Chester Ridgeway Memorial Lecture, Egyptian Association of Endocrinology, Diabetes and Atherosclerosis, Alexandria, Egypt (2014)

William McBride Memorial Lecture, Consortium for Southeastern Hypertension Control, Tampa (2017)

Opening Plenary Lecture, American Heart Association Hypertension Council/American Society of Hypertension Meeting, San Francisco (2017)

Elected Societies:

The Endocrine Society (1974)

Finance Committee (1988-94)

Development Committee (1991-95); Chair 1991-94)

Member of Council (1995-97)

Council Representative, Publications Committee (1995-97)

Chair, Hormone Foundation Initiation Committee (1997)

Council Representative, Clinical Initiatives Committee (1998)

Blue Ribbon Committee on the Hormone Foundation (1998)

Clinical Research Sub-Committee (2003-2005)

Cardiovascular Endocrinology Task Force (2003)

Research Advisory Committee (2003-2005)

Hormone Foundation Committee

Men's Health Task Force (2005-2008)

Clinical Guidelines for Primary Aldosteronism Writing Group (2006-07)

Co-chair, Cardiovascular Endocrinology Dinner (2007)

President-Elect (2007-08)

President (2008-09)

Immediate Past-President (2009-10)

Chair, Advocacy and Public Outreach Core Committee (2009–2011)

Liaison Member, Scientific Statements Task Force

Nominating Committee (2011-2014)

Coalition for Quality Testing (2011-2014)

Chair, Communication, Education and Advocacy Subcommittee (2011-2014)

Chair, Scientific Statements Task Force (2011-present)

Baxter Prize Design Group (2016)

Chair, Baxter Medal Selection Committee (2017-2020)

The Hormone Foundation

Board of Directors (1997-03)
Executive Committee
Nominating Committee

American Federation for Clinical Research (1973)

Councilor, Southern Section (1978-81)
Nominating Committee, Southern Section (1982)

Southern Society for Clinical Investigation (1978)

Nominating Committee (1982)
Secretary-Treasurer (1985-88)
Institutional Representative (2008 – present)

Council for High Blood Pressure Research, American Heart Association

Fellow (1975)
Program Committee (1984-86)
Executive Committee (1991-94)
Long Range Planning Committee (1991-94)
Professional Education Committee (1989)
Task Force on Inter-Council Activities (1992-94)
Ciba Award Selection Committee (1993-95)
Budget Committee (1993-95)
Nominating and Membership Committee (1994-96)
Task Force on Council Structure (1995)
Nominating Committee (2000-04)
Fall Conference Committee (2002-08), Chair (2002-04)
Leadership Committee (2002-08)
Chair, Awards Committee (2002-04)
Novartis Award Selection Committee (2002-06)
Vice-Chair and Chair- Elect (2002-04)
Chair (2004-06)
Chair, Leadership Committee (2004-06)
Chair, Novartis Award Selection Committee (2004-06)
Immediate Past Chair (2006-08)
Immediate Past-Chair (2006-08)
Chair, Nominating Committee (2006-08)
Member, Strategic Planning Committee (2013)
Moderator, Strategic Planning Retreat (2013)

Hypertension Council, American Heart Association

Member, Excellence Award in Hypertension Selection Committee (2014-18)

Inter-American Society of Hypertension (1980)

XVIIth Scientific Sessions Executive Program Committee (2006-07)
Executive Committee (2013-14)

American Society for Clinical Investigation (1980)

Institutional Representative (1997-00)

Association of American Physicians (1985)

Institute of Medicine, National Academy of Sciences (1992)

National Academy of Medicine (2015)

American Clinical and Climatological Association (1982)

Nominating Committee (1994; 1999)

Chair, Nominating Committee (1995; 2003)

Vice President (1998-99)

Member of Council (1999-06)

President-Elect (2000-01)

President (2001-2002)

Ad Hoc Committee on Governance (2014)

Association of Patient-Oriented Research

NIH Advocacy Committee (2005-08)

International Society for Hypertension (1984)

The Raven Society (1988)

The American Physiological Society (2000)

Virginia Academy of Science, Engineering and Medicine (2013)

Founding Member

Executive Committee (2013-present)

Board of Directors (2013-present)

Nominating Committee (2015-2016)

Program Committee (2014 & 2016)

University Community Awards: Hovey S. Dabney Award, United Way Combined Virginia Campaign (2000 and 2001).

Membership in Professional Societies:

Albemarle County Medical Society

Medical Society of Virginia

American College of Physicians

American Federation for Medical Research

American Society of Hypertension

Charter Member
Inter-societal Affairs Committee (1986-90)
Program Committee (2012-13)

American Medical Association

American Heart Association (National)

Science Advisory and Coordinating Committee (2004-08; 2012-2015; 2015-2017)
Council Operations Committee (2004-2008); **Chair (2006-08)**
Chair, International Mentoring Program Task Force (2006)
Fellows Task Force (2006)
Member Benefit Task Force (2007-08)
COC Task Force on "Proposed Science Subcommittee: Vascular Imaging & Intervention (2011)
Advocacy Coordinating Committee (2006-08)
Manuscript Oversight Committee (2004-07)
Prevention VIII Conference: Kidney Disease, Hypertension and Cardiovascular Disease (2006)
Program Committee
Chair, Writing Group
Research Strategic Planning Retreat (2006)
Chair, Working Group 3: Collaboration and Setting the Research Agendas (2006)
Writing Committees:
Resistant Hypertension (2005-08)
Cardiovascular Pharmacology and Kidney Insufficiency (2006-07)
Vice-Chair, AHA/ACC Hypertension Clinical Guidelines (2014-2017)
Chair, Resistant Hypertension (2016-2018)
Recommendations for Blood Pressure Measurement in Humans (2016-18)
Search Committee for Editor-in-Chief, *Hypertension* (2010-11)
Member, Board of Directors (2012-2013)
Chair, Scientific Publications Committee (first term 2013-2015; second term 2015-2017)
Blue Ribbon Panel on Research Investment (2013)
Member, Nominating and Awards Committee (2013-2017)
Member, Awards Subcommittee (2013-17)
Member, Conflict of Interest Review Committee (2013-2015; 2015-2017))
Chair, Search Committee for Editor-in-Chief of *Circulation* (2014-2015)
Vice-Chair, Hypertension Clinical Guidelines Writing Committee (2014-present)
Chair, SACC Nominating Subcommittee (2015-16)
Member, Search Committee for Editors-in-Chief, *Circulation: Cardiovascular Genetics* and *Circulation: Quality and Outcomes* (2015-16)
Chair, Search Committee for Editors-in-Chief, *Circulation: Heart Failure* and *Circulation: Arrhythmias and Electrophysiology* (2016)
Chair, Search Committee for Editor-in-Chief, *Circulation: Cardiovascular Genetics* (2016-17)
Member, AHA/AMA Target BP Advisory Group (2017-2019)

Member, Search Committee for Editors-in-Chief, *Circulation: Cardiovascular Imaging and Circulation: Cardiovascular Interventions* (2016-17)
Member, ACC/AHA Guideline Clinical Tool Work Group

American Heart Association/Mid-Atlantic Affiliate

Ex Officio Member, Board of Directors (2012-2013)

American Heart Association/Virginia Affiliate

Chair, Committee on Hypertension (1975-78)

Executive Committee (1978-81)

Vice Chair, Long Range Planning Committee (1980-81)

Chair, Long Range Planning Committee (1981-82)

Search Committee for Executive Vice-President (1981)

Board of Directors (1977-83)

President (1979-80)

Association of American Medical Colleges

Council of Deans (1986-2002)

L.C.M.E. Site Visit, Oregon Health Sciences University (1990)

Selection Committee, AAMC Award for Distinguished Biomedical Research (1991 and 1993)

Selection Committee for AAMC Abraham Flexner Award (1993)

Task Force on Medical School Finance (1994-95)

Planning Committee for Council of Deans Meeting (1995)

Member, Electronic Residency Application Service Advisory Committee (1995)

Member, Council of Deans Nominating Committee(1995)

Member, Organizing Committee, Dean's Roundtable on Research (1996)

Chair, Panel on Quantifying Faculty Productivity, Southern Council of Deans (1996)

Chair, Dean's Roundtable on Clinical Investigation (1996)

Chair, L.C.M.E. Site Visit, Stanford Medical School (1997)

Chair, AAMC 1998 Award for Distinguished Research Selection Committee (1998)

AAMC Advisory Panel on Research (1998-2003)

AAMC Task Force on Clinical Research (2004-06)

Chair, Organization, Administration and Governance Committee

Research Supported Finance Committee

Faculty Development Committee

Southern Medical Association (1986)

Christian Medical and Dental Association (1997-present)

Gordon Research Conference on Angiotensin

Steering Committee (2002-05)

Consortium for Southeastern Hypertension Control

Member, Board of Directors (2006-12)

Co-chair, Program Committee (2007)

Board of Directors (Advisory Member; 2012-present)
Vice President for Development (2013-present)
Facilitator, Strategic Planning Retreat (2014)
Member, Strategic Planning Committee (2014)
Member, Executive Committee (2015-present)
Member, Advisory Board, Practice Transformation Network, CMS TCPI Project (2015-16)
Member, Clinical Best Practices Advisory Board (2016-present)
Member, Cardiovascular Subcommittee

Editorial Positions: Consulting Editor, *Hypertension* (2012 - present)
Review Editor, *Hypertension*, *Frontiers of Cardiovascular Medicine* (2014 - present)

Editorial Boards:

1981-84: *Journal of Clinical Endocrinology and Metabolism*

1983-84: *Hypertension*

1987-89: *American Journal of Physiology: Heart and Circulatory Physiology*

1987-92: *American Journal of Hypertension*

1992-present: *Current Opinion in Endocrinology*

1993-97: *Pathophysiology*

1997-present: *Physiological Medicine*

1997-present: *Hypertension*

1998-present: Section Editor, Hypertension: Kidney, Sodium and Renin-Angiotensin System, *Current Hypertension Reports*, Current Science, Inc.

2003-present: Expert Advisor, *Breakthroughs in Bioscience*, FASEB

2003-06: Editorial Advisory Board, *Endocrine Today*

2004-present: *Current Hypertension Reviews*

2012-present: *Hypertension Research*

Ad Hoc Reviewer:

Hypertension, Journal of Hypertension, American Journal of Hypertension, Clinical and Experimental Hypertension, Journal of Clinical Endocrinology and Metabolism, Endocrinology,

Endocrine Reviews, New England Journal of Medicine, Journal of the American Medical Association, Lancet, Nature, Circulation, Circulation Research, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences USA.

National Public Service Boards:

- 1988-92:** Cardiovascular and Renal Advisory Committee, United States Food and Drug Administration
- 1994-98:** National Advisory Research Resources Council, National Institutes of Health
- 1995-97:** Council Representative, Advisory Committee to the Director, National Institutes of Health
- 1996-97:** Inter-Council Advisory Committee, National Institutes of Health
- 1997:** Chair (with Joshua Lederberg), National Center for Research Resources Scientific Forum for Strategic Planning
- 2003:** Chair (with Franklyn Prendergast), National Center for Research Resources (NCRR) Scientific Forum for Strategic Planning

NIH Scientific Review Boards:

- 1982-85:** Study Section on Experimental Cardiovascular Sciences, National Institutes of Health
- 2009:** National Institutes of Health Distinguished Editorial Panel
- 2011:** Quadrennial Site Visit, NIH Program in Reproductive and Adult Endocrinology, National Institute of Child Health and Human Development

Personal NIH/American Heart Association Research Support:

1. NIH Grant RR-00847, University of Virginia General Clinical Research Center, December 1, 1995-November 30, 2000; \$15,000,000; July 1, 1973- present, **Investigator**; July 1, 1975-March 31, 1986, Associate Director; April 1, 1986-July 1, 2002, **Principal Investigator**.
2. American Heart Association Established Investigatorship; #76-115 - July 1, 1975 through June 30, 1980, **Principal Investigator**.
3. NIH Grant #R01-AM-17523, Role of the Gastrointestinal Tract in Control of Sodium Excretion, May 1, 1974 through April 30, 1977, \$75,761, **Principal Investigator**.
4. American Heart Association/Virginia Affiliate, Sensitivity to Mineralocorticoids in

- Hypertension, July 1, 1975 through June 30, 1976, \$7,849, **Principal Investigator.**
5. NIH Grant #1T32HL-07355, Research Training Grant in Hypertension, July 1, 1978 through June 30, 1983, \$370,356, **Co-Principal Investigator.**
 6. NIH Grant #R01-HL-22306, Renal Catecholamines in the Pathophysiology of Hypertension, April 1, 1978 through March 31, 1981, \$123,916, **Principal Investigator.**
 7. NIH Grant #R01-HL-22306, Renal Catecholamines in the Pathophysiology of Hypertension, April 1, 1981 through March 31, 1984, \$247,709, **Principal Investigator.**
 8. NIH Grant #R23-HL-28118, Renal Dysfunction in Respiratory Failure, July 1, 1982-June 30, 1985, \$107,301, **Co-Investigator.**
 9. NIH Grant #2T32-HL-07355, Research Training Grant in Hypertension, July 1, 1983-June 30, 1988, \$682,500, **Co-Principal Investigator and Co-Director.**
 10. NIH Grant # RR-00847-I0-5I, Clinical Research Information System (CLINFO), July 1, 1983-June 30, 1988, \$217,358, **Investigator and Associate Director.**
 11. NIH Grant # R01-HL-32129, Control of Renal Function by Intrarenal Angiotensin, April 1, 1984 through March 31, 1987, \$336,382, **Principal Investigator.**
 12. NIH Grant # P01-HL-19242, Vascular Smooth Muscle Program Project, Richard A. Murphy, Principal Investigator; Subproject: Juxtaglomerular Cells and Regulation of Renin Release; January 1, 1985 - December 31, 1987, \$252,663; **Principal Investigator.**
 13. NIH Grant #3T32 - AM-O7320, Research Training in Diabetes and Hormone Action, September 1, 1983-August 31, 1988, \$556,000, **Principal Investigator and Director.**
 14. NIH Grant #R01-HL-32129, Control of Renal Function by Intrarenal Angiotensin, April, 1987-March 31, 1992, \$695,008, **Principal Investigator.**
 15. NIH Grant P01-HL-19242-S1, Vascular Smooth Muscle Program Project, Richard A. Murphy, Principal Investigator; Subproject: Juxtaglomerular Cells and Regulation of Renin Release; January 1, 1988-December 31, 1989, \$280,496; **Principal Investigator.**
 16. NIH Grant #2T32-HL-07355, Research Training Grant in Hypertension, July 1, 1988-June 30, 1993, \$945,063, **Co-Principal Investigator and Co-Director.**
 17. NIH Grant #R01-HL-41899, Regulation of renin synthesis and release in the kidney, December, 1988-November, 1994, \$493,768, **Co-investigator.**
 18. NIH Grant P01-HL-19242, Vascular Smooth Muscle Program Project, Richard A. Murphy, Principal Investigator; Subproject: Juxtaglomerular Cells and Regulation of Renin Release; January 1, 1990-December 31, 1994, \$1,082,495; **Principal Investigator.**

19. NIH Grant F05-TWO4547, Fogarty International Research Fellowship on behalf of Dr. Damian P. O'Connell, Physiology and pathophysiology of renal dopamine mechanisms; September 1, 1991-August 31, 1993; \$46,000; **Sponsor**.
20. NIH Grant #1-RO1-HL-49575, Paracrine mechanisms of renal dopamine and angiotensin II; July 1, 1993 - June 30, 1998, \$1,353,000, **Principal Investigator**.
21. NIH Grant #2-T32-HL-07355, Training Grant in High Blood Pressure Research, July 1, 1994-June 30, 1999, \$924,934, **Co-Investigator and Member, Executive Committee**.
22. NIH Grant #1-R01-HL-59948, AT₂ receptor mechanisms in angiotensin II-dependent hypertension; April 1, 1998-March 31, 2003, \$1,079,873, **Principal Investigator**.
23. NIH Grant #1-R01-HL65659, AT₂ receptors in blood pressure and renal function, July 1, 2001-June 30, 2006, \$1,000,000, **Principal Investigator**.
24. NIH Grant #1-PO1-HL-074940 Dopamine and angiotensin receptor interactions in genetic hypertension, Robin A. Felder, Principal Investigator; \$11,266,641. Project 2: D₁ and AT₁ receptor interaction in human hypertension: clinical mechanisms, Robert M. Carey, **Project Principal Investigator and Director**. April 1, 2004-March 31, 2009, \$1,974,327.
24. NIH Grant #1-R01-HL-081891, Pressure-natriuresis mediated by extracellular cGMP. July 1, 2005- June 30, 2010, \$2,257,431, **Principal Investigator**.
25. NIH Grant #1-T32-DK-07646, Research Training Grant in Neuroendocrinology, September 1, 2005-August 31, 2010, \$1,000,000, **Principal Investigator and Director**.
26. NIH Grant #1-RO1-HL-087998, Natriuretic mechanisms of AT₂ receptors. July 1, 2009 – June 30, 2011, \$ 886,951, **Principal Investigator**.
27. NIH Grant #1-PO1-HL-074940 Dopamine and angiotensin receptor interactions in genetic hypertension, Robin A. Felder, Principal Investigator; \$10,777,479. Project 2: D₁ and AT₁ receptor interactions in human hypertension: clinical mechanisms, Robert M. Carey, **Project Principal Investigator and Director**. September 30, 2009-December 31, 2014, \$2,028,270.
28. NIH Grant # 1-T32-DK-07646, Research Training Grant in Neuroendocrinology, September 1, 2010-August 31, 2015, \$1,000,000, **Principal Investigator and Program Director**.
29. NIH Grant # 1-RO1-HL-095796 Renal AT₂ receptors in hypertension, April 1, 2010 – March 31, 2014, \$ 1,844,696, **Principal Investigator**.
30. NIH Grant # P01-HL-074940, Robin A. Felder, Principal Investigator, June 1, 2016 – May 31, 2021. \$12,945,665. Molecular mechanisms in salt sensitivity of blood pressure Project 2: “Renal sodium-bicarbonate co-transporter (SLC4A5) activity

in human subjects with salt-sensitivity of blood pressure: intrarenal mechanisms and role in blood pressure regulation. \$2,058,485. **Project Principal Investigator and Director.**

31. NIH Grant # 1-RO1-HL-128189; Renal AT₂ receptors in hypertension; April 1, 2016 - March 31, 2020, \$ 2,280,852. **Principal Investigator.**

Major Institutional Grants:

1. Robert Wood Johnson Foundation, Virginia Generalist Medicine Initiative; 1994 - 2000; \$4,000,000; **Principal Investigator.**
2. Markey Charitable Trust, Center for Cell Signaling; 1990 – 2002; \$6,100,000; **Principal Investigator.**
3. The Whitaker Foundation, Special Development Award in Biomedical Engineering; 1998-2002, \$10,500,000; **Co-Principal Investigator.**

Post-doctoral Research Trainees:

Name	Dates	Funding Source	Present Position
Yee Szemen, MBBS, MRCP	2017-18	Government of Singapore	Associate Consultant, National University of Singapore
Christina Gherghe, MD, PhD	2010-12	NIH T32 Grant	Practice- endocrinology
Nilberto Nascimento, Ph.D	2009-10	NIH R01 Grant	Professor of Pharmacology and Therapeutics Director, Biomedical Institute, State University of Ceara Fortaleza, Brazil
David C. Lieb, M.D	2007-09	NIH T32 Grant NIH NRSA Grant	Associate Professor of Medicine and Program Director, Division of Endocrinology, Eastern Virginia School of Medicine, Norfolk, VA
Shetal H. Padia, MD	2004-07	NIH T32 Grant AHA Fellow-to-Faculty Award NIH K Award	Assistant Professor of Medicine, Division of Endocrinology and Metabolism, University of Virginia
Brandi Salomone, MD	2004-06	NIH T32 Grant	Assistant Clinical Professor of Medicine, University of Florida
Cynthia Schoeffel, MD	2004-14	NIH P01 Grant	Clinical Research Associate, University of Virginia
Yoshihiko Oishi, MD	2004-06	NIH R01 Grant	Assistant Professor of Medicine

			Hiroshima University Hiroshima, Japan
Shota Sasaki, MD	2001-03	NIH R01 Grant	Assistant Professor of Medicine Hiroshima University Hiroshima, Japan
Lesley J. Millatt, PhD	1998-99	NIH R01 Grant	Lille Pasteur Institute and Faculty of Pharmacology, University of Lille, Lille, France
John Phipps, MD	1997-98	Medical Center	Practice-endocrinology
Xiao-Hong Jin, MD, PhD	1996-2003	NIH R01 Grant	Practice-medicine
Crystal A. Gadegbeku, MD	1995-97	NIH T32 Grant	Professor of Medicine Chief of the Division of Nephrology, Hypertension and Kidney Transplantation, Temple University Philadelphia, PA
Zhi-Qin Wang, MD	1994-2000	NIH R01 Grant	Practice-pathology
Ryoji Ozono, MD	1994-96	NIH R01 Grant	Associate Professor of Medicine Hiroshima University Hiroshima, Japan
Fang Fan, PhD, MD	1994-95	NIH T32 Grant	Practice-medicine
Michael McGarrity, MD	1991-94	NIH T32 Grant	Practice-endocrinology
Damian P. O'Connell, MD, PhD	1990-93	NIH International Fogarty Grant	Senior Vice President and Head, Global Clinical Sciences, Bayer Corporation, Berlin, Germany
Cinzia Pupilli, MD	1989-91	Italian Government Fellowship	Director of Endocrinology, University of Careggi, Florence, Italy
Princess V. Dougan, MD	1988-90	Smith, Kline and French Laboratories	Clinical Trials Coordinator, Orange County, CA
Paul Stewart, MB, ChB	1987-88	Welcome Trust of Great Britain	Dean of Medicine and Health Professor of Medicine Consultant Endocrinologist University of Leeds Leeds, United Kingdom
Marie Lynd, MD	1987-88	NIH T32 Grant	Practice-endocrinology
Michael Solenberger, MD	1986-87	NIH T32 Grant	Clinical Professor of Medicine Wake Forest University Winston-Salem, NC
Ian B. Puddey, MD	1986-88	Medical Research Council of Australia	Professor and Chair, Department of Medicine, University of

			Western Australia, Perth, Australia
Joseph M. Hughes, MD	1984-87	NIH T32 Grant	Head, Division of Endocrinology, The Mary Imogene Bassett Hospital, Cooperstown, NY Professor of Medicine, Columbia University
Helmy M. Siragy, MD	1985-86	NIH T32 Grant	Harrison Distinguished Teaching Professor of Medicine University of Virginia
Michael E. May, MD, PhD	1983-86	NIH T32 Grant	Assistant Professor of Medicine, Vanderbilt University, Nashville, TN
Carl D. Malchoff, MD, PhD	1982-85	NIH T32 Grant	Professor of Medicine, University of Connecticut, Farmington, CT
Gabriel M. Dickstein, MD	1983-84	Israeli Fellowship	Professor of Endocrinology University of Haifa Haifa, Israel
Lawrence M. Dolan, MD	1980-83	NIH T32 Grant	Professor of Pediatrics University of Cincinnati Cincinnati, OH
Charles R. Drake, MD	1981-83	NIH T32 Grant	Practice-endocrinology
Fred A. Williams, MD	1981-83	Medical Center	Clinical Professor of Medicine University of Louisville Louisville, KY
Thomas A. Wilson, MD	1979-82	NIH T32 Grant	Professor of Pediatrics State University of New York Stoney Brook, NY
Nigel R. Levens, PhD	1978-81	NIH R01 Grant	Vice President, Research and Preclinical Development, Bellus Health; Vice President, Research and Chief Scientific Officer, Innodia; Independent Pharmaceuticals Consultant, Montreal, Quebec
Steven Herf, MD	1976-78	Medical Center	Practice-endocrinology
Richard E. Katholi, MD	1975-76	NIH T32 Grant	Professor of Medicine University of Southern Illinois Springfield, IL
Houston M. Kimbrough, Jr. MD	1976-77	Medical Center	Practice-urology
Edwin Swart, MD	1975-77	Medical Center	Practice-endocrinology
William Jennings, MD	1973-75	Medical Center	Clinical Professor of Medicine Marshall University

			Huntington, WV
--	--	--	----------------

Dissertation Committee for Ph.D. Degree:

Seth Dupuy	Pharmacology	University of Virginia
Lisa Duke	Pharmacology and Physiology	Monash University, Melbourne, Australia

Medical Residents Mentored in Research:

Farah Ahmed Morgan, M.D.	Chief Resident in Medicine, UVA (2007-08) Fellow in Endocrinology and Metabolism, UVA (2008-2011); practice of endocrinology
Jennifer Park, M.D.	Resident in Medicine, UVA (2005-2008) Fellow in Endocrinology, University of California San Francisco (2008-2011); medical faculty, UCSF (2011-2013)
Danielle Rottkamp, M.D.	Resident in Medicine, UVA (2006-2009) Chief Resident in Medicine (2009-2010) Fellow in Endocrinology, University of California San Francisco (2010 – 2013)
John Bell, M.D.	Resident in Medicine, UVA (2008-2010) Hospitalist Program, UVA (2010-2012) Asst Prof of Medicine, University of California San Diego (2012-2014)
Samim Enayat, M.D.	Resident in Medicine, UVA (2010-2011) Fellow in Endocrinology, New York – Presbyterian Hospital, New York City (2011-2014).

Undergraduate Students Mentored in Research:

Allan F. Moore	UVA Jefferson and Echols Scholar (1995-99) Harry S. Truman Scholar MD, Vanderbilt University School of Medicine, 2003 (Canby Robinson Scholar); Resident in Medicine, Massachusetts General Hospital (2003-06) Fellow in Endocrinology, Mass Gen Hospital and University of Pennsylvania (2006-08)
Nicholas T. Heiderstadt	UVA (1997-2000)

Esther Huang	UVA Jefferson and Echols Scholar (1998-2002) Harrison Undergraduate Research Award Jack Kent Cooke Graduate Fellowship Matriculated at Harvard Medical School
Mary Boukarakis	UVA (2000-04)
Brandon A. Kemp	UVA (2003-06) Laboratory Specialist, UVA Division of Endocrinology (2007-present)
Peter Meliagros	UVA (2004-06)
Jacek Slowikowski	UVA (2006-07)

University of Virginia Administrative and Committee Assignments:

- 1973-86:** Clinical Research Center Advisory Committee
- 1974-76:** Staige-Blackford Lectureship Committee, Department of Internal Medicine, Chair, 1976
- 1975-77:** Council on Medical Education, School of Medicine; Executive Committee
- 1977-79:** Director, First Year Residency Selection Committee, Department of Internal Medicine
- 1978:** Search Committee for Chair, Department of Psychiatry
- 1977-79:** Medical Policy Committee
- 1980-82:** Chair, Search Committee for Head, Division of Gastroenterology
- 1981-83:** University of Virginia Faculty Forum for Scientific Research
- 1981:** Chair, Charles Culpeper Foundation Visiting Professorship Award Committee
- 1982:** Chair, Search Committee for Clinical Director, NIH Diabetes Research and Training Center
- 1982-86:** Medical Student Appeals Board School of Medicine
- 1982-86:** Committee on Fringe Benefits, Health Services Foundation
- 1982-84:** Chair, Task Force on Research, Program and Planning

- 1982-84:** Committee for University Replacement Hospital
- 1983:** Nominating Committee, Clinical Staff
- 1986:** Co-Chair, School of Medicine Faculty Research Retreat (Appointed by Dean Knorr)
- 1986-2002:** Chair, Executive Committee, School of Medicine
- 1986-2002:** Chair, Medical Advisory Committee, School of Medicine
- 1986-2002:** Chair Salem VA Dean's Committee
- 1986-2002:** Health Services Foundation Finance Committee
- 1986-2002:** Chair, School of Medicine General Faculty
- 1986-2002:** Academic Deans, University of Virginia
- 1986-2002:** Principal Investigator, General Clinical Research Center
- 1986-90:** Vice Chair, Medical Policy Committee
- 1986-91:** University of Virginia Hospital Advisory Board
- 1986-98:** University of Virginia Research Policy Advisory Committee
- 1986-2001:** Co-Chair, Institute for Law, Psychiatry and Public Policy
- 1992-94:** Principal Investigator, Basic Science Cancer Center
- 1986-96:** Chair, Advisory Committee, Center for Prevention of Disease and Injury
- 1988-98:** Health Sciences Council
- 1988-98:** Chair, Advisory Board, Center for Biomedical Ethics
- 1988-2002:** Chair, Advisory Committee, Center for Study of the Mind and Human Interaction
- 1989-2002:** Chair, General Clinical Research Center Advisory Committee
- 1989-90:** Search Committee for Vice President for Development and Community Relations, University of Virginia
- 1989-90:** Selection Advisory Panel for Executive Director, University of Virginia Medical Center

- 1990-94:** Principal Investigator, Markey Center for the Study of Molecular Mechanisms of Cell Signaling
- 1989-90:** Chair, Task Force on Evaluation and Documentation of Clinical Excellence
- 1990:** Ambulatory Care Task Force
- 1991-94:** Ambulatory Services Board
- 1991-96:** Strategic Planning Committee, Health Sciences Center
- 1991:** Advisory Committee for Search for Vice President and Provost, University of Virginia
- 1992-98:** University Development Council, University of Virginia
- 1992 - 94:** Building Committee, Ambulatory Care Facility
- 1993-97:** Clinical Practice Board
- 1994-96:** Chair, Academic Strategic Planning Subcommittee, Health Sciences Center
- 1994-96:** Strategic Planning Committee, Health Sciences Center
- 1996-97:** Executive Committee, Health Sciences Center
- 1997-2002:** Health Sciences Senior Staff
- 1998-2002:** Executive Committee, University of Virginia Health System
- 1997-2002:** Vice President's Council, Health Sciences Center
- 1998-2001:** Member, Nominating Committee, Vice President and Provost for Health Sciences Lifetime Achievement Award Committee
- 1998-2002:** M.D./Ph.D. Program Executive Committee (ex officio)
- 1998-2000:** Chair, School of Medicine Strategic Planning Steering Committee
- 2000; 2003:** Jefferson Scholars Selection Committee
- 2000:** Task Force on Quality Issues, Health System
- 2000:** Chair, Health System Patient Appreciation Committee
- 2005-pres:** Data and Safety Monitoring Board, Human Islet Cell Transplantation Program

- 2007:** Search Committee for Chief of Cardiology, Department of Medicine
- 2009-2010:** Department of Medicine Task Force on the Financial Development Plan
- 2010-pres:** Dean's Advisory Committee on Clinical Research
- 2011:** Chair, Five Year Review Committee for the Director, Center for Public Health Genomics
- 2014:** Member, Search Committee for Chief of Clinical Pathology
- 2014:** Member, Strategic Planning Subcommittee for Institutional Reputation
- 2014:** Member, School of Medicine Endowed Chairs Task Force
- 2014-2016:** Member, School of Medicine Reputation Task Force
- 2015-2018:** Chair, School of Medicine Prestigious Awards Committee

Board of Directors Membership:

- 1986-2002:** University of Virginia Health Services Foundation Executive Committee and Board of Directors
- 1986-2002:** Board of Directors and Vice-President, Virginia Ambulatory Surgery, Inc.
- 1986-2002:** Board of Directors, Virginia Kidney Stone Foundation, Inc.
- 1986-93:** Board of Directors, The Harrison Foundation, Inc., University of Virginia
- 1986-88:** Board of Directors, The Dyslexia Center, Charlottesville, VA
- 1986-2002:** Chair, Board of Directors, Center for Study of the Mind and Human Interaction, University of Virginia
- 1993-2002:** Medical School Foundation Board of Trustees, University of Virginia
- 1996-2000:** Advisory Board, Strickler Transplantation Center, University of Virginia
- 1998-2002:** Advisory Board, Center for Governmental Studies, University of Virginia
- 1997-2003:** Board of Trustees, The Hormone Foundation
- 2000-2004:** Board of Directors, Ivy Charitable Foundation

- 2002-2006:** Advisory Board, Quadrant Venture Capital, Inc., Atlanta, GA
- 2002-2008** Chair, Advisory Board, “Musicians Inspire Health” Initiative, Inc.
- 2005-2010:** Dean’s Advisory Board, University of Kentucky College of Medicine (Founding Member)
- 2008-present:** Board of Trustees, University of Virginia Medical School Foundation
- 2012-2013:** Board of Directors, American Heart Association (National)
- 2013-present:** Board of Directors, Consortium for Southeastern Hypertension Control
- 2013-present:** Board of Directors, Virginia Academy of Sciences, Engineering and Medicine

Other External Administrative and Committee Assignments:

- 1981-82:** Working Group for the Definition of Normal and High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee, National Institutes of Health
- 1983:** Subcommittee on Definition and Prevalence of High Blood Pressure, Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure, National Heart, Lung and Blood Institute
- 1983-84:** Consultant, Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure
- 1986:** Chair, Review Group for Abstracts on Hypertension, AAP/ASCI/AFCR Annual Meeting
- 1987:** Program Committee, American College of Physicians Regional Meeting
- 1992-95:** American Heart Association Group on Vascular Biology
- 1994:** Founding Member, Consortium of Southeast Hypertension Centers
- 1994:** International Council on the Role of Aldosterone in Cardiovascular Disease
- 2001-02:** External Review Committee, Pathobiology of Vascular Disease Training Grant, Wake Forest University School of Medicine
- 2003:** Representative, Community of Stakeholders, Chronic Kidney Disease, American Society of Nephrology, National Kidney Foundation and Renal Physicians Association

2009-10: Harvard Medical School *Ad Hoc* Committee for Evaluation of Ellen W. Seely MD for Promotion

Visiting Professor:

1979

Division of Nephrology, Department of Medicine, University of Miami, Miami, Florida (Dr. Murray Epstein)

1980

Pfizer Traveling Fellow, Clinical Research Institute of Montreal, Montreal, Quebec, Canada (Dr. Otto Kuchel)

1981

Hospital das Clinicas da Universidade, Federal do Ceara, Fortaleza, Brazil (Dr. Nogiera Paes)

Hypertension Division, Mt. Sinai School of Medicine, New York, New York (Dr. Lawrence Krakoff)

Division of Pediatric Endocrinology, The New York Hospital/Cornell Medical Center, New York, New York (Dr. Maria New)

1982

Department of Endocrinology, St. Vincent's Hospital, University College, Dublin Ireland (Dr. T. Joseph McKenna)

1983

Division of Nephrology, Department of Medicine, University of Miami, Miami, Florida (Dr. Murray Epstein)

1984

Division of Endocrinology and Metabolism, and the Department of Medicine, Medical College of Virginia, Richmond, Virginia (Drs. Gordon Weir and Harold Fallon)

Honorary Visiting Professor, Departments of Physiology and Endocrinology, Mayo Graduate School of Medicine, Rochester, Minnesota (Drs. J. Carlos Romero and Robert C. Northcutt)

Division of Research, Cleveland Clinic Foundation, Cleveland, Ohio (Drs. F.M. Bumpus and Subha Sen)

Genentech, Inc., San Francisco, California (Dr. Ann Johanson)

Division of Endocrinology, University of Kentucky, Lexington, Kentucky (Dr. Theodore Kotchen)

Division of Nephrology, Department of Medicine, University of Miami, Miami, Florida (Dr. Murray Epstein)

1985

Division of Endocrinology and Metabolism, Departments of Medicine and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina (Dr. T. Kenneth Gray)

National Institutes of Health, Bethesda, Maryland (Dr. Kevin Catt)

1987

Department of Medicine, Harvard Medical School (Brigham and Women's Hospital), Boston, Massachusetts (Dr. Gordon Williams)

Bley Stein Visiting Professor in Endocrinology, University of Southern California, Los Angeles, California (Dr. Richard Horton)

1988

Pfizer Visiting Professor of Pharmacology, University of Chicago, Chicago, Illinois (Dr. Leon I. Goldberg)

Smith, Kline and French Laboratories, Philadelphia, Pennsylvania (Dr. Randall T. Curnow)

Abbott Laboratories, Chicago, Illinois (Dr. Ferid Murad)

Fuller-Sherman Visiting Professor, Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania (Dr. Willis S. Maddrey)

1989

National Institutes of Health, Endocrinology Branch (Dr. Gerald Auerbach)

1990

Division of Hypertension and Endocrinology, Case Western Reserve University School of Medicine, Cleveland, Ohio, (Dr. Janice Douglas)

Research Division, Cleveland Clinic Foundation, Cleveland, Ohio (Dr. Carlos Ferrario)
Department of Pharmacology University of Pennsylvania (Dr. Perry Molinoff)

1993

Research Division, Ochsner Clinic Foundation, New Orleans, Louisiana (Dr. Edward D. Frohlich)

1996

Department of Medicine, University College Cork, Ireland (Dr. Michael Murphy)

Department of Medicine, University of Miami (Dr. Murray Epstein)

Department of Medicine, University of Tennessee College of Medicine, Memphis (Dr. Jay Sullivan)

1998

Karolinska Institute, Stockholm, Sweden (Dr. Anita Aperia)

1999

Nephrology Division, Georgetown University (Dr. Chris Wilcox)

New Jersey Medical School , Newark (Dr. Abraham Aviv)

Harvard Medical School, Boston (Dr. Gordon H. Williams).

Wake Forest University School of Medicine, Winston-Salem (Dr. Carlos Ferrario)

2001

Tulane University (Dr. Gabriel Navar)

Medical College of Wisconsin, Milwaukee (Dr. Allen W. Cowley)

Leonard Share Distinguished Visiting Professor, University of Tennessee College of Medicine, Memphis (Dr. Hiroko Nishimura)

2002

New York University Medical College (Dr. Jerome Lowenstein)

National Institutes of Health (Dr. Kevin Catt)

2003

Wake Forest University School of Medicine (Dr. Carlos Ferrario)

University of Houston (Dr. Mustafa Lokhandwala)

New York Medical College (Dr. John C. McGiff)

University of Mississippi (Dr. Joey Granger)

University of Tokyo (Dr. Toshihiro Fujita)

University of Hiroshima (Dr. Ryoji Ozono)

2004

University of Connecticut (Dr. Carl Malchoff)

2005

Texas A & M College of Medicine, Frank and Sheila Thompson Visiting Professor (Dr. Don DiPette)

Vanderbilt University School of Medicine (Dr. Nancy J. Brown)

2006

Pfizer Global Research and Development (Dr. Brian R. Bond)

Hiroshima University School of Medicine (Dr. Ryoji Ozono)

Emory A. Wilson Dean's Distinguished Lecture, University of Kentucky (Dr. Alan Daugherty)

Hypertension Center, University of Texas Southwestern School of Medicine (Dr. Ronald Victor)

2008

Hypertension Center, University of Florida (Dr. Mohan Raisada)

Center for Functional Genomics in Hypertension, University of Iowa (Dr. Curt Sigmund)

National Institutes of Health (Dr. Kevin Catt)

University of Louisville School of Medicine, Beverly Towery Lectureship (Dr. Stephen J. Winters)

2009

McGill University, Montreal (Dr. Ernesto Schiffrin)

2010

Mt. Sinai School of Medicine (Dr. Elliott Rayfield)

Eastern Virginia Medical School (Dr. Jerry Nadler)

2012

Massachusetts General Hospital, Harvard Medical School (Dr. Jose Florez)

Indiana University School of Medicine (Dr. J. Howard Pratt)

2014

University of Michigan (Dr. William Rainey)

2017

Medical University of South Carolina (Dr. Dan Lackland)

2018

University of Alabama Birmingham (Dr. Suzanne Oparil)

Scientific Meetings Organized:

1988: 3rd International Meeting on the Peripheral Actions of Dopamine, Charlottesville, VA
(Robert M. Carey and Robin A. Felder, co-organizers)

1990: Dopamine and Hypertension, a Satellite Symposium of the International Society of

Hypertension, Montreal, Quebec, Robert M. Carey, Chair.

1992: United States Organizing Committee for the Pan Arab Conference on Hypertension, National Heart, Lung and Blood Institute

1996: Section Chair, Novel Catecholaminergic Systems, 8th International Catecholamine Symposium, CA.

1998: Organizing Committee and Section Chair, 7th International Conference on Peripheral Dopamine, Dublin, Ireland

2002: 115th Meeting of the American Clinical and Climatological Association, Williamsburg, VA

2003: 57th Annual Fall Conference of the Council for High Blood Pressure Research, American Heart Association, Washington, D.C.

2004: 58th Annual Fall Conference of the Council for High Blood Pressure Research, American Heart Association, Chicago, IL.

Pharmaceutical Consultant:

1991-94: E.M. Industries, Inc., Hawthorne, New York

1996-2000: Neurex, Inc., Menlo Park, CA., Member, Scientific Advisory Board

1996-2000: CIBA-Geigy, Inc., Basel, Switzerland, Member, Scientific Advisory Board

1999-2002: Pfizer Inc., Educational Advisor, Mini-Med School Program

1999-2001: Bristol-Meyers Squibb, Inc. (omipatrilat)

2004: Concurrent Pharmaceuticals, Philadelphia, PA

Takeda North American, Chicago, IL

2004-08: Venture Partner, Quadrant Venture Capital, Atlanta, GA

2006-09: Novartis, Inc., Direct Renin Inhibition Expert Research Council

Pfizer, Inc., Visiting Lecturer, St. Louis

Takeda Pharmaceuticals North America, Cardiovascular Portfolio Review Advisory Board

Novartis, Inc., Diabetes Cardiology Advisory Board

Daiichi Sankyo, Inc Medical Advisory Board

Patent Disclosures:

1992: A rapid method for the amplification and preparation of specific messenger RNA for expression in *Xenopus* oocytes (with Durieux, O'Connell and Lynch)

In situ hybridization and detection of RNA (with O'Connell, Durieux and Lynch)

1999: Angiotensin AT₁ receptor blockade in *Clostridium difficile* enteritis (with Guerrant, Jin and Alcantara)

2000: Angiotensin AT₂ and bradykinin B₂ receptor heterodimer formation (with Siragy)

2012: Compositions and methods for identifying and diagnosing salt-sensitivity of blood pressure (with Felder, Jones, Jose, and Williams)

Patents:

2017: U. S. Patent # 9,708,664 issued 18 July 2017: Compositions and methods for identifying and diagnosing salt-sensitivity of blood pressure (with. Felder, Jones, Jose, and Williams)

Visiting Consultant:

1985: University of Kentucky Clinical Research Center, Lexington (Theodore Kotchen)

1994: Oregon Health Sciences University Department of Medicine, Practice Plan Consultant (D.Lynn Loriaux)

2002: Chair, Review Committee for the Department of Medicine, Pennsylvania State University

2004: External Advisory Board, Center for Biomedical Research Excellence, University of Mississippi Medical Center, Jackson, MS

2005-10: Dean's Council, University of Kentucky College of Medicine

2008: Cardiovascular Research Program, College of Medicine, Texas A & M Health Science Center, College Station, TX

Congressional Testimony:

1998: U.S. House of Representatives, Committee on Appropriations, Subcommittee on Labor, Health and Human Services, Education and Related Agencies on behalf of the Association of American Universities, the National Association of State Universities and

Land Grant Colleges and the American Council on Higher Education.

U.S. House of Representatives Committee on Appropriations; Subcommittee on Labor, Health and Human Services, Education and Related Agencies, on behalf of the University of Virginia.

Citation Indices (Google Scholar):

(August 2017)

H-Index: 77; i10 Index 262

Number of times cited: 23,167

Number of papers cited 100 times or more: 60

BIBLIOGRAPHY

I. ORIGINAL PEER-REVIEWED SCIENTIFIC PUBLICATIONS

1. Schweikert JR, **Carey RM**, Liddle, GW, Island DP. Evidence that the renal pressor substance of Grollman is related to angiotensin I. *Circulation Research*. 1972;30 & 31 (Suppl. II): II-132-II-142.
2. **Carey RM**, Douglas JG, Schweikert JR, Liddle GW. The syndrome of essential hypertension and suppressed plasma renin activity: normalization of blood pressure. *Archives of Internal Medicine*. 1972;130:849-854 (**206 citations**).
3. **Carey RM**, Kimball AC, Armstrong D, Leiberman PH. Toxoplasmosis: Clinical experience in a cancer hospital. *American Journal of Medicine*. 1973;54:30-38.
4. **Carey RM**, Coleman, M, Feder, A. Pericardial tamponade: A major presenting manifestation of hydralazine-induced lupus syndrome. *American Journal of Medicine*. 1973;54:84-87.
5. **Carey RM**, Hartman W, Orth DN. Malignant melanoma with ectopic production of ACTH: palliative treatment with adrenal inhibitors. *Journal of Clinical Endocrinology and Metabolism*. 1973;36:482-487.
6. Liddle GW, **Carey RM**, Douglas JG. Role of the adrenal cortex in hypertension. *Southern Medical Journal*. 1973;66:51-54.
7. Lennane, R.J., Peart, W.S., **Carey RM**, Shaw J. Differential natriuresis following oral and intravenous sodium loading: evidence for a sodium input monitor in sodium-deplete rabbits, *Clinical Science and Molecular Medicine*. 1975; 49: 433-436.
8. Curnow RT, **Carey RM**, Taylor A, Johanson A, Murad F. Somatostatin inhibition of insulin secretion in islet-cell carcinoma. *New England Journal of Medicine*. 1975;292:1385-1386.

9. Lennane RJ, **Carey RM**, Goodwin TJ, Peart WS. Evidence for a gastrointestinal role in the regulation of sodium excretion in man. *Clinical Science and Molecular Medicine*. 1975;49: 437-440,.
10. **Carey RM**, Reid RA, Ayers CR, Lynch SS, McLain WL, Vaughan ED Jr. The Charlottesville Blood Pressure Survey: value of repeated blood pressure measurements. *Journal of the American Medical Association*. 1976;237:847-851.
11. **Carey RM**, Smith JR, Ortt EM. Gastrointestinal regulation of renal sodium excretion in sodium-deplete conscious rabbits. *American Journal of Physiology*. 1976; 230:1504-1508.
12. Reid RA, **Carey RM**, Ayers CR, Lynch SS, McLain WL, Vaughan ED Jr. The Charlottesville Blood Pressure Survey: the role of the physician in hypertension case findings. *Medical Care*. 1977; 15:324-330.
13. Kimbrough HM, Vaughan ED Jr, **Carey RM**, Ayers CR. Effect of intrarenal angiotensin II on renal function in conscious dogs. *Circulation Research*. 1977;40:174-178.
14. **Carey RM**, Johanson A, Seif SM. The effects of ovine prolactin on water and electrolyte excretion in man are attributable to vasopressin contamination. *Journal of Clinical Endocrinology and Metabolism*. 1977;44:850-858.
15. Katholi RE, **Carey RM**, Ayers CR, Vaughan ED Jr. Production of sustained hypertension by chronic intrarenal norepinephrine infusion in conscious dogs. *Circulation Research*. 1977;35: (Suppl. I);I-118-I-126.
16. Ayers CR, Katholi RE, Vaughan ED Jr, **Carey RM**. Kimbrough, H.M., Yancey, M.R., Morton, C.L., Mechanism of chronic renal arteriolar vasoconstriction and negative renin feedback in chronic one-kidney dog Goldblatt hypertension. *Circulation Research*. 1977;40:238-242.
17. Tegtmeyer CJ, Latour EA, Vaughan ED Jr., Ayers CR, **Carey RM**, Wellons HA Jr. Identification of renovascular hypertension: renin determinations and saralasin infusion. *Investigative Radiology*. . 1977;12:496-504.
18. **Carey RM**, Vaughan ED Jr, Ackerly JA, Peach MJ, Ayers CR. The immediate pressor effect of Sar¹, Ala⁸ Angiotensin II in man. *Journal of Clinical Endocrinology and Metabolism*. 1978; 46: 36-43.
19. Vaughan ED Jr, **Carey RM**, Peach MJ, Ackerly JA, Ayers CR. The renin response to diuretic therapy: A limitation of antihypertensive potential. *Circulation Research*. 1978; 42: 376-381.
20. **Carey RM**. Evidence for a splanchnic sodium input monitor regulating renal sodium excretion in man: lack of dependence upon aldosterone. *Circulation Research*. 1978;43: 19-23.

21. **Carey RM**, Vaughan ED Jr, Peach MJ, Ayers CR. Activity of (des-aspartyl¹)-angiotensin II and angiotensin II in man: differences in blood pressure and adrenocortical responses during normal and low sodium intake. *Journal of Clinical Investigation*. 1978;61:20-31.
22. **Carey RM**, Peach MJ, Vaughan ED Jr, Ayers CR. Responses to angiotensin II and (des-aspartyl¹)-angiotensin II in man: are there different receptors? *Circulation Research*. 1978;43 (Suppl. I):I-63-I69.
23. Williamson BRJ, **Carey RM**, Innes DJ, Teates CD, Bray ST, Lees RF, Sturgill BC. Poorly differentiated lymphocytic lymphoma with ectopic parathormone production: visualization of metastatic calcification by bone scan. *Clinical Nuclear Medicine*. 1978;3:382-384.
24. Oberfield SE, Levine LS, **Carey RM**, Bejar R, New MI. Pseudoaldosteronism: absence of aldosterone receptor responsiveness involving multiple target organs. *Journal of Clinical Endocrinology and Metabolism*. 1979;48:228-234.
25. **Carey RM**, Ayers CR, Vaughan ED Jr, Peach MJ, Herf S. Activity of (des-aspartyl¹)-angiotensin II in primary aldosteronism. *Journal of Clinical Investigation*. 1979;63:718-726.
26. Vaughan ED Jr, **Carey RM**, Ayers CR, Peach MJ, Tegtmeyer CJ, Wellons HA. A physiologic definition of blood pressure response to renal revascularization in patients with renovascular hypertension. *Kidney International*. 1979;15 (Suppl.) 83-92.
27. **Carey RM**, Thorner MO, Ortt EM. Effects of metoclopramide and bromocriptine on the renin-angiotensin system in man: dopaminergic control of aldosterone. *Journal of Clinical Investigation*. 1979;63:727-735 (**266 citations**).
28. Vaughan ED Jr, **Carey RM**, Ayers CR. Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin converting enzyme. *Journal of Clinical Endocrinology and Metabolism*. 1979;48:869-871.
29. **Carey RM**, Dacey RG, Jane JA, Wills MR, Ayers CR, Tyson GW. Production of sustained hypertension by lesions of the nucleus tractus solitarii of the American foxhound. *Hypertension*. 1979;1:246-254.
30. Hodge RH, Lynch SS, Davison J, Knight JG, **Carey RM**. Estimating compliance with diuretic therapy: urinary hydrochlorothiazide-creatinine ratios in normal subjects. *Hypertension*. 1979;1: 537-542.
31. Herf S, Teates DC, Tegtmeyer CJ, Vaughan ED Jr, Ayers CR, **Carey RM**. Evaluation and differentiation of surgically correctable hypertension due to primary aldosteronism. *American Journal of Medicine*. 1979;67: 397-402.
32. Laugen RH, Hess CE, Wills MR, **Carey RM**. Hypercalcemia associated with chronic lymphocytic leukemia. *Archives of Internal Medicine*. 1979;139:1307-1309.

33. Hall JE, Mills SE, **Carey RM**. Effects of rat adrenal extract on induction of atherosclerosis in cholesterol-fed rabbits. *Atherosclerosis*. 1979;35:87-92.
34. Baker KM, Johns DW, Ayers CR, **Carey RM**. Ischemic cardiovascular complications concurrent with the administration of captopril: a clinical note. *Hypertension*. 1980;2:73-74.
35. **Carey RM**, Thorner MO, Ortt EM. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man: dissociation of responses to dopamine and bromocriptine. *Journal of Clinical Investigation*. 1980;66:10-18.
36. **Carey RM**. Suppression of ACTH by cortisol in dexamethasone non-suppressible Cushing's disease. *New England Journal of Medicine*. 1980;302:275-279.
37. Johns DW 74, Baker KM, Ayers CR, Vaughan ED Jr, **Carey RM**, Peach MJ, Yancey MR, Ortt EM, Williams SC. Acute and chronic effect of captopril in hypertension patients. *Hypertension*. 1980; 2: 567-575.
38. Tegtmeyer CJ, Dyer R, Teates CD, Ayers CR, **Carey RM**, Wellons HA, Stanton LW. Percutaneous transluminal dilatation of the renal arteries: techniques and results. *Radiology*. 1980;135:589-599.
39. Baker KM, Johns DW, Vaughan ED Jr, Ayers CR, **Carey RM**. Antihypertensive effects of angiotensin blockade: saralasin versus captopril. *Clinical and Experimental Hypertension*. 1980;2: 947-954.
40. Levens NR, Vaughan ED Jr, Peach MJ, **Carey RM**. Demonstration of a primary antidiuretic action of angiotensin II: effects of intrarenal converting enzyme inhibition in the dog. *Endocrinology*. 1981; 107:318-330.
41. Levens NR, Peach MJ, **Carey RM**, Poat JA, Munday KA. Stimulation of intestinal sodium and water transport in vivo by angiotensin II and analogs. *Endocrinology*. 1981;107:1946-1953.
42. Levens NR, Peach MJ, **Carey RM**, Poat JA, Munday KA. Changes in an electroneutral transport process mediated by angiotensin II in the rat distal colon *in vivo*. *Endocrinology*. 1981;108: 1497-1504.
43. Levens NR, Peach MJ, **Carey RM**, Poat JA, Munday KA. Responses of rat jejunum to angiotensin II: role of norepinephrine and prostaglandins. *American Journal of Physiology Gastrointestinal and Liver Physiology*. 1981;240:G17-G24.
44. Levens NR, Peach MJ, Vaughan ED Jr, Weed W, **Carey RM**. Responses of blood pressure and angiotensin converting enzyme activity to acute captopril administration in normotensive and hypertensive rats. *Endocrinology*. 1981;108:536-544..
45. **Carey RM**, Van Loon GR, Baines AD, Ortt EM. Decreased plasma and urinary dopamine

- during dietary sodium depletion in man. *Journal of Clinical Endocrinology and Metabolism*. 1981;52: 903-909.
46. Levens NR, Peach MJ, **Carey RM**. Interactions between angiotensin II and the sympathetic nervous system mediating intestinal sodium and water absorption in the rat. *Journal of Clinical Investigation*. 1981;67:1197-1207.
 47. Wilson TA, Kaiser DL, Wright EM Jr, Peach MJ, **Carey RM**. Ontogeny of blood pressure and the renin-angiotensin-aldosterone system: sequential studies in the newborn lamb. *Circulation Research*. 1981;49: 416-423.
 48. Wilson TA, Kaiser DL, Wright EM Jr, Peach MJ, **Carey RM**. Importance of plasma angiotensin concentration in a comparison of angiotensin responses in the maturing newborn lamb. *Hypertension*. 1981;3 (Suppl. II): II-18-II-24.
 49. Levens NR, Peach MJ, **Carey RM**. Angiotensin as a neuromodulator of intestinal sodium and water absorption. *Annals of the New York Academy of Sciences*. 1981;372:646-648.
 50. Ayers CR, Katholi RE, **Carey RM**, Yancey MR, Morton CL. Acute and chronic alpha- and beta-adrenergic receptor stimulation of renin release in the conscious dog. *Hypertension*. 1981;3: 615-621.
 51. **Carey RM**. Acute dopaminergic inhibition of aldosterone secretion in man is independent of angiotensin II and adrenocorticotropin. *Journal of Clinical Endocrinology and Metabolism*. 1982; 54:463-469.
 52. **Carey RM**, Van Loon GR. Bromocriptine does not inhibit the aldosterone response to sodium depletion. *Journal of Clinical Endocrinology and Metabolism*. 1982;55:162-165.
 53. Rose CE, Walker BR, Erickson A, Kaiser DL, **Carey RM**, Anderson RJ. Effect of angiotensin II on renal function during hypercapnic acidosis in the conscious dog. *Journal of Cardiovascular Pharmacology*. 1982;4:676-687.
 54. Oberfield SE, Levine LS, **Carey RM**, Greig F, Ulich S, New MI. Metabolic and blood pressure responses to hydrocortisone in a syndrome of apparent mineralocorticoid excess. *Journal of Clinical Endocrinology and Metabolism*. 1983;56:332-339.
 55. Levens NR, Freedlender AE, Peach MJ, **Carey RM**. Control of renal function by intrarenal angiotensin II. *Endocrinology*. 1983;112:43-49,1983.
 56. Rose CE Jr, Kimmel DP, Kaiser DL, **Carey RM**. Synergistic effects of acute hypoxemia and hypercapnic acidosis in conscious dogs: renal dysfunction and activation of the renin-angiotensin system. *Circulation Research*. 1983;53:202-213.
 57. **Carey RM**, Van Loon GR, Baines AD, Kaiser DL. Suppression of basal and stimulated noradrenergic activity by the dopamine agonist, bromocriptine, in man. *Journal of Clinical Endocrinology and Metabolism*. 1983;6:595-602.

58. Wilson TA, Kaiser DL, Peach MJ, **Carey RM**. Possible mechanisms of action of metoclopramide-induced aldosterone secretion: *in vivo* and *in vitro* studies in the sheep. *Endocrinology*. 1982;7:892.
59. Wilson TA, Kaiser DL, **Carey RM**. Dopaminergic inhibition of aldosterone secretion in man is independent of the autonomic nervous system. *Journal of Clinical Endocrinology and Metabolism*. 1983;57:200-203.
60. Rose CE Jr, Althaus JA, Kaiser DL, Miller ED Jr, **Carey RM**. Acute hypoxemia and hypercapnic acidosis: increase in catecholamines in conscious dogs. *American Journal of Physiology Heart and Circulatory Physiology*. 1983;245:H924-H929.
61. Williams FA, Schambalan M, Biglieri EG, **Carey RM**. Acquired primary hypoaldosteronism due to an isolated zona glomerulosa defect. *New England Journal of Medicine*. 1983;309:1623-1627.
62. Levens NR, Marriscotti SP, Peach MJ, Mundy KA, **Carey RM**. Angiotensin II mediates increased small intestinal fluid absorption with extracellular volume depletion in the rat. *Endocrinology*. 1984;114:1692-1701.
63. Rose CE Jr, **Carey RM**, Anderson RJ. Antidiuresis and vasopressin release with hypoxemia and hypercapnia in conscious dogs. *American Journal of Physiology Regulatory, Integrative and Comparative Physiology*. 1984;247:R127-R134.
64. Malchoff CD, Kaiser DL, Pohl SL, **Carey RM**. Determinants of glucose and ketoacid concentrations in acutely hyperglycemic diabetic patients. *American Journal of Medicine*. 1984;77:275-285.
65. Johns DW, Ayers CR, **Carey RM**. Bromocriptine induces venous and arteriolar dilation in man. *Journal of Cardiovascular Pharmacology*. 1984;6:582-587.
66. Drake CR, Ragsdale NV, Kaiser DL, **Carey RM**. Dopaminergic suppression of angiotensin II-induced aldosterone secretion in man: differential responses during sodium loading and depletion. *Metabolism*. 1984;33:696-702.
67. Drake CR, **Carey RM**. Dopamine modulates sodium-dependent aldosterone responses to angiotensin II in man. *Hypertension*. 1984;6 (Suppl. 1):I-119-I-123.
68. Rose CE Jr, Godine RL Jr, Rose KY, Anderson RJ, **Carey RM**. Role of arginine vasopressin and angiotensin II in renal and cardiovascular responses to combined acute hypoxemia and hypercapnic acidosis in conscious dogs. *Journal of Clinical Investigation*. 1984;74:321-331.
69. **Carey RM**, Stote RM, Dubb JW, Townsend LH, Rose CE Jr, Kaiser DL. Effects of selective peripheral dopamine-1 (DA-1) receptor stimulation in human essential hypertension. *Journal of Clinical Investigation*. 1984;74:2198-2207.

70. Ventura HO, Messerli FH, Frolich ED, Kobrin I, Oigman W, Dunn FG, **Carey RM**. Immediate hemodynamic effects of a dopamine receptor agonist (SKF 82526-J) in essential hypertension. *Circulation*. 1984;69:1142-1145.
71. **Carey RM**, Sen S, Dolan LM, Malchoff CD, Bumpus FM. Idiopathic adrenal hyperplasia: a potential pathophysiologic role for aldosterone stimulating factor. *New England Journal of Medicine*. 1984;311:94-99.
72. **Carey RM**, Varma SK, Drake CR Jr, Thorner MO, Kovacs K, Rivier J, Vale W. Ectopic secretion of corticotropin releasing factor as a cause of Cushing's syndrome. *New England Journal of Medicine*. 1984;311:13-19. **(258 citations)**
73. McCarty R, Kirby RF, **Carey RM**. Dopamine may be a neurohormone in the rat adrenal cortex. *American Journal of Physiology Endocrinology and Metabolism*. 1984;247:E709-E713.
74. Rose CE Jr, Anderson RJ, **Carey RM**. Acute hypercapnic acidosis diminishes renal water excretion in conscious dogs. *Mineral and Electrolyte Metabolism*. 1985;11:131-136.
75. May M, **Carey RM**. The rapid ACTH test in practice - a retrospective review. *American Journal of Medicine*. 1985;79:679-684, 1985.
76. Dickstein G, Woodson J, Lamb N, Rose, CE, Jr, Peach MJ, **Carey RM**. Escape from the sodium retaining action of intrarenal angiotensins II and III in the conscious dog. *Endocrinology*. 1985; 117:2160-2169.
77. **Carey RM**, Drake CR Jr. Dopamine selectively inhibits aldosterone responses to angiotensin II in man. *Hypertension*. 1986;8:399-406.
78. Malchoff CD, Hughes J, Sen S, Jackson S, **Carey RM**. Dopamine inhibits the aldosterone response to upright posture. *Journal of Clinical Endocrinology and Metabolism*. 1986;63:197-201.
79. McCarty R, Kirby RF, **Carey RM**. Effects of dietary sodium on dopamine content of the rat adrenal cortex. *Physiology and Behavior*. 1986;37:785-789.
80. Chevalier RL, **Carey RM**, Kaiser DL. Endogenous prostaglandins modulate autoregulation of renal blood flow in young rats. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1987;253:F66-F75.
81. Malchoff CD, Hughes JM, **Carey RM**. Effect of upright posture on the aldosterone response to low dose dopamine, metoclopramide, angiotensin II and ACTH. *Journal of Clinical Endocrinology and Metabolism*. 1987;65:203-207.
82. Siragy HM, Lamb NE, Woodson JF, Ragsdale NV, Rose CE Jr, Peach MJ, **Carey RM**. Renal sensitivity to angiotensin II in the conscious dog. *Endocrinology*.

1987;120:1272-1278.

83. Johns DW, **Carey RM**, Gomez RA, Saye J, Geary KM, Harnois D, Farnsworth B, Peach M.J. Isolation of renin rich rat kidney cells. *Hypertension*. 1987;10:488-496.
84. Siragy HM, Lamb NE, Khosla MC, Rose CE Jr, Peach MJ, **Carey RM**. Demonstration of a direct renal tubular action of intrarenal angiotensin. *Endocrinology*. 1988;122:359-363.
85. Johns RA, Kron IL, **Carey RM**, Lake CL. Atrial myxoma: case report, brief review and recommendations for anesthetic management. *Journal of Cardiovascular Anesthesia*. 1988;2:207-212.
86. Gomez RA, Lynch KR, Chevalier RL, Wilfong N, Everett A, **Carey RM**, Peach MJ. Renin and angiotensinogen gene expression in the maturing rat kidney. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1988;254:F582-F587.
87. Hughes JM, Ragsdale NV, King B, Chevalier RL, Felder RA, **Carey RM**. Diuresis and natriuresis with continuous dopamine-1 receptor stimulation in man. *Hypertension*. 1988;11(Suppl 1):I-69-I-74.
88. Gomez RA, Lynch KR, Chevalier RL, Everett AD, Johns DW, Wilfong N, Peach MJ, **Carey RM**. Renin and angiotensinogen gene expression and intrarenal renin distribution during angiotensin converting enzyme inhibition. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 23)1988;254;:F1-F6.
89. Rose CE Jr, Latham LB, Brashers VL, Rose KY, Sandridge MP, **Carey RM**, Althaus JS, Miller ED Jr. Hypoxemia and hypercapnia in conscious dogs: opioid modulation of catecholamines. *American Journal of Physiology Heart and Circulatory Physiology*. 1988;254:H72-H80.
90. Hughes JM, Beck TR, Rose CE Jr, **Carey RM**. Effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man. *Journal of Clinical Endocrinology and Metabolism*. 1988;66:518-525.
91. Malchoff CD, Orth DV, Abboud C, Carney JA, Pairolero PC, **Carey RM**. Ectopic ACTH syndrome caused by bronchial carcinoid responsive to dexamethasone, metyrapone and corticotropin releasing factor. *American Journal of Medicine*. 1988;84:760-764.
92. Siragy HM, Lamb NE, Rose CE Jr, Peach MJ, **Carey RM**. Intrarenal modulation of atrial natriuretic factor action by angiotensin II. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1988;255:F545-F551..
93. Siragy HM, Lamb NE, Woodson JF, Rose CE Jr, Peach MJ, **Carey RM**. Intrarenal renin inhibition increases renal function by an angiotensin II-dependent mechanism. *American Journal of Physiology Renal, Fluid, Electrolyte Physiol*. 1988;255:F749-F754..
94. Vieweg WVR, **Carey RM**, Godleski LS, Tisdelle DA, Pruzinski T, Yank GR. The syndrome

of psychosis, intermittent hyponatremia and polydipsia: evidence for diurnal volume expansion. *Psychiatric Medicine*. 1990;8:135-144.

95. Gomez RA, Cassis L, Lynch KR, Chevalier RL, Wilfong N, **Carey RM**, Peach MJ. Fetal expression of the angiotensinogen gene. *Endocrinology*. 1988;123:2298-2302.
96. Chevalier RL, Gomez RA, **Carey RM**, Peach MJ, Linden JM. Renal effects of atrial natriuretic peptide infusion in young and adult rats. *Pediatric Research*. 1988;24:333-337.
97. Rose CE Jr, Dougherty MJ, Brashers VL, Godine RL Jr, Latham LB, Rose KY, **Carey RM**. Effect of alpha-adrenergic blockade on the cardiovascular responses to hypoxemia and hypercapnic acidosis in conscious dogs. *Proceedings of the Society for Experimental Biology and Medicine*. 1989;190:155-162.
98. Siragy HM, Felder RA, Howell NL, Chevalier RL, Peach MJ, **Carey RM**. Evidence that intrarenal dopamine acts as a paracrine substance in the control of renal function. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1989;257:F469-F477, 1989.
99. Gomez RA, Lynch KR, Sturgill BC, Chevalier RL, **Carey RM**, Peach MJ. In situ localization of renin gene expression in the developing rat kidney. *American Journal of Physiology* 257(Renal, Fluid, Electrolyte Physiology). 1989;257:F850-F858.
100. Siragy HM, Howell NL, Peach MJ, **Carey RM**. Combined blockade of the intrarenal renin-angiotensin system in conscious dogs. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1990;258:F522-F529.
101. **Carey RM**, Geary K, Hunt MK, Harnois D, Inagami T, Peach MJ, Leong D. Identification of individual renocortical cells which secrete renin. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1990;258:F649-F659.
102. El-Dahr SS, Chevalier RL, Gomez RA, Gray MS, Peach MJ, **Carey RM**. Distribution of renin and its mRNA in the developing kidney with unilateral ureteral obstruction. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1990;258:F854-F862 (**209 citations**).
103. Bierd TM, Kattwinkel J, Chevalier RL, Rheuban KS, Smith DJ, Teague WG, **Carey RM**, Linden J. The interrelationship of atrial natriuretic peptide, atrial volume and renal function in premature infants. *Journal of Pediatrics*. 1990;116:753-759.
104. Ragsdale NV, Lynd M, Chevalier RL, Felder RA, Peach MJ, **Carey RM**. Selective peripheral dopamine-1 (DA-1) receptor stimulation in man: differential responses to sodium loading and depletion. *Hypertension*. 1990;15:914-921.
105. Rose CE Jr, Ragsdale NV, **Carey RM**. Role of vasopressin in renal vascular changes with hypoxemia and hypercapnic acidosis in conscious dogs. *American Journal of Physiology Regulatory, Integrative, Comparative Physiology*. 1990;259:R690-R702.

106. Gomez RA, Chevalier RL, Everett AD, Elwood JP, Peach MJ, Lynch KR, **Carey RM**. Recruitment of renin gene expressing cells in adult rat kidneys. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1990;259:F660-F665.
107. Everett AD, **Carey RM**, Peach MJ, Gomez RA. Renin release and gene expression in intact rat kidney microvessels and single cells. *Journal of Clinical Investigation*. 1990;86:169-175.
108. Chevalier RL, Thornhill BA, Peach MJ, **Carey RM**. Hematocrit modulates response of ANP to volume expansion in immature rats. *American Journal of Physiology Regulatory, Integrative, Comparative Physiology*. 1990;258:R729-R735.
109. Chevalier RL, Thornhill B, Gomez RA, Ragsdale NV, Peach MJ, **Carey RM**. Role of atrial natriuretic peptide in the response to blood volume expansion in the weanling rat. *Pediatric Research*. 1990;27:396-400.
110. El-Dahr SS, Gomez RA, Khare G, Peach MJ, **Carey RM**, Chevalier RM. Expression of renin and its mRNA in the adult rat kidney with chronic ureteral obstruction. *American Journal of Kidney Diseases*. 1990;15:575-582.
111. Siragy HM, Felder RA, Howell NL, Peach MJ, **Carey RM**. Evidence that dopamine-2 (DA-2) mechanisms control renal function. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1990;259:F793-F800.
112. Johns DW, Peach MJ, Gomez RA, Inagami T, **Carey RM**. Angiotensin II regulates renin gene expression. *American Journal of Physiology Renal, Fluid and Electrolyte Physiology*. 1990;259:F882-F887.
113. El-Dahr SS, Gomez RA, Gray MS, Peach MJ, **Carey RM**, Chevalier RL. Renal nerves modulate renin gene expression in the developing rat kidney with ureteral obstruction. *Journal of Clinical Investigation*. 1991;87:800-810.
114. Pupilli C, Gomez RA, Tuttle JB, Peach MJ, **Carey RM**. Spatial association of renin-containing cells and nerve fibers in the developing rat kidney. *Pediatric Nephrology*. 1991;5:690-695.
115. Chevalier RL, Scarborough RM, Linden JM, Gomez RA, Peach MJ, **Carey RM**. Inhibition of ANP clearance receptors and endopeptidase 24.11 in the maturing rat. *American Journal of Physiology Regulatory, Integrative and Comparative Physiology*. 1991;260:R1218-R1227.
116. Rose CE Jr, Vance JE, Dacus WS, Brashers VL, Peach MJ, **Carey RM**. Role of intrarenal angiotensin II and α -adrenoceptors in renal vasoconstriction with acute hypoxemia and hypercapnic acidosis in conscious dogs. *Circulation Research*. 1991;69:142-156.
117. Carey AV, Gomez RA, **Carey RM**. Expression and distribution of alpha-actin in the

- developing vascular system of the rat kidney. *Hypertension*. 1992;19(Suppl II): II-168 - II-175.
118. Vieweg WV, Veldhuis JD, **Carey RM**. Temporal pattern of renin and aldosterone secretion in man: effects of sodium balance. *American Journal of Physiology Renal, Fluid, Electrolyte Physiol*. 1992;262:F871-F877.
 119. Siragy HM, Felder RA, Howell NL, Peach MJ, **Carey RM**. Intrarenal DA₂ dopamine receptor stimulation in the conscious dog. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1992;262:F932-F938.
 120. Siragy HM, Johns RA, Peach MJ, **Carey RM**. Nitric oxide alters renal function and cyclic GMP. *Hypertension*. 1992;19:775-779.
 121. Hunt MK, Geary KM, Norling LL, Ramos SP, Peach MJ, Gomez RA, **Carey RM**. Co-localization and release of angiotensin and renin by renocortical cells. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1992;263:F363-F373.
 122. Rose CE Jr, Ragsdale, NV, **Carey RM**. Combined acute hypoxemia and hypercapnic acidosis increases atrial natriuretic peptide in conscious dogs. *Mineral and Electrolyte Metabolism*. 1992; 18:24-34.
 123. Pupilli C, Chevalier RL, **Carey RM**, Gomez RA. Distribution and content of renin and its mRNA in the remnant kidney of the adult rat. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1992;263:F731-F738.
 124. Geary KM, Hunt M, Johns DW, Peach MJ, Gomez RA, **Carey RM**. Effect of converting enzyme inhibition, sodium depletion, calcium, isoproterenol and angiotensin II on renin secretion from individual renocortical cells. *Endocrinology*. 1992;131:1588-1594.
 125. Saye JA, Ragsdale NV, **Carey RM**, Peach MJ. Localization of angiotensin peptide forming enzymes of 3T3-F442A adipocytes. *American Journal of Physiology Cell Physiology*. 1993;264:C1570-C1576.
 126. Rose CE Jr, Brashers VL, Peach MJ, **Carey RM**. Role of angiotensin II in renal vasoconstriction with combined acute hypoxemia and hypercapnic acidosis in conscious dogs. *Renal Failure*. 1994; 16:229-242.
 127. Tufro-McReddy A, Johns DW, Geary KM, Dagli H, Everett AD, Chevalier RL, **Carey RM**, Gomez RA. The angiotensin AT₁ receptor: role in renal growth and gene expression during normal development. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1994;266:F911-F918, 1994.
 128. Norwood VF, **Carey RM**, Geary KM, Jose PA, Gomez RA, Chevalier RL. Neonatal ureteral obstruction stimulates recruitment of renin-secreting renal cortical cells. *Kidney International*. 1994;45:1333-1339.

129. Pupilli C, Lanzillotti R, Ianni L, Fiorelli G, Selli C, Gomez RA, **Carey RM**, Serio M, Mannelli M. Dopamine D₂ receptor gene expression and binding sites in adrenal medulla and pheochromocytoma. *Journal of Clinical Endocrinology Metabolism*. 1994;79:56-61.
130. Siragy HM, Howell NL, Ragsdale NV, **Carey RM**. Anesthesia, epinephrine, sodium depletion and renin inhibition modulate renal interstitial angiotensin II. *Hypertension*. 1995;25:1021-1024.
131. O'Connell DP, Hannum DB, Ramos SP, Botkin SJ, Sibley DR, Ariano MA, Felder RA, **Carey RM**. Localization of the dopamine D_{1A} receptor in the rat kidney. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1995;268:F1185-F1197.
132. Ozono R, O'Connell DP, Vaughan CJ, Botkin SJ, Walk SF, Felder RA, **Carey RM**. Expression of the dopamine D_{1A} receptor in the rat heart. *Hypertension*. 1996;27:693-703.
133. Siragy HM, **Carey RM**. The subtype-2 (AT₂) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT₁ receptor-mediated prostaglandin E₂ production in conscious rats. *Journal of Clinical Investigation*. 1996;97:1978-1982. (**Rapid Publication; 297 citations; article accompanied by editorial**).
134. Siragy HM, Jaffa AA, Margolius HS, **Carey RM**. The renin-angiotensin system modulates renal bradykinin production. *American Journal of Physiology Regulatory, Integrative, Comparative Physiology*. 1996;271:R1090-R1095, 1996.
135. O'Connell DP, Ragsdale NV, Boyd DG, Felder RA, **Carey RM**. Differential human renal tubular responses to dopamine-1 receptor stimulation are determined by blood pressure status. *Hypertension*. 1997;29:115-122.
136. Wang ZQ, Siragy HM, Felder RA, **Carey RM**. Intrarenal dopamine production and distribution in the rat. *Hypertension*. 1997;29:228-234.
137. Yamaguchi I, Yao L, Sanada H, Mouradian MM, Jose PA, **Carey RM**, Felder RA. Dopamine D_{1A} receptors and renin release in rat juxtaglomerular cells. *Hypertension*. 1997;29:962-968.
138. Aherne AM, Vaughan CJ, **Carey RM**, O'Connell DP. Co-localization of dopamine D_{1A} receptor protein and messenger RNA in the rat adrenal cortex. *Endocrinology*. 1997;138:1282-1288.
139. Ozono R, Wang ZQ, Moore AF, Siragy HM, **Carey RM**. Expression of the subtype-2 (AT₂) angiotensin receptor protein in the rat kidney. *Hypertension*. 1997;30:1238-1246. (**301 citations**)
140. Ozono R, O'Connell DP, Moore AF, Wang ZQ, Sanada H, Felder RA, **Carey RM**. Localization of the dopamine D₁ receptor protein in the human heart and kidney. *Hypertension*. 1997;30:725-729.

141. Siragy HM, **Carey RM**. The subtype-2 (AT₂) angiotensin receptor mediates renal production of nitric oxide in conscious rats. *Journal of Clinical Investigation*. 1997;100:264-269. (**Rapid Publication; 497 citations**).
142. Siragy HM, **Carey RM**. The subtype 2 angiotensin receptor regulates renal prostaglandin F_{2α} formation in conscious rats. *American Journal of Physiology Regulatory, Integrative, Comparative Physiology*. 1997;273:R1103-R1107.
143. **Carey RM**, McGrath HE, Pentz ES, Gomez RA, Barrett PQ. Biomechanical coupling in renin releasing cells. *Journal of Clinical Investigation*. 1997;100:1566-1574.
144. Karginova EA, Pentz ES, Kazakova IG, Norwood VF, **Carey RM**, Gomez RA. ZISS: A developmentally regulated gene expressed in juxtaglomerular cells. *American Journal of Physiology Renal, Fluid and Electrolyte Physiology*. 1997;273:F731-F738.
145. Tufro-McReddie A, Norwood VF, Aylor KW, Botkin SJ, **Carey RM**, Gomez RA. Oxygen regulates vascular endothelial growth factor-mediated vasculogenesis and tubulogenesis. *Developmental Biology*. 1997;183:139-149.
146. O'Connell DP, Aherne A, Lane E, Felder RA, **Carey RM**. Detection of dopamine receptor subtype specific messenger RNA by in situ amplification. *American Journal of Physiology Renal, Fluid, Electrolyte Physiology*. 1998;274:F232-F241. (**Special Communication**).
147. Wang ZQ, Moore AF, Ozono R, Siragy HM, **Carey RM**. Immunolocalization of the subtype-2 angiotensin II (AT₂) receptor protein in rat heart. *Hypertension*. 1998;32:78-83.
148. Brismar H, Asghar M, **Carey RM**, Greengard P, Aperia A. Dopamine-induced recruitment of dopamine-1 receptors to the plasma membrane. *Proceedings of the National Academy of Sciences USA*. 1998;95:5573-5578.
149. **Carey RM**, Wang ZQ, Siragy HM, Felder RA. Renal dopamine production and release in the rat: a microdialysis study. *Advances in Pharmacology* 1998;42:873-876.
150. Jin X-H, Wang ZQ, Siragy HM, Guerrant RL, **Carey RM**. Regulation of jejunal fluid absorption by angiotensin subtype receptors in the rat: role of cyclic nucleotides and prostaglandin E₂. *American Journal of Physiology Regulatory, Integrative and Comparative Physiology*. 1998;275:R515-R523.
151. Asico LD, Ladines C, Fuchs S, Accili D, **Carey RM**, Felder RA, Eisner GM, Jose PA. Disruption of the dopamine D₃ receptor gene produces renin-dependent hypertension. *Journal of Clinical Investigation*. 1998;102:493-498.
152. O'Connell DP, Vaughan CJ, Aherne AM, Botkin SJ, Felder RA, **Carey RM**. Expression of the dopamine D₃ receptor protein in the rat kidney. *Hypertension*. 1998;32:886-895.
153. Fang K, Ragsdale NV, **Carey RM**, MacDonald T, Gaston B. Reductive assays for S-nitrosothiols: implications for measurements in biological systems. *Biochemical and*

Biophysical Research Communications. 1998;252:535-540.

154. Hilgers KF, Nagaraji SN, Karginova EA, Kazakova I, Chevalier RL, **Carey RM**, Pentz ES, Gomez RA. Molecular cloning of KS, a novel rat gene expressed exclusively in the kidney. *Kidney International*. 1998;54:1444-1454.
155. Wang ZQ, Millatt LJ, Heiderstat NT, Siragy HM, Johns RA, **Carey RM**. Differential regulation of renal angiotensin subtype AT_{1A} and AT₂ receptor protein in rats with angiotensin-dependent hypertension. *Hypertension*. 1999;33:96-101.
156. Sanada H, Jose PA, Hazen-Martin D, Yu P-Y, Xu J, Bruns DE, Phipps J, **Carey RM**, Felder RA. Dopamine-1 receptor defect in renal proximal tubular cells in essential hypertension. *Hypertension*. 1999;33:1036-1042.
157. Jin X-H, Siragy HM, Guerrant RL, **Carey RM**. Compartmentalization of extracellular guanosine cyclic 3', 5' monophosphate determines absorptive or secretory responses in the rat jejunum. *Journal of Clinical Investigation*. 1999;103:167-174.
158. Wang ZQ, Felder RA, **Carey RM**. Selective inhibition of the renal dopamine D_{1A} receptor induces antinatriuresis in conscious rats. *Hypertension*. 1999;33 (Part II):504-510.
159. Siragy HM, **Carey RM**. Protective role of the angiotensin AT₂ receptor in renal vascular hypertension in conscious rats. *Hypertension*. 1999;33:1237-1242. (**249 citations**)
160. Siragy HM, Senbonmatsu T, Ichiki T, Inagami T, **Carey RM**. Increased renal vasodilator prostanoids prevent hypertension in mice lacking the subtype-2 (AT₂) receptor. *Journal of Clinical Investigation*. 1999;104:181-188.
161. Siragy HM, Inagami T, Ichiki T, **Carey RM**. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT₂) angiotensin receptor. *Proceedings of the National Academy of Sciences USA*. 1999;96:6506-6510. (**322 citations**)
162. Tufro A, Norwood VF, **Carey RM**, Gomez RA. Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. *Journal of the American Society of Nephrology*. 1999;10:2125-2134.
163. Vaughan CJ, Aherne AM, Lane E, Power O, **Carey RM**, O'Connell DP. Identification and regional distribution of the dopamine D_{1A} receptor in the gastrointestinal tract. *American Journal of Physiology Regulatory, Integrative and Comparative Physiology*. 2000;279:R599-R609.
164. Siragy HM, deGasparo M, **Carey RM**. Angiotensin type 2 receptor mediates valsartan-induced hypotension. *Hypertension*. 2000;35:1074-1077.
165. Norwood VF, Garmey M, Wolford J, **Carey RM**, Gomez RA. Novel expression and regulation of the renin-angiotensin system (RAS) in metanephric organ culture-evidence of

an avascular RAS. *American Journal of Physiology Regulatory, Integrative and Comparative Physiology*. 2000;279: R522-R530.

166. Ozono R, Matsumoto T, Sasaki N, Shingu T, Oshima T, Teranishi Y, Kambe M, Matsuura H, Kajiyama G, Wang ZQ, Moore AF, **Carey RM**. Decreased type 2 and increased type 1 angiotensin receptor protein expression in left ventricular hypertrophy in spontaneously hypertensive rats. *American Journal of Physiology Regulatory, Integrative and Comparative Physiology*. 2000;278:R781-R789.
167. Matsumoto T, Ozono R, Sasaki N, Oshima T, Matsuura H, Kajiyama G, **Carey RM**, Kambe M. Type 1A dopamine receptor expression in the heart is not altered in spontaneously hypertensive rats. *American Journal of Hypertension*. 2000;13:673-677.
168. Xu J, Li XX, Abbrecht FE, Ladines C, Hopfer U, **Carey RM**, Jose PA. D₁ receptor, G_{Sα} and Na⁺/H⁺ exchanger interactions in the kidney in hypertension. *Hypertension*. 2000;36:395-399.
169. Moore AF, Heiderstadt NT, Huang E, Howell NL, Wang Z-Q, Siragy HM, **Carey RM**. Selective inhibition of the renal angiotensin type-2 (AT₂) receptor increases blood pressure in conscious rats. *Hypertension*. 2001;37:1285-1291.
170. Webbi GJ, Zimpelmann J, **Carey RM**, Levine DZ, Burns KD. Early streptozotocin-diabetes mellitus down regulates rat kidney AT₂ receptors. *American Journal of Physiology Renal Physiology*. 2001;280:F254-F265.
171. Siragy HM, deGasparo M, El-Kersh M, **Carey RM**. Angiotensin converting enzyme inhibition potentiates AT₂ receptor effects on renal bradykinin and cyclic guanosine 3', 5'-monophosphate. *Hypertension*. 2001;38:183-186.
172. Jin X-H, Siragy HM, **Carey RM**. Renal interstitial guanosine cycle 3', 5' monophosphate induces natriuresis by a direct tubule mechanism. *Hypertension*. 2001; 38:309-316.
173. Bonnet F, Cooper ME, **Carey RM**, Casley D, Cao Z. Vascular expression of the angiotensin type-2 receptor in the adult rat: infusion of angiotensin II. *Journal of Hypertension*. 2001;14:98S-102S.
174. **Carey RM**, Howell NL, Jin X-H, Siragy HM. Angiotensin type-2 (AT₂) receptor-mediated hypotension in type-1 (AT₁) receptor-blocked rats. *Hypertension*. 2001;38:1272-1277.
175. Okada H, Inoue T, Kanno Y, Kobayashi T, Watanabe Y, Kopp JB, **Carey RM**, Suzuki H. Interstitial fibroblast-like cells express renin-angiotensin system components in a fibrosing murine kidney. *American Journal of Pathology*. 2002;160:765-772.
176. Siragy HM, El-Kersh MA, deGasparo M, Webb RL, **Carey RM**. Differences in AT₂-receptor stimulation between the AT₁ receptor blockers valsartan and losartan quantified by renal interstitial fluid cyclic GMP. *Journal of Hypertension*. 2002 20:1157-1163.

177. Felder RA, Sanada H, Xu J, Yu, P-Y, Wang Z, Wang W, Yamaguchi I, Hazen-Martin, D, Wong L-JC, **Carey RM**, Jose PA. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. *Proceedings of the National Academy of Sciences USA*. 2002;97:3872-3877. (241 citations)
178. Bonnet F, Candido R, **Carey RM**, Casley D, Russo LM, Osicka TM, Cooper ME, Cao Z. Renal expression of angiotensin II receptors in long term diabetes and effects of angiotensin type-1 receptor blockade. *Journal of Hypertension*. 2002;20:1615-1624.
179. Yang Z, Bove CM, Epstein FH, French BA, Berr SS, DiMaria JM, Gibson JJ, **Carey RM**, Kramer CM. Angiotensin type-2 receptor overexpression preserves left ventricular function after myocardial infarction. *Circulation*. 2002;106:106-111.
180. Cao Z, Bonnett F, Candido R, Nesteroff SP, Burns WC, Kawachi H, Shimizu F, **Carey RM**, DeGasparo M, Cooper ME. Angiotensin type 2 receptor antagonism confers renal protection in a model of progressive renal injury. *Journal of the American Society of Nephrology*. 2002;13:1773-1787.
181. Abadir P, **Carey RM**, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2 receptor-null mice. *Hypertension*. 2003;42:600-604.
182. Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, **Carey RM**, Johns RA. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. *Circulation*. 2003;108:1493-1498.
183. Korshunov VA, Massett MP, **Carey RM**, Berk BC. Role of angiotensin converting enzyme and neutral endopeptidase in flow-dependent remodeling. *Journal of Vascular Research*. 2004; 41:148-156.
184. Sasaki S, Siragy HM, Gildea JJ, Felder RA, **Carey RM**. Production and role of extracellular guanosine cyclic 3',5'-monophosphate in sodium uptake in human proximal tubule cells. *Hypertension*. 2004;43:286-291.
185. Jin X-H, McGrath HE, Gildea JJ, Siragy HM, Felder RA, **Carey RM**. Renal interstitial guanosine cyclic 3', 5'-monophosphate mediates pressure-natriuresis via protein kinase G. *Hypertension*. 2004;43:1133-1139.
186. Bove CM, Yang Z, Gilson WD, Epstein FH, French BA, Berr SS, Bishop SP, Matsubara H, **Carey RM**, Kramer CM. Nitric oxide mediates benefits of angiotensin II type 2 receptor overexpression during post-infarction remodeling. *Hypertension*. 2004;43:680-685.
187. Awad AS, Webb RL, **Carey RM**, Siragy HM. Renal nitric oxide production is decreased in diabetic rats and improved by AT₁ receptor blockade. *Journal of Hypertension*. 2004;22:1571-1577.
188. Awad AS, Webb RL, **Carey RM**, Siragy HM. Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats. *American Journal of Hypertension*.

2005;18:544-548.

189. Siragy HM, Xue C, Abadir P, **Carey RM**. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. *Hypertension*. 2005; 45:133-137.
190. Alcantara CS, Jin X-H, Brito GAC, Carneiro-Filho BA, Barrett LJ, **Carey RM**, Guerrant RL. Angiotensin II subtype-1 receptor blockade inhibits *Clostridium difficile* toxin-A-induced intestinal secretion in a rabbit model. *The Journal of Infectious Diseases*. 2005;191: 2090-2096.
191. Voros S, Yang Z, Bove CM, Gilson WD, Epstein FH, French BA, Berr SS, Bishop SP, Conway M, Matsubara H, **Carey RM**, Kramer CM. The interaction between the AT₁ and AT₂ receptors during post-infarction left ventricular remodeling. *American Journal of Physiology: Heart and Circulatory Physiology*. 2006;290:H1004-H1010.
192. Bek MJ, Wang X, Ascico L, Jones JE, Zheng S, Li XX, Eisner GM, Grandy DK, **Carey RM**, Soares-da-Silva P, Jose PA. Angiotensin type 1 receptor-mediated hypertension in D₄ receptor deficient mice. *Hypertension*. 2006;47:288-295.
193. Padia SH, Howell NL, Siragy HM, **Carey RM**. Renal AT₂ receptors mediate natriuresis via angiotensin III in the AT₁ receptor blocked rat. *Hypertension*. 2006;47 [part 2]: 537-544.
194. Abadir PM, Periasamy A, **Carey RM**, Siragy HM. Angiotensin II AT₂ receptor-bradykinin B₂ receptor functional heterodimerization. *Hypertension*. 2006;48:316-322.
195. Yao J, Davies LA, Howard JD, Adney SK, Welsby PJ, Howell NL, **Carey RM**, Colbran RJ, Barrett PQ. Molecular basis for the modulation of native T-type Ca⁺⁺ channels *in vivo* by Ca⁺⁺/calmodulin-dependent protein kinase II. *Journal of Clinical Investigation*. 2006;116:2403-2412.
196. Salomone L, Howell NL, McGrath HE, Kemp BA, Keller SR, Gildea JJ, Felder RA, **Carey RM**. Intrarenal dopamine D₁-like receptor stimulation induces natriuresis via an angiotensin AT₂ receptor mechanism. *Hypertension*. 2007;49:155-161.
197. Padia SH, Kemp BA, Howell NL, Siragy HM, Fournie-Zaluski M-C, Roques BP, **Carey RM**. Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in AT₁ receptor-blocked rats. *Hypertension*. 2007;49:625-630.
198. Siragy HM, Inagami T, **Carey RM**. NO and cGMP mediate angiotensin AT₂ receptor-induced renin inhibition in young rats. *American Journal of Physiology Renal Physiology*. 2007;293:R1461-R1467.
199. Ahmed F, Kemp BA, Howell NL, Siragy HM, **Carey RM**. Extracellular renal guanosine cyclic 3',5'-monophosphate modulates nitric oxide- and pressure-induced natriuresis. *Hypertension*. 2007;50:958-963.
200. Isbell D, Voros S, Yang Z, Berr S, French B, Epstein F, Bishop S, Wang H, Roy R, Kemp

- BA, Matsubara H, **Carey RM**, Kramer C. Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling. *American Journal of Physiology Heart Circulatory Physiology*. 2007;293:H3372-H3378.
201. Hu C, Dandapat A, Chen J, Liu Y, Hermonat PL, **Carey RM**, Mehta JL. Over-expression of angiotensin II type2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. *Atherosclerosis*. 2008;199:288-294.
202. Dandapat A, Hu CP, Chen J, Liu Y, Khan JA, Remeo F, **Carey RM**, Hermonat PL, Mehta JL. Over-expression of angiotensin type 2 receptor (agtr) decreases collagen accumulation in atherosclerotic plaque. *Biochemical and Biophysical Research Communications*. 2008;366:871-877.
203. Padia SH, Kemp BA, Howell NL, Fournie-Zaluski M-C, Roques BP, **Carey RM**. Conversion of renal angiotensin II to angiotensin III is critical for angiotensin type-2 receptor mediated natriuresis in rats. *Hypertension*. 2008;51:460-465.
204. Davies, LA, Hu C, Guagliardo NA, Sen N, Chen X, Talley EM, **Carey RM**, Bayliss DA, Barrett PQ. TASK channel deletion in mice causes primary hyperaldosteronism. *Proceedings of the National Academy of Sciences USA*. 2008;105:2203-2208.
205. Park J, Kemp BA, Howell NL, Gildea JJ, Keller SR, **Carey RM**. An intact microtubulin network is required for natriuretic response to nitric oxide and increased renal perfusion pressure in the rat. *Hypertension*. 2008;51:494-499.
206. Padia SH, Kemp BA, Howell NL, Gildea JJ, Keller SR, **Carey RM**. Intrarenal angiotensin III infusion induces natriuresis and AT₂ receptor translocation in WKY but not in SHR. *Hypertension*. 2009;53 [part 2]:338-343. **Article featured on the front cover of the journal.**
207. Lieb DC, Kemp BA, Howell NL, Gildea JJ, **Carey RM**. Reinforcing feedback loop of renal cyclic GMP and interstitial hydrostatic pressure in pressure natriuresis. *Hypertension*. 2009;54:1278-83.
208. Chai W, Wang W, Liu J, Barrett EJ, **Carey RM**, Cao W, Liu Z. Angiotensin AT₁ and AT₂ Receptors regulate skeletal muscle microvascular volume and glucose utilization. *Hypertension*. 2010; 55:523-530,
209. Padia SH, Howell NL, Kemp BA, Fournie-Zaluski M-C, Roques BP, **Carey RM**. Intrarenal aminopeptidase N inhibition restores defective angiotensin AT₂ receptor-mediated natriuresis in SHR. *Hypertension*. 2010;55:474-480.
210. Gildea JJ, Kemp BA, Howell NL, Van Sciver RE, **Carey RM**, Felder RA. Inhibition of renal caveolin-1 reduces natriuresis and produces hypertension in sodium-loaded rats. *American Journal of Physiology Renal Physiology*. 2011;300:F914-F920.

211. Padia SH, Kemp BA, Howell NL, Keller SR, Gildea JJ, **Carey RM**. Mechanisms of dopamine D₁ and angiotensin AT₂ receptor interaction in natriuresis. *Hypertension*. 2012;59:437-445. **Article featured on front cover of the journal.**
212. Abadir PM, Walston JD, **Carey RM**, Siragy HM. Angiotensin II type-2 receptors modulate inflammation through STAT3 phosphorylation and TNF α production. *Journal of Interferon and Cytokine Research*. 2011;31:471-474.
213. Nascimento NRF, Kemp BA, Howell NL, Gildea JJ, Santos CF, Harris TE, **Carey RM**. Role of Src-family kinase in extracellular renal cyclic GMP-induced natriuresis and pressure-natriuresis. *Hypertension*. 2011;58:107-113.
214. Abadir PM, Foster DB, Crow MT, Cooke CA, Rucker J, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, **Carey RM**, O'Rourke B, Walston JD. Identification and characterization of a functional mitochondrial angiotensin system. *Proceedings of the National Academy of Sciences USA*. 2011;108:14849-14854.
215. Reardon MA, Angle JF, Abi-Jaoudeh N, Bruns DE, Haverstick DM, Matsumoto AH, **Carey RM**. Intra-procedural cortisol levels in the evaluation of proper catheter placement in adrenal venous sampling. *Journal of Vascular and Interventional Radiology*. 2011;22:1175-1180.
216. Jehle AB, Xu Y, DiMaria JM, French BA, Epstein FH, Berr SS, Roy RJ, Kemp BA, **Carey RM**, Kramer CM. Selective non-peptide angiotensin type 2 receptor agonism does not attenuate post-myocardial infarction left ventricular remodeling in mice. *Journal of Cardiovascular Pharmacology*. 2012;59:363-368.
217. Kemp BA, Bell JF, Rottkamp DM, Howell NL, Navar LG, Padia SH, **Carey RM**. Intrarenal angiotensin III is the predominant agonist for proximal tubule AT₂ receptors. *Hypertension*. 2012;60:387-395.
218. Wagner F, Malice M-P, Wiegert E, McGrath HE, Mitta S, Van Dyck K, De Lepeleire I, Johnson-Levonas AO, Sisk CM, Fernandez R, Greenwalt D, Beals C, McLeod J, **Carey RM**, Nunes I. A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive human subjects. *Journal of Hypertension*. 2012; 30:819-827.
219. Guagliardo NA, Yao J, Schertz E, Tyson D, **Carey RM**, Bayliss DA, Barrett PQ. TASK-3 channel deletion in mice recapitulates low rennin essential hypertension. *Hypertension*. 2012;59:999-1005.
220. Gildea JJ, Shah N, Tran H, Spinosa M, Van Sciver R, Sasaki M, Yatabe J, **Carey RM**, Jose PA, Felder RA. Dopamine and angiotensin receptors cooperatively inhibit sodium transport in human renal proximal tubule cells. *Hypertension*. 2012;60:396-403.
221. **Carey RM**, Schoeffel CD, Gildea JJ, Jones JE, McGrath HE, Sobota R, Gordon LN, Park MJ, Underwood, PC, Williams J, Sun B, Raby B, Lasky-Su J, Hopkins PN, Adler

- GK, Williams SM, Jose PA, Felder RA. Salt-sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbonate co-transporter. *Hypertension*. 2012;60:1359-1366.
222. Bailey AP, Schutt AK, **Carey RM**, Angle JF, Modesitt SC. Hyperandrogenism of ovarian origin: etiology utilizing differential venous sampling for diagnosis. *Obstetrics & Gynecology*. 2012;120(2Pt 2Suppl 1):476-479.
223. Felder RA, Gildea JJ, Lahiff DT, Weiss RS, Shah N, McGrath HE, Schoeffel CD, VanSciver RE, Jose PA, **Carey RM**. A linear relationship between the ex-vivo sodium mediated expression of two sodium regulatory pathways as a surrogate marker of salt-sensitivity of blood pressure in exfoliated human renal proximal tubule cells: the virtual renal biopsy. *Clin Clim Acta*. 2013; 421:236-242.
224. Gildea JJ, Carlson JM, Schoeffel CD, **Carey RM**, Felder RA. Urinary exosome miRNome analysis and its application to salt-sensitivity of blood pressure. *Clinical Biochemistry*. 2013;46:1131-1134.
225. Cechova S, Zeng Q, Billaud M, Mutchler S, Rudy CK, Straub AC, Chi L, Chan FR, Hu J, Griffiths R, Howell NL, Madsen K, Jensen B, Palmer LA, **Carey RM**, Sung SJ, Malakauskas SM, Isakson BE, Le TH. Loss of collectrin, an ACE2 homologue, uncouples endothelial nitric oxide synthase and causes hypertension and vascular dysfunction. *Circulation*. 2013; 128:1770-1780.
226. Shada A, Stokes JB, Simpson GB, Turrentine BE, **Carey RM**, Hanks JB, Padia SH, Smith PW. Adrenalectomy for adrenal-mediated hypertension: national surgical quality improvement program analysis of an institutional experience. *The American Surgeon*. 2014;80:1152-1158.
227. Kemp BA, Howell NL, Keller SR, Gildea JJ, Padia SH, **Carey RM**. AT₂ receptor activation induces natriuresis by increasing renal cyclic GMP production and proximal tubule sodium transporter internalization. *Circulation Research*. 2014;115:388-399.
228. Fu Z, Zhao L, Aylor KW, **Carey RM**, Barrett EJ, Liu Z. Angiotensin (1-7) recruits muscle microvasculature and enhances insulin's metabolic action via endothelial mas receptor. *Hypertension* 2014; 63:1219-1227.
229. Gildea JJ, Xu P, Carlson JM, Gaglione RT, Wang DB, Kemp BA, Reyes CM, McGrath HE, **Carey RM**, Jose PA, Felder RA. The sodium-bicarbonate cotransporter NBCe2 (SLC4A5) expressed in human renal proximal tubules shows increased apical expression under high salt conditions. *American Journal of Physiology Regulatory, Integrative and Comparative Physiology*. 2015;309:R1447-R1459.

230. Natarajan AR, Eisner GM, Armando I, Browning S, Pezullo JC, Rhee L, Dajani M, **Carey RM**, Jose PA. The renin-angiotensin renal dopaminergic systems interact in normotensive humans. *Journal of the American Society of Nephrology*. 2016;27:265-279.
231. Kemp BA, Howell NL, Keller SR, Gildea JJ, Padia SH, **Carey RM**. AT₂ receptor activation prevents sodium retention and reduces blood pressure in angiotensin II-dependent hypertension. *Circulation Research*. 2016; 119:532-543. Research Highlight in *Nature Reviews/Nephrology* by Andrea Aguilar; Faculty 1000 citation; **article featured on front cover of the journal**.
232. Manichaikul A, Rich SS, Allison MA, Guagliardo NA, Bayliss DA, Carey RM, Barrett PQ. *KCNK3* variants are associated with hyperaldosteronism and hypertension. *Hypertension*. 2016; ePub ahead of print
233. Gasparetto A, Angle JF, Darvishi P, Freeman CW, Norby RG, **Carey RM**. Clinical impact of strict criteria for selectivity and lateralization in adrenal vein sampling. *Hormones (Athens)*. 2016;15:264-270.
234. Yuan A, Yan F, Wang N, Aylor KW, **Carey RM**, Zhou X, Chen L, Liu Z. Direct activation of angiotensin II type-2 receptors enhances microvascular perfusion, oxygenation and insulin uptake in muscle. *Endocrinology*. 2017; (submitted for publication).
235. Gildea JJ, Xu P, Carlson JM, Tran HT, Wang DB, Kemp BA, Langouet-Astrie CJ, McGrath HE, **Carey RM**, Jose PA, Felder RA. Gene variants in sodium bicarbonate cotransporter NBCe2 increase sodium and bicarbonate transport in human renal proximal tubule. *PLoS One*. 2017; (submitted)
236. Chu P-L, Gigliotti JC, Chechova S, Bodonyi-Kovacs G, Chan F, Ralph DL, Howell N, Kalantari K, Klibanov AL, **Carey RM**, McDonough AA, Le TH. Renal collectrin protects against salt-sensitive hypertension and is downregulated by angiotensin II. *J Am Soc Nephrol*. 2017;28:
237. Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WFJr Gomez-Sanchez CE, Funder JW, Reincke M for the **PRIMARY ALDOSTERONISM SURGERY OUTCOME (PASO) investigators (Carey RM, Study Participant)**. *Lancet Endocrinol Diabetol*. 2017; pii: S2213-8587(17)30135-3. doi: 10.1016/S2213-8587(17)30135-3. [Epub ahead of print]
238. Gildea JJ, Van Sciver RE, McGrath HE, Kemp BA, Jose PA, **Carey RM**, Felder RA. Dopaminergic immunofluorescence studies in kidney tissue. *Methods Mol Biol*. 2017;1527:151-161.

239. Li J, Kemp BA, Howell NL, Chordia M, Roy J, Patrie JT, Davogustto G, Epstein F, **Carey RM**, Taegtmeier H, Keller SR, Kundu BK. Cardiac metabolic remodeling precedes structural remodeling in spontaneously hypertensive rats. *Circ Research*. Submitted.

II. ORIGINAL PEER REVIEWED PUBLICATIONS ON MEDICAL EDUCATION

1. Martin J, **Carey RM**. Evaluation of clinical teaching: a student-initiated, faculty-assisted system of clerkship evaluation and modification. *Academic Medicine*. 1991;66:773-775.
2. **Carey RM**, Wheby MS, Reynolds RE. Faculty clinical excellence in the academic health center. *Academic Medicine*. 1993;68:813-817.
3. **Carey RM**, Engelhard CL. Academic medicine meets managed care: a high-impact collision. *Academic Medicine*. 1996;71:839-845.
4. Rein MF, Randolph WJ, Short JG, Coolidge KG, Coates ML, **Carey RM**. Defining the cost of medical education. *Academic Medicine*. 1997;72:218-227.
5. Fang WL, Woode MKA, **Carey RM**, Apprey M, Schuyler JM, Atkins-Brady TL. Effective strategies for increasing minority representation in medicine: The Medical Academic Advancement Program at the University of Virginia School of Medicine. *Academic Medicine*. 1999;74:366-369.
6. **Carey RM**. "Spacetime" and the academic and clinical missions of medical schools. *Transactions of the American Clinical and Climatological Association*. 2003;114: 1-35.

III. REVIEWS, INVITED PAPERS, EDITORIALS, CLINICAL PRACTICE GUIDELINES AND SCIENTIFIC STATEMENTS

1. Schweikert JR, **Carey RM**. Evaluation of renin activity. *New England Journal of Medicine*. 1971;284: 54..
2. Liddle GW, **Carey RM**, Douglas JG. Role of the adrenal cortex in the pathogenesis of essential hypertension with suppressed renin, *In Endocrinology, Proceedings of the Fourth International Congress of Endocrinology, International Congress Series No. 273, Exerpta Medica, Amsterdam, pp. 752-756, 1972.*
3. **Carey RM**. Idiopathic edema, Medical Grand Rounds of the Department of Medicine, University of Virginia Medical Center, *Virginia Medical Monthly*. 1974;101: 961-974.
4. Curnow RT, **Carey RM**, Taylor A, Johanson A, Murad F. Depression of serum insulin by somatostatin, *New England Journal of Medicine*. 1975; 293: 723.

5. **Carey RM**, Ayers CR. Labile hypertension-Precursor of sustained essential hypertension?, *American Journal of Medicine*. 1977;61: 811-814.
6. Curnow RT, **Carey RM**, Taylor AM, Johanson AJ, Murad F. Inhibition of follicle stimulating hormone release by somatostatin, *Southern Medical Journal*. 1977;70: 781.
7. **Carey RM**, Owen JA, Tompkins WF, Pohl SL, Russell RG, Newman GC, Paulsen EP, Lomax CW. Standards of quality care of diabetic patients in office and hospital practice, *Virginia Medical Monthly*. 1978;105: 195-218.
8. **Carey RM**. New drugs for blockading the renin-angiotensin system, Medical Grand Rounds of the Department of Medicine, University of Virginia Medical Center, *Virginia Medical Monthly*. 1979; 106: 809-818..
9. **Carey RM**, Levens NR, Peach MJ. Studies of the functional role of the intrarenal renin-angiotensin system, *In Progress in Biochemical Pharmacology*, S. Karger AG Medical and Scientific Publishers, Basel, 1980, pp. 6-13.
10. Wilson TA, **Carey RM**. Low-renin essential hypertension: diminution of aldosterone suppression, *In Frontiers in Hypertension Research*, J.H. Laragh, F.R. Buhler and D.W. Seldin, eds., Springer-Verlag, New York, 1981, pp 199-203.
11. Levens NR, Peach MJ, **Carey RM**. Role of the intrarenal renin-angiotensin system in the control of renal function, *Circulation Research*. 1981;48: 157-167. **(216 citations)**
12. **Carey RM**. Screening for surgically correctable hypertension due to primary aldosteronism. *Archives of Internal Medicine*. 1981;141:1594..
13. New MI, Oberfield SE, **Carey RM**, Grieg F, Ulick S, Levine LS. A genetic defect in cortisol metabolism as the basis for the syndrome of apparent mineralocorticoid excess, *In Endocrinology of Hypertension* (F. Mantero, E.G. Biglieri and C.R.W. Edwards, eds), Proceedings of the Sero Symposia, V.50 Academic Press, London, pp. 85-101, 1982.
14. **Carey RM**, Levens NR, Peach MJ. Regulation of intestinal fluid transport by angiotensin II: mechanisms and physiological significance, *Transactions of the American Clinical and Climatological Association*. 1984;96:93-104.
15. 1984-Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure, *Archives of Internal Medicine*. 1984;144:1045-1057. (**Carey RM**, Writing Committee member).
16. **Carey RM**, Bright GM, Schambelan M, Biglieri EG. Acquired primary hypoaldosteronism due to an isolated zona glomerulosa defect. *New England Journal of Medicine*. 1984;310:1394-1395.
17. **Carey RM**, Drake CR. Dopamine selectively inhibits aldosterone responses to angiotensin II in man. *Journal of Hypertension*. 1984;2 (Suppl 3):267-269, 1984.

18. Dolan LM, Malchoff CD, Sen S, **Carey RM**, (Introduced by Edward W. Hook). Aldosterone stimulating factor is increased in idiopathic hyperaldosteronism, *Transactions of the Association of American Physicians*. 1984;407:10-18.
19. Ibrahim M, Chobanian AV, Horan M, Rocella EJ, **Carey RM**, Drizd TA, Haines CM, Labarthe DR, Payne G, Thom T. Hypertension prevalence and the status of awareness, treatment and control in the United States: Final Report of the Subcommittee on Definition and Prevalence of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure, 1984.
20. Labarthe DR, Blaufox MD, **Carey RM**, Gifford RW Jr, Kirkendall WM, Moser RH, Smith WM, Viteri FE. Recommendations for a revised approach to defining high blood pressure: final report of the Working Group of the National High Blood Pressure Coordinating Committee. *Hypertension*. 1985;7:457-468.
21. **Carey RM**. Dopaminergic control of aldosterone secretion in man: physiologic and possible pathophysiologic significance. *In The Adrenal Gland and Hypertension*, E.G. Biglieri, F. Mantero, J.W. Funder and B.A. Scoggins, eds., Raven Press, N.Y., PP 55-66, 1985.
22. Gomez RA, Chevalier RL, Sturgill B, Peach MJ, **Carey RM**. Maturation of intrarenal renin distribution in Wistar-Kyoto rats. *Journal of Hypertension*. 1986;4(Suppl 5):531-544.
23. Hughes J, Beck T, Peach MJ, **Carey RM**. Selective peripheral dopamine-1 (DA-1) receptor stimulation produces natriuresis. *Journal of Hypertension*. 1986;4(Suppl 6):5106-5108.
24. Atuk NO, Turner S, **Carey RM**, Ayers CR. Induced uptake and accumulation of catecholamines by red blood cells in pheochromocytoma. *Journal of Hypertension*. 1986;4(Suppl 5):558-560.
25. **Carey RM**, Sen S. Aldosterone stimulating factor: physiologic and pathophysiologic importance. *Recent Progress in Hormone Research*. 1986;42:251-296.
26. Siragy HM, **Carey RM**. Management of primary aldosteronism. *Drug Therapy*. 1986;16:89-103.
27. **Carey RM**. Volume control and adrenal responsiveness to angiotensin in normal and hypertensive patients. *Journal of Cardiovascular Pharmacology*. 1986;8 (Suppl. I):535.
28. Siragy HM, **Carey RM**. Intrarenal angiotensin II influences renal function by a direct renal tubular action. *Journal of Hypertension*. 1987;4(Suppl 6):560-565..
29. Hughes J, **Carey RM**. Selective dopamine-1 (DA-1) receptor stimulation in man produces natriuresis and diuresis. *Journal of Hypertension*. 1987;4(Suppl 6):5106-5108.
30. **Carey RM**, Hughes JM. Selective dopamine-1 receptor stimulation. *Clinical and Experimental Hypertension*. 1987;A9:1009-1020.

31. **Carey RM**, Malchoff CD, Hughes JM. Regulation of aldosterone secretion: studies of the effect of upright posture. *In* Corticosteroids and Polypeptide Hormones in Hypertension. F. Mantero, and P. Vesci, eds. Serono Symposia Publications, V. 39, Raven Press, NY, pp 103-113, 1987.
32. Rose CE Jr, Althaus JS, Kaiser DL, Miller DD, **Carey RM**. Plasma catecholamines during hypoxemia and hypercapnia: A reply, *American Journal of Physiology*. 1987;247:H341-H342. (letter).
33. **Carey RM**, Rose CE Jr, Peach MJ. Role of the renin-angiotensin-aldosterone system in stress. *Stress: Neurochemical and Humoral Mechanisms*. Ed. by G.R. Van Loon, R. Kvetnansky, R. McCarty and J. Axelrod, Gordon and Breach Science Publications, New York, pp. 833-844, 1989.
34. **Carey RM**. Dopamine and aldosterone secretion. *In* The Peripheral Dopaminergic System: Its Role in Cardiovascular Homeostasis. M. Manelli, ed., Serono Symposia Review No. 15, Ares-Serono, Rome, 1988, pp 53-64.
35. **Carey RM**. Angiotensin as a paracrine substance in the kidney. *In* Cell to Cell Communication in Endocrinology. S. Rosetti, ed., Serono Symposia Publication, 1988.
36. Ice K, Geary KM, Gomez RA, Johns DW, Peach MJ, **Carey RM**. Cell and molecular studies of renin secretion. *Clinical and Experimental Hypertension*. 1988;A10:1169-1187.
37. Siragy HM, Felder RA, Howell NL, Chevalier RL, Peach MJ, **Carey RM**. Dopamine acts as a paracrine substance in the control of renal function. *Transactions of the Association of American Physicians*. 1988;C1:288-291.
38. **Carey RM**, Peach MJ, Siragy HM. Renin-angiotensin mediated cell-to-cell interaction in the kidney. *In* The Adrenal and Hypertension: from Cloning to Clinic. F. Montero, et al., Serno Symposia Publications from Raven Press, NY, 1989, pp. 303-312.
39. Siragy HM, Felder RA, Howell NE, Chevalier RL, Peach MJ, **Carey RM**. Intrarenal dopamine acts at the dopamine-1 (DA-1) receptor to control renal function. *Journal of Hypertension*. 1988; 6:S479-S481.
40. Pepper SJ, Reed HL, **Carey RM**, Lewis SB. Hormonal and hemodynamic effects of heat and cold tolerance tests before and after multiple cold air exposures. *Naval Medical Institute Technical Report*, 1988.
41. Siragy HM, Howell NL, Peach MJ, **Carey RM**. Combined intrarenal renin-angiotensin blockade increases renal function and is reversed by angiotensin II. *Journal of Hypertension*. 1989;7 (Suppl 6): S174-S175.
42. **Carey RM**, Siragy HM, Ragsdale NV, Howell NL, Chevalier RL, Peach MJ, Felder RA. Dopamine-1 (DA-1) and dopamine-2 (DA-2) mechanisms in the control of renal function.

American Journal of Hypertension. 1990;3:595-635.

43. Purdy-Ramos SI, Van Niel EE, Forbes MS, **Carey RM**. Use of conventional embedment procedures for post-embedding immunocytochemistry of secretory proteins. Proceedings of the 47th Annual Meeting of the Electron Microscopy Society of America (ed. G.W. Bailey), 1989, pp. 1052-53.
44. **Carey RM**, Felder RA, Siragy HM. Physiological modulation of renal function by the renal dopaminergic system. *Journal of Autonomic Pharmacology*. 1990;10:S47-S51.
45. Gomez RA, Chevalier RL, **Carey RM**, Peach MJ. Molecular biology of the renin-angiotensin system. *Kidney International*. 1990;38(Suppl. 30): S-18-S-23.
46. Jose, P.A., Raymond, J.R., Bates, M.D., Aperia, A., Felder, R.A. and **Carey, R.M.** The renal dopamine receptors. *Journal of the American Society of Nephrology*. 1992;2:1265-1278.
47. Macho L, Kvetnansky R, Fickova M, Jezova D, Lichardus B, **Carey RM**. Circulating levels of catecholamines, aldosterone, atrial natriuretic peptide and plasma renin activity during immobilization stress in rats. *In Stress: Neuroendocrine and Molecular Approaches*, volume 1. R. Kvetnansky, R. McCarty and J. Axelrod, editors. Gordon and Breech Science Publishers, New York, 1992, pp. 187-195.
48. **Carey RM**. In Memoriam: Michael J. Peach, Ph.D. (1940-1992). *Newsletter of the Council for High Blood Pressure Research*, American Heart Association 1(2):12, 1992.
49. **Carey RM**. In Memoriam: Michael J. Peach 1940-1992. *Hypertension*. 1992;20:264.
50. Felder RA, Yamaguchi I, Horiuchi A, Jose PA, **Carey RM**. A molecular approach to the study of renal dopamine receptors in hypertension. *In Cardiovascular and Renal Actions of Dopamine* (P. Soares-Da-Silva, ed.) *Advances in the Biosciences* 88:155-164, 1993
51. Lanzilotti R, Pupilli C, Ianni L, Fiorelli G, **Carey RM**, Manelli M. Presence of dopamine DA₂ binding sites in pheochromocytoma. *In Cardiovascular and Renal Actions of Dopamine* (P. Soares-Da-Silva, ed.) *Advances in the Biosciences*. 1993;88:175-182.
52. Jose PA, Eisner GM, Drago J, **Carey RM**, Felder RA. Dopamine receptor signaling defects in spontaneous hypertension. *American Journal of Hypertension*. 1996;9:400-405.
53. **Carey RM**. Institutions and health. *In 2020 Vision: Health in the 21st Century*, National Academy Press, Washington, D.C., 1996, pp. 74-80.
54. Wang ZQ, Siragy HM, Felder RA, **Carey RM**. Preferential release of renal dopamine into the tubule lumen. *Clinical and Experimental Hypertension*. 1997;19:107-116.
55. **Carey RM**. The Changing Clinical Spectrum of Adrenal Insufficiency. *Annals of Internal Medicine* 1997;127:1103-1105.

56. Sanada H, Yao L, Jose PA, **Carey RM**, Felder RA. Dopamine D₃ receptors in rat juxtaglomerular cells. *Clinical and Experimental Hypertension*. 1997;19:93-105.
57. Ray PE, McCune BK, Geary KM, **Carey RM**, Klotman PE, Gomez RA. Modulation of renin release and renal vascular smooth muscle contractility by TGF-B₂. *In Contributions in Nephrology* (G.M. Berlyne, ed.), S. Karger, Basel, vol. 118, pp. 238-248, 1996.
58. **Carey RM**, Wang ZQ, Siragy HM, Felder RA. Renal dopamine production and release in the rat: a microdialysis study. *In Catecholamines: Bridging Basic Science with Clinical Medicine* (D.S. Goldstein, G. Eisenhofer and R. McCarty, eds.) Academic Press, San Diego, 1998, pp. 873-876.
59. *Report of the AAMC Task Force on Medical School Financing*, The Financing of Medical Schools (David Korn, Chair; **RM Carey**, member), Association of American Medical Colleges, Washington, D.C., 1996.
60. *NCCR: A Catalyst for discovery*. A plan for the National Center for Research Resources 1998-2003. (**R.M. Carey**, Co-moderator and Participant), NCCR, 1998.
61. Berecek KH, **Carey RM**. Adrenergic and dopaminergic receptors and actions. *In Hypertension Primer: The essentials of high blood pressure*. Izzo, J.L. and Black, H.R., editors. American Heart Association, Dallas, 1999, pp. 3-6.
62. **Carey RM**, Wang ZQ, Siragy HM. Novel actions of angiotensin II at its renal type-2 (AT₂) receptor. *Current Hypertension Reports*. Hypertension: Kidney, Sodium and the Renin-Angiotensin System (**Carey RM** and Weinburger MH, eds), *Current Science*, Philadelphia, 1999, pp. 151-157.
63. **Carey RM**. Invited Commentary: Angiotensin receptors and the kidney. *Current Science*, Philadelphia, 1999, pp. 117.
64. **Carey RM**, Siragy HM, Jin X-H, Wang ZQ. Nitric oxide: A physiologic mediator of the type-2 (AT₂) receptor. *Acta Physiologica Scandinavica*. 2000;168: 65-71.
65. **Carey RM**, Wang ZQ, Siragy HM. Role of the angiotensin type-2 (AT₂) receptor in the regulation of blood pressure and renal function. *Hypertension*. 2000;35 [Part 2]: 155-163. **(390 citations)**
66. **Carey RM**, Wang ZQ, Siragy HM. Update: Role of the AT₂ receptor in blood pressure regulation. *Current Hypertension Reports*. 2000;2:198-201..
67. Siragy HM, **Carey RM**. Prospective trials of angiotensin receptor blockers. *Current Hypertension Reports*. 2000;2:163-164.
68. Siragy HM and **Carey RM**. Angiotensin type 2 (AT₂) receptors: potential importance in blood pressure regulation. *Current Opinion in Nephrology and Hypertension*.

2001;10:99-103.

69. **Carey RM**, Jin X-H, Siragy HM. Role of the angiotensin AT₂ receptor in blood pressure regulation and the therapeutic implications. *American Journal of Hypertension*. 2001;14: 985-1025.
70. **Carey RM**. The Theodore Cooper Lecture: The renal dopamine system-paracrine regulator of sodium homeostasis and blood pressure. *Hypertension*. 2001;38: 297-302
71. **Carey RM**, Howell NL, Jin XH, Siragy HM. AT₂ receptor-mediated hypotension. *Hypertension*. 2001 (letter).
72. Berecek KH, **Carey RM**. Adrenergic and dopaminergic receptors and actions. *In: Hypertension Primer: the essentials of high blood pressure, 3rd Edition*. Izzo J, Black HR, eds. American Heart Association, Dallas, 2003.
73. **Carey RM**, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. *Trends in Endocrinology and Metabolism*. 2003;14:274-281.
74. **Carey RM**, Siragy HM. Newly recognized components of the renin-angiotensin system: potential role in cardiovascular and renal regulation. *Endocrine Reviews*. 2003;24:261-271. **(576 citations)**
75. **Carey RM**, Logan AG. Mineralocorticoid receptor blockade in hypertensive patients during ACE inhibition: effects on left ventricular mass. *Current Hypertension Reports*. 2004;6:113-114.
76. Patlak M, **Carey RM** (Scientific Advisor). From viper's venom to drug design: treating hypertension. *Breakthroughs in Bioscience*, FASEB, 2003.
77. **Carey RM**. Angiotensin type-1 receptor blockade increases ACE-2 expression in the heart. *Hypertension*. 2004;43:943-944.
78. **Carey RM**, Prendergast F and the NCRR Strategic Planning forum. *NCRR: A catalyst for discovery, 2004-2008 Strategic Plan: Challenges and critical choices*. US Department of Health and Human Services document. 2004.
79. **Carey RM**, Logan AG. Acute candesartan cilexetil therapy in stroke survivors. *Current Hypertension Reports*. 2004;6:114-116.
80. Giacchetti G, Sechi LA, Rilli S, **Carey RM**. The renin-angiotensin system, glucose metabolism and diabetes. *Trends in Endocrinology and Metabolism*. 2005;16:120-126 **(222 citations)**.
81. **Carey RM**. Update in the role of the AT₂ receptor. *Current Opinion in Nephrology and Hypertension*. 2005;14:67-71.

82. **Carey RM.** Cardiovascular regulation by the angiotensin type-2 (AT₂) receptor: The AT₂ receptor comes of age. *Hypertension*. 2005;45:840-844.
83. **Carey RM**, Siragy HM. Role of AT₂ receptor in cardiovascular function: a brief synopsis. Basic Science for the Cardiologist, Kluwer Academic Publishers, 2005.
84. **Carey RM.** Angiotensin type-2 (AT₂) receptors and cardiovascular function: Are AT₂ receptors protective? *Current Opinion in Cardiology*. 2005;20: 264-269,
85. **Carey RM.** ACE inhibitors in patients with vascular disease: Should the PEACE Trial change medical practice? *Current Hypertension Reports*. 2005;7:120-126..
86. **Carey RM.** Should we employ combination ACEI and ARB therapy in primary hypertension? *Current Hypertension Reports*. 2006;8:111-102.
87. Report of Task Force II on Clinical Research of the Association of American Medical Colleges. Promoting Translational and Clinical Science: The Critical Role of Medical Schools and Teaching Hospitals. Association of American Medical Colleges, Washington, DC, 2006.
88. **Carey RM**, Park J. Role of angiotensin type 2 receptors in vasodilation of resistance and capacitance vessels. *Hypertension*. 2006;48:824-825..
89. **Carey RM.** Phosphodiesterase type V: a novel therapeutic target for hypertension. *Current Hypertension Reports*. 2007;9:119-120..
90. **Carey RM.** Angiotensin receptors and aging. *Hypertension*. 2007;50:33-34
91. Berecek KH, **Carey RM.** Adrenergic and dopaminergic receptors and actions. *In: Hypertension Primer: the essentials of high blood pressure, 4th Edition.* Izzo J, Sicca DA, Black HR, eds. American Heart Association, Dallas, 2008.
92. **Carey RM**, Padia SH. Angiotensin AT₂ receptors: control of renal sodium excretion and blood pressure. *Trends in Endocrinology and Metabolism*. 2008;19:84-87.
93. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, **Carey RM.** Resistant hypertension: diagnosis, evaluation and treatment. A Scientific Statement of the American Heart Association. *Hypertension*. 2008;51:1403-19 and *Circulation*. 2008;117:e510-26. **(2,300 citations)**
94. Funder JW, **Carey RM**, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM. Case detection, diagnosis and treatment of patients with primary aldosteronism: An Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology and Metabolism*. 2008;93:3266-3281. **(1,436 citations)**
95. **Carey RM.** Primary aldosteronism. *Hormone Research*. 2009;71(Suppl 1):8-12.

96. **Carey RM.** INVESTing in hypertension. *Current Hypertension Reports.* 2010;12:53-55.
97. **Carey RM.** Are kidneys not ischemic in human renal vascular disease? *Hypertension.* 2010; 55:474-480, 2010.
98. **Carey RM.** Aldosterone and cardiovascular disease. *Current Opinion in Endocrinology, Diabetes and Obesity.* 2010;17:194-198.
99. Siragy HM, **Carey RM.** The role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. *Journal of the American Society of Nephrology.* 2010;31:541-550.
100. **Carey RM.** How much blood pressure control is beneficial in patients with hypertensive kidney disease? *Current Hypertension Reports.* 2011;13:93-95.
101. **Carey RM.** Overview of endocrine systems in primary hypertension. *Endocrinology and Metabolism Clinics of North America.* 2011;40:265-277.
102. **Carey RM.** Angiotensin AT₂ receptors: control of renal sodium excretion and blood pressure. In *Hormonal and Genetic Basis of Sexual Differentiation Disorders and Hot Topics in Endocrinology.* Maria I. New and Joe Leigh Simposn, Eds. *Advances in Experimental Medicine and Biology 707,* Springer, New York, pp.115-118, 2011.
103. **Carey RM.** Adrenal disease update 2011. *Journal of Clinical Endocrinology and Metabolism.* 2011; 96:3583-3591.
104. **Carey RM.** Double-barreled assault: aldosterone and salt in the heart. *Journal of Clinical Endocrinology and Metabolism..* 2011;96:2714-2716.
105. **Carey RM.** Functional intracellular renin-angiotensin systems: potential for pathophysiology of disease. *American Journal of Physiology Regulatory Integrative and Comparative Physiology.* 2012;302:R479-R481.
106. **Carey RM.** Role of K⁺ channels in the pathophysiology of primary aldosteronism. *Hypertension.* 2012;59:534-536, 2012.
107. **Carey RM.** Primary aldosteronism. *Journal of Surgical Oncology.* 2012;106:575-579.
108. Padia SH, **Carey RM.** AT₂ receptors: beneficial counter-regulatory role in cardiovascular and renal function. *Pflugers Archives.* 2013;465:99-110.
109. Abidir, PM, **Carey RM.** Subcellular characteristics of functional intracellular renin-angiotensin systems. *Peptides.* 2012;38:437-445.

110. **Carey RM.** Excellence Award in Hypertension Research. The intrarenal renin-angiotensin and dopaminergic systems: control of sodium excretion and blood pressure. *Hypertension*. 2013;61:673-680.
111. **Carey RM.** Best papers in *Hypertension*: resistant hypertension. *Hypertension*. 2013;61:746-750.
112. **Carey RM.** Role of angiotensin AT₂ receptors in natriuresis: intrarenal mechanisms and therapeutic potential. *Clinical and Experimental Pharmacology and Physiology*. 2013;40:527-534.
113. **Carey RM.** Newly discovered components and actions of the renin-angiotensin system. *Hypertension*. 2013;62:818-822.
114. **Carey RM.** Citation for the 2013 Fred Conrad Koch Award of The Endocrine Society to Dr. Michael O. Thorner. *Endocrinology*. 2013;154:2965-66 and *Endocrine Reviews*. 2013;34:599-600.
115. **Carey RM.** Role of the intrarenal renin-angiotensin system in hypertension. *Advances in Chronic Kidney Diseases*. 2015;22:204-210.
116. Kemp BA, Howell NL, Gildea JJ, Keller SR, Padia SH, **Carey RM.** Response to letter regarding article: "AT₂ receptor activation induces natriuresis and lowers blood pressure". *Circulation Research*. 2014;115:e26-7.
117. Funder JW, **Carey RM**, Mantero F, Reincke M, Hirotaka S, Stowasser M, Young WF Jr. The management of primary aldosteronism: case detection, diagnosis and treatment. An Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology and Metabolism*. 2016; 101:1889-1916,
119. **Carey RM.** Diagnosing and managing primary aldosteronism in hypertensive patients: a case-based approach. *Current Cardiology Reports*. 2016; (accepted for publication)
120. **Carey RM.** AT₂ receptors: potential therapeutic targets for hypertension. *American Journal of Hypertension*. 2016; (accepted for publication)
121. **Carey RM.** Salt sensitivity of blood pressure. Available in: American Heart Association Learning Library http://my.americanheart.org/professional/General_UCM_432539_Article.jsp . Posted April, 2016.
122. **Carey RM.** Hormones and Your Heart: What You Need To Know. Hormone Health Network, the Endocrine Society; <http://hormone.org>.
123. **Carey RM.** Viewpoints: Quantifying Scientific Merit: Is it time to transform impact factor? *Circulation Research*. 2016; 119:1273-1275

124. **Carey RM.** Update on the angiotensin AT₂ receptor. *Current Opinion in Nephrology and Hypertension*. 2016;
125. **Carey RM.** Blood pressure and renal actions of AT₂ receptors. *Current Hypertension Reports*. 2017;19:21. doi: 10.1007/s11906-017-0720-7
126. Whelton PK, **Carey RM**, Aronow WS, Casey DE, Collins KJ, Dennison-Himmelfarb C, DePalma SM, Gidding S, Goff DC Jr, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner PK, Ovbiable B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. A guideline for the prevention, detection, evaluation and management of high blood pressure. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2017; (in preparation)
127. **Carey RM**, Calhoun D, Bakris G, Brook RD, Daugherty S, Dennison-Himmelfarb C, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan T, White WB. Resistant hypertension: detection, evaluation and management. A Scientific Statement of the American Heart Association. *Hypertension*. 2018; (in preparation)
128. Muntner P, Shimbo D, **Carey RM**, Charleston J, Gaillard T, Meyers MG, Misra S, Ogedegbe G, Schwartz JE, Townsend RR, Urbina EM, Viera AJ, White WB, Wright JR. Measurement of blood pressure in humans. A Scientific Statement of the American Heart Association. *Hypertension*. 2017; (in preparation)
129. **Carey RM.** New intermediate phenotype of resistant hypertension. *Hypertension*. 2017; 69:789-790

V. PAPERS RELATED TO THE UNIVERSITY OF VIRGINIA

1. **Carey RM.** Medicine as a career. *UVA Medical Examiner* 1:5, 1986.
2. **Carey RM.** Medical education: more than a little learning. *Helix*, January, 1987.
3. **Carey RM.** Medical Education - The Dean's View. *Albemarle County Medical Society Newsletter*, December, 1992.
4. **Carey RM.** How much does it cost to educate a doctor these days? *Capitol Forum* 2:1, pp. 15 and 20, 1993.
5. Morse RM, **Carey RM.** Update on Generalist Medicine. *Albemarle Medical News* 3:7, 1994.
6. **Carey RM.** The present and future of biomedical research. *UVA Medical Alumnews* 3:2-3,

1994.

7. **Carey RM.** Visits offer opportunities for alumni involvement. *UVA Medical AlumNews* 3:11, 1994.
8. **Carey RM.** Cost accountability and reward for teaching: medical education under pressure. *Albemarle Medical News* 3:2-3, 1995.
9. **Carey RM.** Cost accountability and reward for teaching: medical education under pressure. *UVA MedAlum News* 4:6-7, 1995.
10. **Carey RM.** In medical education, teaching's place must be assured. Op-Ed piece, *The Daily Progress*, April 9, 1995, p. A9.
11. **Carey RM.** Managed care presents difficult challenges for medical education. *UVA Medical Alumnews* 4:18-19, 1995.
12. **Carey RM.** A tribute to Kenneth R. Crispell, M.D. *UVA MedAlumnews*, 1996.
13. **Carey RM.** History of the University of Virginia School of Medicine: Selected Milestones. *UVA MedAlumNews*, 1997.
14. **Carey RM.** *In Memoriam: Robert J. Roberts, M.D.* *UVA MedAlumNews*, 1997.
15. **Carey RM.** Tribute to Gerald D. Aurbach, M.D., *UVA MedAlumNews*, 1997.
16. **Carey RM.** William H. Muller, Jr., pioneer cardiovascular surgeon, wins the Walter Reed Distinguished Leadership Award. *UVA MedAlumNews*, 1997.
17. **Carey RM.** Memorial: Kenneth R. Crispell. *Transactions of the American Clinical and Climatological Association* 109: xliii, 1998.
18. **Carey RM.** Tribute to Dr. Thomas H. Hunter: Master Scientist and Educator 1913-1997. *UVA MedAlumNews* 7:1, 1998.
19. **Carey RM.** Rethinking old paradigms: from self-sufficiency to interconnectedness--The School of Medicine and International Health. *UVA MedAlumNews* 7:2, 1998.
20. **Carey RM.** Our School of Medicine at the turn of the century. *UVA MedAlumNews* 8:2-4, 1999.
21. **Carey RM.** Dr. Edward W. Hook, Jr. *UVA MedAlumNews* 8:19-20, 1999.
22. **Carey RM.** Memorial: Edward W. Hook, Jr. *Transactions of the American Clinical and Climatological Association* 111:, 2000.
23. **Carey RM.** A call to action: choosing our future research goals for the School of Medicine

2000-2005. *UVA Med Alum News* 9:7, 2000.

24. **Carey RM.** Memorial: Oscar A. Thorup, Jr. *Transactions of the American Clinical and Climatological Association* 114: 55-57, 2003.
25. **Carey RM.** Dr. Sharon L. Hostler: Pioneer of developmental pediatrics and champion of professionalism in the School of Medicine. *UVA Med Alum News*, 2003.
26. **Carey RM.** Dr. Benjamin C. Sturgill *In Memorium*. *UVA Med Alum News*, 2004.

VI. CHAPTERS IN BOOKS

1. **Carey RM.** Neuroendocrine regulation of the renin-angiotensin- aldosterone system, *In Neuroendocrine Perspectives*, E.E. Muller and R.M. MacLeod, eds., Elsevier/North Holland Biomedical Press, Amsterdam, 1982, Vol 1, pp 253-303.
2. **Carey R.M.** Experimental neurogenic hypertension: a critical review, *In Hypertension and the Brain* (T.A. Kotchen and G.P. Guthrie, eds), Futura Publications, New York, 1984, pp. 281-305.
3. **Carey RM.** Dopamine mechanisms in the control of aldosterone secretion: a critical appraisal, *In Dopamine Receptor Agonists* (G. Poste and S.T. Crooke, eds.), Academic Press, 1984, pp. 317-332.
4. **Carey RM, Kotchen TA.** Neuroendocrine control of the renin-angiotensin system, aldosterone and blood pressure. *In Clinical Neuroendocrinology* (R. Collu, G.M. Brown and G.R. Van Loon, eds.), Year Book Medical Publishers, 1988, pp 352-366.
5. **Carey RM, Sen S.** Aldosterone stimulating factor: a new aldosterone secretagogue. *In Frontiers in Neuroendocrinology* (W.F. Ganong and L. Martini, eds.), Raven Press, 1986, pp. 191-204.
6. Reckler JM, Vaughan ED Jr, Amberson JB, Kazam E, Tjeuw M, **Carey RM.** Pheochromocytoma. *In Urologic Endocrinology* (J. Rajfer, ed.), W.B. Saunders Co., Philadelphia, 86-105, 1986.
7. Howards SS, **Carey RM.** The Adrenals. *In Adult and Pediatric Urology* (J. Rajfer, ed.) Yearbook Medical Publishers, Chicago, 1987.
8. **Carey RM.** Dopaminergic control of aldosterone secretion. *In Cardiovascular Function of Peripheral Dopamine Receptors* (J.P. Hieble, ed.), Marcel Dekker, New York, 1990, pp. 297-314.
9. Dolan LM, **Carey RM.** Adrenal cortical and medullary function: diagnostic tests, *In Adrenal Disorders*, Thieme Medical Publisher Inc., New York, 1989, pp. 81-145.

10. May ME, Vaughan ED Jr, **Carey RM**. Adrenocortical insufficiency-clinical aspects, In Adrenal Disorders, Thieme-Medical Publishers, Inc., New York, 1989. pp. 171-189.
11. Siragy HM, Vaughan ED Jr, **Carey RM**. Cushing's syndrome, In Adrenal Disorders, Thieme Medical Publishers, Inc., New York, 1989, pp. 147-169.
12. Vaughan ED Jr, Atlas S, **Carey RM**. Primary aldosteronism, In Adrenal Disorders, Thieme Medical Publishers Inc., New York, 1989, pp. 243-258.
13. Vaughan ED Jr, **Carey RM**. Adrenal carcinoma, In Adrenal Disorders, Thieme Medical Publishers, Inc., New York 1989.
14. Reckler JM, Vaughan ED Jr, Tjeuw M, **Carey RM**. Pheochromocytoma. In Adrenal Disorders, Thieme Medical Publishers Inc., New York, 1989, pp. 259-273.
15. Felder RA, **Carey RM**. Role of dopamine in cardiovascular regulation. In Brain Peptides and Catecholamines in Cardiovascular Regulation in Normal and Disease States (C. Ferrario and J.P. Buckley, eds.), Raven Press, New York, 1987, pp. 79-81.
16. Siragy HM, **Carey RM**. Biomedical Tests: Disorders of Aldosterone Metabolism. In: Functional Endocrine Pathology, edited by K. Kovacs and S. Asa, Blackwell Scientific Publications Inc., Boston, 1990, pp. 50-52.
17. Howards SS, **Carey RM**. The Adrenals, In Adult and Pediatric Urology, (J.Y. Gillenwater, J.T. Grayhack, S.S. Howards and J.W. Duckett, Eds.), Mosby Yearbook Publishers, St. Louis, 1991, pp. 523-543.
18. **Carey RM**. Sudden onset of polyuria and polydipsia. In Applied Laboratory Medicine (N.W. Tietz, R.B. Conn and E.L. Pruden, eds.) W.B. Saunders Company, Philadelphia, 1992, pp. 155-160.
19. **Carey RM**, Siragy HM. Pathogenesis: Sodium, the Kidney and the Renin-Angiotensin System. In Atlas of Heart Diseases; Hypertension: Mechanisms and Treatment. Edited by Norman Hollenberg and Eugene Braunwald, Current Medicine, Philadelphia, 1994, pp. 3.1-3.16.
20. **Carey RM**. Dopamine, hypertension and the potential for agonist therapy. In Hypertension: Pathophysiology, Diagnosis, Treatment. Edited by John H. Laragh and Barry M. Brenner. Raven Press, New York, 1994, pp. 2937-2952.
21. **Carey RM**, Laragh JH. Carmoxirole. In Cardiovascular Drug Therapy. Edited by Franz H. Messerli. W.B. Saunders Co., Philadelphia, 1996, pp. 1189-1194.
22. Siragy HM, **Carey RM**. Disorders of Aldosterone Secretion. In Functional Endocrine Pathology, edited by K. Kovacs and S. Asa, Blackwell Scientific Publications Inc., Boston, 1996.

23. Malchoff CD, **Carey RM**. Adrenal Insufficiency. *In* Current Therapy in Endocrinology and Metabolism (Sixth edition). Edited by C.W. Bardin. Mosby Inc., 1997.
24. **Carey RM**, Siragy HM. Pathogenesis: Sodium, the Kidney and the Renin-Angiotensin System. *In* Atlas of Heart Diseases; Hypertension: Mechanisms and Treatment. Edited by Norman Hollenberg and Eugene Braunwald, Current Medicine, Philadelphia, 1998, pp. 3.0-3.17.
25. **Carey RM**. Immunocytochemical detection. *In* *Angiotensin Protocols, Methods in Molecular Medicine*, Humana Press, Inc, Totowa, NJ, 1999.
26. **Carey RM**, Siragy HM. Hypertension: Kidney, Sodium and the Renin-Angiotensin System. *In: Atlas of Heart Diseases; Hypertension: Mechanisms and Treatment*. Edited by Norman Hollenberg and Eugene Braunwald, Current Medicine, Philadelphia, 2001, pp.59-79.
27. Liu Z, Siragy HM, **Carey RM**. Diagnostic tests of adrenal cortical and medullary function. *In: Renal and Adrenal Tumors: Biology and Management*. Edited by Beldegrun A, Ritchie AWS, Figlin RA, Oliver T and Vaughan ED, Jr., Oxford University Press. 2003, pp. 486-529.
28. **Carey RM**. Dopamine mechanisms in the kidney. *In: Primer on the Autonomic Nervous System* (Robertson, D., Low, P.A., Burnstock, G., Biaggioni, I., eds.) 2nd Edition. Academic Press, 2003.
29. **Carey RM**. Interactions of the intrarenal renin-angiotensin and dopaminergic systems. *In: Gomez RA, The Juxtaglomerular Apparatus. Advances in Organ Biology. Elsevier Publishers, Inc. 2003.*
30. Siragy HM and **Carey RM**. The angiotensin AT₂ receptor. *In* *Hypertension*; 2nd Edition; S. Oparil and M. Weber, eds. Elsevier Inc, Burlington, MA; 2005.
31. **Carey RM**, Felder RA, Jose PA. The renal dopamine system: paracrine regulator of salt-sensitivity and blood pressure. *In: Molecular Mechanisms of Hypertension*. Re R, Schiffrin EL, Sowers JR, DiPette D, eds. Taylor & Francis, New York. 2006. pp 351-360.
32. **Carey RM**. The angiotensin type-2 (AT₂) receptor in cardiovascular and renal regulation. *In: Molecular Mechanisms of Hypertension*, R Re, EL Schiffrin, J Sowers, D DiPette, eds. Taylor & Francis, New York. 2006. pp 41-50.
33. **Carey RM**. Hypertension. *In: Handbook of Physiology: The Microcirculation*. American Physiological Society, Oxford Press, 2008.
34. **Carey RM**. The renin-angiotensin system in the pathophysiology of essential hypertension. *In: Comprehensive Hypertension*, G Y H Lip and J E Hall, eds. Mosby, Inc., Philadelphia, 2007, pp.299-316.
35. **Carey RM**, Siragy HM. Angiotensin AT₂ receptors in blood pressure regulation. *In: Hypertension and Hormone Mechanisms*, R M Carey, ed. Humana Press, Totowa, NJ,

2007, pp.75-90.

36. Felder RA, **Carey RM**, Jose PA. The renal dopaminergic system, hypertension and salt sensitivity. In: *Hypertension and Hormone Mechanisms*, R M Carey, ed. Humana Press, Totowa, NJ, 2007, pp. 159-174.
37. **Carey RM**, Padia SH. Physiology and regulation of the renin-angiotensin-aldosterone system. In: *Textbook of Nephroendocrinology*, A Singh and GH Williams, eds. Elsevier Press 2009.
38. **Carey RM**, Padia SH. Primary mineralocorticoid excess syndromes and hypertension. In: *Endocrinology*, Sixth Edition. JL Jameson and L J DeGroot, eds. W B Saunders Company, Philadelphia, 2010.
39. **Carey RM**, Padia SH, Gildea JJ, Keller SR. Role of renal aminopeptidases and angiotensin type-2 (AT₂) receptors in sodium excretion and hypertension. In: *The Local Cardiac Renin-Angiotensin-Aldosterone System*, ED Frohlich and R RE, eds. Springer Science, 2009.
40. **Carey RM**. AT₁ receptors, angiotensin receptor blockade and clinical hypertensive disease. In: *Renin-Angiotensin System and Cardiovascular Disease*, WC Demello and ED Frohlich, eds., pp 59-79, Contemporary Cardiology, Humana Press, 2009.
41. **Carey RM**, Padia SH. Primary mineralocorticoid excess disorders and hypertension. In: *Endocrinology*, Sixth Edition. JL Jameson and L J DeGroot, eds. W B Saunders Company, Philadelphia, 2014.
42. **Carey RM**. AT₂ receptors and natriuresis. In: Protective Arm of the Renin-Angiotensin System. UM Steckelings, RAS Santos and T Unger, eds. Elsevier Publishers. 2015
43. **Carey RM**, Padia SH. Physiology and regulation of the renin-angiotensin-aldosterone system. In: *Textbook of Nephroendocrinology* Second Edition, A Singh and GH Williams, eds. Elsevier Press 2016

VII. **BOOKS**

1. *Essential Hypertension: An Endocrine Disease*, edited by **RM Carey** and CRW Edwards, Butterworth Publications, London 1985.
2. *Adrenal Disorders*, by **RM Carey** and ED Vaughan Jr. Thieme Medical Publishers Inc., New York, 1989.
3. *Thomas Jefferson's Legacy to Health: A Pictorial Compendium*. Photographs by Robert Llewellyn. Introduction and research by **Robert M. Carey**.
4. *Hypertension and Hormone Mechanisms*, edited by **RM Carey**, Humana Press, Totown, NJ, 2007. **Received a score of 96/100 in Doody's Reviews.**

VII. Blogs

1. **Carey RM.** Hormones Play Key Role in Heart Health. Endocrine Society Centennial Blog Post American Heart Association, 2016.

IX. SYMPOSIA

1. The peripheral dopaminergic system, edited by RA Felder and **RM Carey.** *American Journal of Hypertension*, supplement, 1990.
2. Workshop on Hypertension and the Insulin Resistance Syndrome, Council for High Blood Pressure Research, American Heart Association, 2003.

X. INVITED/ STATE -OF-THE ART LECTURES

1. Carey RM. Dopamine agonists and aldosterone regulation. Presented at the First Annual Smith Kline and French Laboratories International Research Symposium, Philadelphia, 1983.
2. **Carey RM.** Control of aldosterone secretion: clinical and experimental studies. Presented at the Interinstitute Endocrine Grand Rounds, National Institutes of Health , Bethesda, 1983.
3. **Carey RM.** Dopaminergic modulation of aldosterone secretion. Presented at the satellite meeting of the International Society of Hypertension, Hypertension and the Adrenal Gland, Padova, Italy, 1984.
4. **Carey RM,** and (by invitation) Levens NR, Peach MJ. Regulation of intestinal fluid transport by angiotensin II: mechanisms and physiological significance. Presented at the 96th Annual Meeting of the American Clinical and Climatological Association, Bermuda, 1983.
5. **Carey RM.** Dopaminergic control of aldosterone secretion in man: Physiological and possible pathophysiological significance. Presented at a Satellite Symposium of the International Society for Hypertension, Hypertension and the Adrenal Gland, Padua, Italy, 1984.
6. **Carey RM.** Paracrine action of angiotensin II on renal function. Presented at the Symposium on Hormones, Blood Pressure and the Kidney, 3rd Joint Meeting of British Endocrine Societies, Edinburgh, Scotland, 1984.
7. **Carey RM.** Control of aldosterone secretion: new mechanisms and relevance to essential hypertension. Presented to the Research Division, Cleveland Clinic Foundation, Cleveland,

1984.

8. **Carey RM.** New mechanisms of control of aldosterone secretion and relevance to hypertension in man. Presented at the Interinstitute Endocrine Grand Rounds, National Institutes of Health, Bethesda, 1984.
9. **Carey RM.** Aldosterone stimulating factor is increased in idiopathic hyperaldosteronism. Presented at the Eighth Searle Aldosterone Conference, Montreal, Canada, 1984.
10. **Carey RM.** Control of aldosterone secretion in primary aldosteronism and essential hypertension: role of aldosterone stimulating factor. The 15th Annual Edward Rose Lecture, University of Pennsylvania School of Medicine, Philadelphia, 1984.
11. **Carey RM.** Overview of the Regulation of Renin Secretion. Presented at the Gordon Conference on Angiotensin, Oxnard, California, 1985.
12. **Carey RM, Sen S.** Aldosterone stimulating factor: physiologic and pathophysiologic importance. Presented at the Laurentian Hormone Conference, Banff, Canada, 1985.
13. **Carey RM.** Aldosterone stimulating factor: physiologic and pathophysiologic significance. Presented at the Symposium on New Peptide Hormones, Annual Meeting of the Endocrine Society, Baltimore, 1985.
14. **Carey RM.** Aldosterone stimulating factor. Presented at the Second Joint Meeting of Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology, Baltimore, 1985.
15. **Carey RM.** Escape from the sodium retaining action of angiotensins II and III. Presented at the 11th Annual Aldosterone Conference, Baltimore, 1985.
16. **Carey RM.** Volume control and renal and adrenal responsiveness to angiotensin in essential hypertension-implications for treatment with converting enzyme inhibitors. Presented at a symposium on converting enzyme inhibition in hypertension and congestive heart failure, Rotterdam, Netherlands, 1985.
17. **Carey RM.** Aldosterone stimulating factor. Presented at the International Society of Nephrology, New Orleans, 1985.
18. **Carey RM.** Dopamine in cardiovascular regulation. Presented at the Symposium on Neuropeptides in Cardiovascular Regulation, University of Houston, 1986.
19. **Carey RM.** Central regulation of aldosterone secretion, Presented at the Sero Symposium, "Corticosteroids and Peptides in Hypertension", Heidelberg, Germany, 1986.
20. **Carey RM.** Experimental mineralocorticoid hypertension, Presented as a Symposium Lecture at the Seventh International Congress on Hormonal Steroids, Madrid, Spain, 1986.

21. **Carey RM.** Dopaminergic control of blood pressure in man: renal, adrenal and vascular mechanisms. Presented at a Satellite Symposium of the 11th Scientific Meeting of the International Society of Hypertension: Dopaminergic Systems in Hypertension, Gent, Belgium, 1986.
22. **Carey RM.** Control of renin secretion in isolated juxtaglomerular cells. Presented at the Angiotensin Gordon Research Conference, Santa Barbara, 1987.
23. **Carey RM.** Role of the renin-angiotensin-aldosterone system in stress. Presented at the Fourth Symposium on Catecholamines and Other Neurotransmitters in Stress, Smolenice Castle, Czechoslovakia, 1987.
24. **Carey RM.** Angiotensin as a paracrine substance in the control of renal function. Presented at a Sero Symposium on Cell to Cell Communication in Endocrinology, Florence, Italy, 1987.
25. **Carey RM.** Dopamine and aldosterone secretion, Presented at a Sero Minicourse on Dopaminergic Systems in Cardiovascular Disease, Florence, Italy, 1987.
26. **Carey RM.** Cell and molecular studies of renin secretion. Presented at a satellite symposium of the International Society of Hypertension, New Aspects of Renin Research, Kyoto, Japan, 1988.
27. **Carey RM.** Renin biosynthesis and secretion from single juxtaglomerular cells. Presented at the Annual Gordon Conference on Angiotensin, Oxnard, California, 1989.
28. **Carey RM.** Dopaminergic control of renal function, Satellite Symposium of the Meeting of the International Society of Hypertension, Montreal, 1990.
29. **Carey RM.** Dopaminergic control of renal function. Presented at the Plenary Symposium on Dopamine and the Kidney, Annual Meeting of the American Society of Nephrology, Washington, 1990.
30. **Carey RM.** The renal dopaminergic system physiologically modulates renal function. Presented at the symposium, "Significance of the Peripheral Dopaminergic System in Cardiovascular and Renal Function", Essen, Germany, 1990.
31. **Carey RM.** Techniques in renal cell biology. Presented at the Workshop on Development of Cell Lines for Hypertension Research, National Institutes of Health, Bethesda, 1991.
32. **Carey RM.** Cell and Molecular Studies of Renal Dopamine Receptors, 4th International Conference on Peripheral Dopamine, Porto, Portugal, 1992.
33. **Carey RM.** Dopaminergic control of renal function. Presented at the FASEB Summer Conference on Renal Hemodynamics: Interactions with Endothelial and Epithelial Systems, Saxton's River, Vermont, 1992.

34. **Carey RM.** Genetics and molecular mechanisms of hypertension. Presented as a Plenary Lecture at the First Pan-Arab Hypertension Conference, Cairo, 1993.
35. **Carey RM.** Endocrine hypertension. Presented as a Meet-the-Expert Session at the First Pan-Arab Hypertension Conference, Cairo, 1993.
36. **Carey RM.** Controversies in hypertension: Genetics of hypertension. Presented at the first annual symposium of the Consortium of Southeast Hypertension Centers, Asheville, 1994.
37. **Carey RM.** The problem of hypertension in America. First Robert D. Bonner Distinguished Leadership Lecture, Hampton University, 1994.
38. **Carey RM.** The intrarenal renin-angiotensin system: cell biology to fractional significance. Presented at The Renin-Angiotensin System: Toward the 21st Century: a symposium honoring William F. Ganong, M.D., University of California San Francisco, 1994.
39. **Carey RM, O'Connell DP, Felder RA.** Renal dopaminergic mechanisms in salt-sensitive hypertension in man. Presented at the 5th International Conference on Peripheral Dopamine, Kyoto, Japan, 1994.
40. **Carey RM.** The changing clinical spectrum of adrenal insufficiency. Presented at the Clinical Symposium on Adrenal Insufficiency; Annual Meeting of The Endocrine Society, Washington DC, 1995.
41. **Carey RM.** The Changing Clinical Spectrum of Adrenal Insufficiency. Presented at the Symposium on the Adrenal Gland, The Endocrine Society Annual Meeting, Washington, DC, 1995.
42. **Carey RM.** Paracrine Mechanisms of Angiotensin Action. Presented at the Satellite Symposium, Tissue Effects of Angiotensin II and Implications of AT₁ Receptor Blockade, The Endocrine Society Annual Meeting, Washington, DC, 1995.
43. **Carey RM.** Does renal dopamine regulate sodium excretion physiologically? Presented at the 6th International Conference on Peripheral Dopamine, Camerino, Italy, 1996.
44. **Carey RM.** Genetics and hypertension. Presented at the Third Annual Meeting of the Consortium of Southeastern Hypertension Centers, Raleigh, N.C., 1996.
45. **Carey RM.** The role of the angiotensin AT₂ receptor in the control of renal function. Presented at Hypertension Research Day, University of Tennessee College of Medicine, Memphis, 1996.
46. **Carey RM.** AT₂ receptors and intrarenal nitric oxide production. Presented at the Angiotensin Gordon Research Conference, Oxnard, CA, 1998.
47. **Carey RM.** Role of the AT₂ receptor in renal function and blood pressure regulation. Presented at the FASEB Summer Research Conference on Renal Hemodynamics:

Integration of Endothelial, Epithelial and Vascular Control Mechanisms, Saxton's River, Vermont, 1998.

48. **Carey RM.** What is the physiologic role of the AT₂ receptor? Presented at the Fourteenth Scientific Meeting of the American Society of Hypertension, New York, 1999.
49. **Carey RM.** The AT₂ angiotensin receptor mediates a bradykinin-nitric oxide cascade. Acta Physiologica Scandanavica Symposium, Uppsala, Sweden, 1999.
50. **Carey RM.** Role of angiotensin AT₂ receptors in the regulation of blood pressure and kidney function. State- of-the Art Lecture, Council for High Blood Pressure Research, Orlando, FL, 1999.
51. **Carey RM.** The Type-2 Angiotensin Receptor: New Insights on Blood Pressure Regulation. Presented at the Tenth Annual UAB Vascular Biology and Hypertension Symposium, Sandestin, FL, 1999.
52. **Carey RM.** Role of the AT₂ receptor in hypertension. Featured Speaker, Annual Meeting of the American Physiological Society, San Diego, CA 2000.
53. **Carey RM.** Role of the angiotensin AT₂ receptor in blood pressure regulation and therapeutic implications. The Jackson Cardiovascular Meeting-2000. Jackson, MS, 2000.
54. **Carey RM.** Richard Underwood Memorial Visiting Lecture, Harvard Medical School, Boston, MA 2000.
55. **Carey RM.** Distinguished Lecturer, Hypertension Research Center, University of Medicine and Dentistry of New Jersey, Newark, NJ.
56. **Carey RM.** Intrarenal angiotensin II and AT₂ receptors. Role of Intrarenal Angiotensin II in the Pathophysiology of Hypertension. Satellite Symposium of the International Society of Hypertension, Chicago, 2000.
57. **Carey RM.** The physiological significance of the AT₂ receptor. Joint Congress of the American Physiological Society/Scandinavian Physiological Society, Stockholm, 2000.
58. **Carey RM.** Peripheral dopamine in the regulation of blood pressure and renal function. The Theodore Cooper Lecture, Hypertension, New Orleans, 2001.
59. **Carey RM.** Role of the AT₂ receptor. Second Annual Diovan Cardiovascular Summit, Montreal, 2002.
60. **Carey RM.** State-of-the-Art Lecture: The angiotensin AT₂ receptor. Inter-American Society of Hypertension, San Antonio, 2003.
61. **Carey RM.** Symposium Lecture: The angiotensin AT₂ receptor. Annual Meeting of Endocrine Society, Philadelphia, 2003.

62. **Carey RM.** The renin-angiotensin-aldosterone system: from basic science to clinical medicine. Annual meeting of the Society of Endocrinology, Charlotte, 2003.
63. **Carey RM.** Keynote address: The AT₂ receptor. Special Cardiovascular Conference, University of Tokyo, Japan, 2003.
64. **Carey RM.** Hormonal control of pressure-natriuresis. University of Hiroshima, Hiroshima, Japan, 2003.
65. **Carey, RM.** Treatment of hypertension: blockade of the renin-angiotensin system. Yokohama, Japan, 2003.
66. **Carey RM.** The AT₂ receptor. Presentation celebrating the 10th anniversary of the Hypertension Center at Wake Forest University School of Medicine, 2003.
67. **Carey RM.** The renin-angiotensin-aldosterone system and glucose metabolism. First International Meeting on Endocrine Hypertension. Ancona, Italy, 2004.
68. **Carey RM.** The angiotensin AT₂ receptor in cardiovascular and renal function. Vth International Symposium on Vasoactive Peptides, Ouro Preto, Brazil, 2004.
69. **Carey RM.** Role of the AT₂ receptor in control of renal function. 2004 FASEB Summer Research Conference: Renal Microcirculatory and Tubule Dynamics: Molecules to Man, Callaway Gardens, GA, 2004.
70. **Carey RM.** The renin-angiotensin system. Takeda Pharmaceuticals North America, Inc. Diabetes and Endocrinology Advisory Board, Chicago, 2004.
71. **Carey RM.** Potential contribution of fetal programming to altered function of the renin-angiotensin system. Symposium on fetal physiological programming. FASEB National Meeting. Washington, D.C., 2004.
72. **Carey RM.** Role of the AT₂ receptor in cardiovascular function. International Meeting on the Renin-Angiotensin System and the Heart. Ochsner Medical Foundation, New Orleans, 2004.
73. **Carey RM.** Frank and Sheila Thompson Lecture, Texas A&M College of Medicine, Temple, TX, 2005.
74. **Carey RM.** Role of extracellular renal interstitial cGMP in natriuresis and pressure-natriuresis. 2nd International Conference on cGMP Generators, Effectors and Therapeutic Implications. Potsdam, Germany, June, 2005.
75. **Carey RM.** The renin-angiotensin system in the pathophysiology of hypertension. Hypertension Summer School, Council for High Blood Pressure Research, Castine, MA, July, 2005.

76. **Carey RM.** Role of the angiotensin AT₂ receptor in natriuresis. VIth International Symposium on Vasoactive Peptides, Oro Preto, Brazil, 2006.
77. **Carey RM.** Vasodilator and natriuretic properties of the angiotensin AT₂ receptor. Glaxo-Smith Kline Pharmaceuticals, Inc. 2005.
78. **Carey RM.** Emerging role of the angiotensin AT₂ receptor in cardiovascular and renal function. Frontiers in Heart Failure Research Distinguished Lectureship, Ottawa Heart Institute, Ottawa, Ontario, Canada, 2006.
79. **Carey RM.** Novel cardiovascular and renal actions mediated by the angiotensin AT₂ receptor. Plenary Lecture, Frontiers in Cardiovascular Medicine International Symposium, Melbourne, Australia, 2005.
80. **Carey RM.** Update on the AT₂ receptor in cardiovascular and renal function. GlaxoSmithKline, Inc., Philadelphia, 2005. International Teleconference with Dr. Bernard Levy, Paris, France.
81. **Carey RM.** Academia: promotion and the need to publish. Clinical Investigators Workshop for Trainees, The Endocrine Society, Boston, 2005 and 2006.
82. **Carey RM.** Emerging role of the AT₂ receptor in cardiovascular and renal function. Plenary Lecture, International Symposium on the Kidney and Hypertension, Sendai, Japan, 2006.
83. **Carey RM.** The role of AT₂ receptors in cardiovascular and renal function. Hiroshima University, School of Medicine, Hiroshima, Japan, 2006
84. **Carey RM.** AT₂ receptors in cardiovascular function. Emory Wilson Dean's Distinguished Lecture, University of Kentucky, College of Medicine, Lexington, KY., 2007.
85. **Carey, RM.** Renin-angiotensin system in 2007. University of Texas Southwestern Medical Center, Dallas, TX, 2007.
86. **Carey RM.** New clinical considerations in renin-angiotensin system blockade. Symposium Lecture at the 89th Annual Meeting of The Endocrine Society, Toronto, Ontario, Canada, 2007.
87. **Carey RM.** Renin-angiotensin system and cardiovascular protection. Daiichi-Sankyo Satellite Symposium, Japanese Endocrine Society, Tokyo, Japan, 2007.
88. **Carey RM.** Angiotensins II and III in cardiovascular and renal function: relative role of AT₁ and AT₂ receptors. Special Plenary Lecture, 80th Annual Congress of the Japan Endocrine Society, Tokyo, Japan, 2007.
89. **Carey RM.** Medical and surgical treatment of primary aldosteronism. Primary Aldosteronism Clinical Guidelines Conference, Venice, Italy, 2007.

90. **Carey RM.** Update on AT₂ receptors. 3rd International Conference on Low Renin Hypertension, Rome, Italy, 2007.
91. **Carey RM.** The renin-angiotensin system in the pathophysiology of hypertension. Hypertension Summer School, Council for High Blood Pressure Research, American Heart Association, Ft. Collins, CO, 2007.
92. **Carey RM.** Extracellular cyclic GMP in natriuresis and pressure natriuresis. FASEB Summer Conference, Saxton's River, VT, 2007.
93. **Carey, RM.** Angiotensin III and the AT₂ receptor in natriuresis. VIIIth International Symposium on Vasoactive Peptides, Oro Preto, Brazil, 2008.
94. **Carey RM.** Primary Aldosteronism. 40th Pfizer International Symposium on Endocrinology and Metabolism, Paris, France, 2008.
95. **Carey RM.** Control of renal sodium excretion by angiotensin peptides and receptors. Plenary Lecture, International Aldosterone Conference, San Francisco, 2008.
96. **Carey RM.** Recent advances in the alternate pathways of the renin-angiotensin system. John and Meredith Oates Distinguished Visiting Professor Lecture, Vanderbilt University School of Medicine, Nashville, 2008.
97. **Carey RM.** Finding and curing mineralocorticoid-induced hypertension. Beverly Towery Lecture, Department of Medicine, University of Louisville, Louisville, 2008.
98. **Carey RM.** Angiotensin III: AT₂ receptor agonist inducing natriuresis. Third International Workshop on the Intracardiac Renin-Angiotensin-Aldosterone System, New Orleans, LA, 2008.
99. **Carey RM.** Update on the AT₁ receptor. Medical Advisory Board, Daiichi-Sankyo, Inc., San Diego, CA, 2008.
100. **Carey, RM.** Metabolic benefits of renin-angiotensin system inhibition. Novartis Direct Renin Inhibition Expert Council, New York, NY, 2008.
101. **Carey RM.** Angiotensin AT₂ receptors: understanding their role in cardiovascular and renal function. Robert Tigerstedt Distinguished Scientist Award Lecture, American Society of Hypertension, San Francisco, CA, 2009.
102. **Carey RM.** Evaluation and treatment of resistant hypertension: where are we now? Opening Plenary Lecture, Italian Society of Endocrinology, Sorrento, Italy, 2009.
103. **Carey RM.** Effects of aliskiren on urinary angiotensinogen and angiotensin II. Novartis

Direct Renin Inhibition Expert Council, Boston, 2009.

104. **Carey RM.** Regulation of renal sodium excretion by angiotensin III and AT₂ receptors. Inter-American Society of Hypertension Satellite Symposium, Belo Horizonte, Brazil 2009.
105. **Carey RM.** Aminopeptidase Inhibition. Interamerican Society of Hypertension, Belo Horizonte, Brazil, 2009.
106. **Carey RM.** Antihypertensive and renoprotective mechanisms of renin inhibition in diabetes. 70th Congress of the Italian Society of Cardiology, Rome, Italy 2009.
107. **Carey RM.** Drug-resistant hypertension: myth or reality? 4th Mantua Workshop on Diabetes Mellitus and Related Conditions. Mantova, Italy, 2010.
108. **Carey RM.** Regulation of renal sodium excretion and its clinical significance. Nachum and Bertha Mizney Memorial Lecture, Sir Mortimer B. Davis – Jewish General Hospital, McGill University, Montreal, Quebec, Canada, 2009.
109. **Carey RM.** Role of AT₂ receptors in the control of renal function. Cardiovascular Research Center, McGill University, Montreal, Quebec, Canada, 2009.
110. **Carey RM.** Angiotensin AT₂ receptors: control of sodium excretion and blood pressure. 2nd World Conference on Hormonal and Genetic Basis of Sexual Differentiation Disorders and Hot Topics In Endocrinology. University of Miami, Miami, 2010.
111. **Carey RM.** Resistant hypertension: evaluation and treatment. Medical Grand Rounds, Eastern Virginia Medical School, Norfolk, 2010.
112. **Carey RM.** Primary aldosteronism. Endocrine Grand Rounds, Eastern Virginia Medical School, Norfolk, 2010
113. **Carey RM.** Update on the renin-angiotensin system. National Kidney Foundation Symposium, University of Virginia, Charlottesville, 2010.
114. **Carey RM.** Angiotensin III is the predominant agonist for AT₂ receptor-induced natriuresis. VIII Vasoactive Peptide Symposium, Ouro Preto, Brazil, 2011.
115. **Carey RM.** Primary Aldosteronism: Diagnosis and Management. Update on Adrenal Disease and Lesions, Cleveland Clinic, Cleveland, 2011.
116. **Carey RM.** The Year-in-the-Adrenal. The Endocrine Society Annual Meeting (ENDO 2011), Boston, 2011.
117. **Carey RM.** New blood pressure guidelines: will there be new targets and approaches? Diabetes Diagnosis and Management 2011 (ENDO 2011; Pre-conference event), Boston, 2011.

118. **Carey RM.** Advocating for higher standards in testosterone testing. Coalition for Quality Testing (ENDO 2011), Boston, 2011.
119. **Carey RM.** Pressure-natriuresis: role and mechanisms in the pathophysiology of human hypertension. André Aisenstadt Memorial Clinical Day honoring Ernesto L. Schiffrin. Jewish General Hospital, Montreal, Quebec, Canada, 2011.
120. **Carey RM.** Alan F. Moore Memorial Lecture: Renal AT₂ receptors: role and mechanisms in the control of sodium excretion and blood pressure. Massachusetts General Hospital, Harvard Medical School, Boston, 2012.
121. **Carey RM** and Stowasser M. Primary hyperaldosteronism. Case Management Forum, The Endocrine Society, Houston, 2012.
122. **Carey RM.** Intrarenal angiotensin and dopamine receptor interactions in the control of sodium excretion and blood pressure. International Society of Hypertension, Sidney, Australia, 2012.
123. **Carey RM.** Angiotensin and dopamine receptor interactions in the kidney. Evolving Concepts of the Renin-Angiotensin System ISH Satellite Meeting, Hunter Valley, Australia, 2012.
124. **Carey RM.** Molecular pathophysiology of low renin essential hypertension and idiopathic hyperaldosteronism. Aldosterone and Salt: Kidney and Heart ISH Satellite Meeting, Palm Cove, Australia, 2012.
125. **Carey RM.** Molecular models of low renin primary hypertension and idiopathic Hyperaldosteronism: role of TASK channels. International Symposium of Aldosterone and Related Substances in Hypertension. Sendai, Japan, 2013.
126. **Carey RM.** AT₂ receptor agonist-induced natriuresis: efficacy and mechanisms. IX International Symposium on Vasoactive Peptides. Belo Horizonte, Minas Gerais, Brazil, 2013.
127. **Carey RM.** The intrarenal renin-angiotensin and dopaminergic systems: control of renal sodium excretion and blood pressure. Closing Lecture, First Symposium on Physiology of the State University of Ceara, Fortaleza, Brazil, 2013.
128. **Carey RM.** Are AT₂ receptor agonists suitable as natriuretic agents? Vicore AT₂ Receptor Meeting, Lucca, Italy, 2014.
129. **Carey RM.** Definition and prevalence of resistant hypertension. Symposium on Resistant Hypertension, American College of Cardiology, Washington, DC. 2014.
130. **Carey RM.** The AT₂ receptor in control of sodium homeostasis and blood pressure. Joint Sessions of the Interamerican Society of Hypertension and the Brazilian Society

of Hypertension, Salvador, Bahia, Brazil, 2014.

131. **Carey RM.** Management of primary aldosteronism: case detection, diagnosis and treatment. Egyptian Association of Endocrinology, Diabetes & Atherosclerosis. Alexandria, Egypt, 2014.
132. **Carey RM.** Management of resistant hypertension. Egyptian Association of Endocrinology, Diabetes & Atherosclerosis. Alexandria, Egypt, 2014.
133. **Carey RM.** Diagnosis and treatment of primary aldosteronism: review of 2015 guidelines. The Endocrine Society Sixth Annual Endocrine Summit, Mumbai, India, 2015.
134. **Carey RM.** Challenges in the diagnosis and management of adrenal insufficiency. The Endocrine Society Sixth Annual Endocrine Summit, Mumbai, India, 2015.
135. **Carey RM.** Hypertension. *Vasculata 2015*. University of Virginia, University of Dusseldorf and North American Vascular Biology Organization. Charlottesville, VA 2015.
136. **Carey RM.** AT₂ receptor activation in hypertension: therapeutic potential. Vasoactive Peptide Symposium, Lagoa dos Ingleses, Brazil, 2015
137. **Carey RM.** Resistant hypertension: diagnosis and management. Atlas 1st Annual Cardiometabolic Summit, Cairo, Egypt, 2016.
138. **Carey RM.** Secondary Hypertension. Atlas 1st Annual Cardiometabolic Summit, Cairo, Egypt, 2016.
139. **Carey RM.** Management of resistant hypertension: where are we now? Presidential Plenary Session: Japanese Society of Hypertension, Sendai, Japan, 2016.
140. **Carey RM.** Natriuretic effects of AT₂ receptors. Vicore Meeting, New Orleans, 2016.
141. **Carey RM.** Contemporary thresholds and targets of blood pressure control. Egyptian Association of Endocrinology, Diabetes & Atherosclerosis. Alexandria, Egypt, 2016
142. **Carey RM.** New approaches to the treatment of hypertension. Egyptian Association of Endocrinology, Diabetes & Atherosclerosis. Alexandria, Egypt, 2016
143. **Carey RM.** Emerging clinical practice guidelines: hypertension. Annual meeting of the Consortium for Southeastern Hypertension Control (COSEHC), Tampa, 2017.
144. **Carey RM.** Implementing hypertension guidelines for the reduction of stroke risk. American Stroke Association. Houston, 2017.
145. **Carey RM.** Redefining hypertension.: 2017 and beyond. Medical grand rounds.

Medical University of South Carolina, Charleston, 2017.

146. **Carey RM.** Opening Plenary Lecture: Current state of adult hypertension in 2017. Annual Meeting, American Heart Association Hypertension Council, San Francisco, CA, 2017
147. **Carey RM.** Resistant hypertension: state-of-the-art in 2017. Annual Meeting, American Heart Association Hypertension Council, San Francisco, CA, 2017.
148. **Carey RM.** Blood pressure treatment thresholds and atherosclerotic cardiovascular disease risk. Plenary Session, Hypertension Guidelines, American Heart Association Scientific Sessions, Anaheim, CA, 2017.
149. **Carey RM.** Detection and management of secondary hypertension. Session for Hypertension Guideline Recommendations in Detail. American Heart Association Scientific Sessions, Anaheim, CA, 2017.
150. **Carey RM.** Hypertension guidelines. 29th Science Conference of the Japanese Study Group for Physiology and Management of Blood Pressure. Kyoto, Japan, 2017

XI. NATIONAL AND INTERNATIONAL PRESENTATIONS (2002-2017)

1. Siragy HM, El-Kersh M, deGasparo M, **Carey RM.** Ace inhibition or AT₁ receptor blockade increases cardiac tissue levels of NO and cGMP in conscious rats post-ischemia. Presented at the 19th Scientific Meeting of the International Society of Hypertension, Prague, 2002.
2. Siragy HM, El-Kersh M, deGasparo M, **Carey RM.** Increases of cardiac tissue levels of PGE₂ and TNF_α in conscious rats post-myocardial infarction. Presented at the 19th Scientific Meeting of the International Society of Hypertension, Prague, 2002.
3. Sasaki S, Siragy HM, Felder RA, **Carey RM.** Guanosine cyclic 3:5'-monophosphate production in human proximal tubule cells from normotensive and hypertensive subjects. Presented at the Council for High Blood Pressure Research, Orlando, 2002.
4. Awad AS, Webb RL, **Carey RM,** Siragy HM. Renal nitric oxide production is decreased in diabetic rats and improved by AT₁ receptor blockade. Presented at the Council for High Blood Pressure Research, Orlando, 2002.
5. Abadir PM, **Carey RM,** Siragy HM. Angiotensin AT₂ receptor directly stimulates renal production of nitric oxide in conscious B₂-null mice. Presented at the Council for High Blood Pressure Research, Orlando, 2002.
6. Abadir PM, Abdel-Rahman EM, **Carey RM,** Siragy HM. Angiotensin AT₁ receptor mediates

renal production of prostaglandin E₂ and F_{2α} in diabetic rats. Presented at the Council for High Blood Pressure Research, Orlando, 2002.

7. Awad AS, **Carey RM**, Siragy HM. Increased renal production of angiotensin II and thromboxane B₂ in conscious diabetic rats. Presented at the Council for High Blood Pressure Research, Orlando, 2002.
8. Bove CM, Yang Z, DiMaria IM, Gilson WD, Epstein FH, French BA, **Carey RM**, Kramer CM. Nitric oxide mediates benefits of angiotensin II type 2 receptor during post-infarct remodeling. Presented at the American Heart Association, 2002.
9. Jin X-H, Siragy HM, **Carey RM**. Regulation of natriuresis and pressure-natriuresis by intrarenal inhibition of type V phosphodiesterase. Presented at the Inter-American Society of Hypertension, San Antonio, 2003.
10. Sasaki S, Siragy HM, Felder RA, **Carey RM**. Sodium absorption in human proximal tubule cells mediated by the angiotensin type-1 receptor. Presented at the Inter-American Society of Hypertension, San Antonio, 2003.
11. Sasaki S, Siragy HM, Felder RA, **Carey RM**. Role of cellular guanosine cyclic 3', 5'-monophosphate in the regulation of Na⁺ reabsorption in the human proximal tubule. Presented at the Inter-American Society of Hypertension, San Antonio, 2003.
12. Sasaki S, Siragy HM, Felder RA, **Carey RM**. Human renal proximal tubule cells generate and export guanosine cyclic 3', 5'-monophosphate but not nitric oxide. Presented at the Inter-American Society of Hypertension, San Antonio, 2003.
13. Jin X-H, Boukarakis M, Howell NL, Siragy HM, **Carey RM**. Renal interstitial cGMP responses to increased renal perfusion pressure are defective in Dahl salt-sensitive rats. Presented at the Council for High Blood Pressure Research, American Heart Association, Washington DC, 2003.
14. Sasaki S, Siragy HM, Felder RA, **Carey RM**. Role of extracellular guanosine cyclic 3', 5'-monophosphate in the regulation of sodium absorption in the human proximal tubule. Presented at the Council for High Blood Pressure Research, American Heart Association, Washington DC, 2003.
15. Sasaki S, Siragy HM, Howell NL, **Carey RM**. Cardiac aldosterone in conscious rats: effects of sodium intake, adrenalectomy and AT₁ receptor blockade. Presented at the Council for High Blood Pressure Research, American Heart Association, Washington DC, 2003.
16. Abadir PM, **Carey RM**, Siragy HM. Renal AT₂ receptor increases angiotensin II generation in diabetic conscious rats. Presented at the Council for High Blood Pressure Research, American Heart Association, Washington DC, 2003.
17. Abadir PM, **Carey RM**, Siragy HM. The angiotensin subtype 2 receptor inhibits renin biosynthesis and secretion in conscious rats. Presented at the Council for High Blood

Pressure Research, American Heart Association, Washington DC, 2003.

18. Varos S, Kramer CM, Bove C, Yang Z, Berr SS, DiMaria JM, Gilson WD, **Carey RM**, French BA. AT₁ receptor knockout, but not blockade, further attenuates post-infarction ventricular remodeling in AT₂ receptor overexpressed mice. American Heart Association Scientific Sessions.
19. Howell NL, Siragy HM, **Carey RM**. Evidence that intrarenal AT₂ receptors mediate natriuretic responses to AT₁ receptor blockade. Presented at the Council for High Blood Pressure Research, American Heart Association, Chicago, 2004
20. Abadir PM, Periasamy A, **Carey RM**, Siragy HM. Angiotensin AT₂ receptors heterodimerize with bradykinin B₂ receptors potentiating nitric oxide production. Presented at the Council for High Blood Pressure Research, Chicago, 2004.
21. Howell NL, Jin X-H, Siragy HM, **Carey RM**. Extracellular renal cyclic GMP regulates natriuresis and pressure-natriuresis. Presented at the Council for High Blood Pressure Research, Chicago, 2004.
22. Voros S, Yang Z, DiMaria JM, Berr SS, Epstein FH, French BA, **Carey RM**, Kramer CM. Angiotensin II type 2 receptor overexpression is additive to AT_{1A} receptor knockout in attenuation of post-MI remodeling, independent of blood pressure. Presented at the American Heart Association Scientific Sessions, New Orleans, 2004.
23. Isbell C, Voros S, Yang Z, Conaway M, DiMaria JM, Berr SS, French BA, Epstein FH, **Carey RM**, Kramer CM. Bradykinin does not mediate the anti-remodeling effects of the angiotensin II type-2 receptor following myocardial infarction.
24. Padia SH, Howell NL, Siragy HM, **Carey RM**. Angiotensin III mediates natriuresis via the AT₂ receptor in the AT₁ receptor blocked rat. Presented at the annual meeting of The Endocrine Society, San Diego, 2005
25. Salomone LJ, Howell NL, McGrath HE, Gildea JJ, Felder RA, **Carey RM**. Direct renal dopamine D₁-like receptor induced natriuresis and AT₂ receptor expression. Presented at the annual meeting of The Endocrine Society, San Diego, 2005.
26. Felder RA, Huntly D, Surace M, Jose PA, **Carey RM**, Gildea JJ. Culture of extollated human renal proximal tubule cells in urine from normal subjects enrolled in a genetic study of salt sensitivity. Presented at the Council for High Blood Pressure Research, Washington, DC, 2005.
27. Oishi Y, Gildea JJ, Felder RA, **Carey RM**. Physiologic angiotensin II increases apical sodium transport in opossum kidney cells via sodium-hydrogen exchanger-3. Presented at the Council for High Blood Pressure Research, Washington, DC, 2005.
28. Salomone LJ, Howell NL, McGrath HE, Gildea JJ, Felder RA, **Carey RM**. Intrarenal dopamine D₁-like receptor stimulation increases renal cortical cell membrane AT₂ receptor

expression and induces natriuresis. Presented at the Council for High Blood Pressure Research, Washington, DC, 2005.

29. Padia SH, Howell NL, Siragy HM, **Carey RM**. Renal AT₂ receptors mediate natriuresis via angiotensin III in the rat. Presented at the Council for High Blood Pressure Research, Washington, DC, 2005.
30. Isbell DC, Voros S, Yang Z, Dimaria JM, Conaway M, Berr SS, French BA, Epstein FH, Roy RJ, **Carey RM**, Kramer CM. Bradykinin does not mediate the antiremodeling effects of the angiotensin II type-2 receptor following myocardial infarction. Presented at Scientific Sessions, American Heart Association, 2005.
31. Meliagros PD, Howell, NL, Kemp BA, Padia SH, **Carey RM**. AT₂ receptor-mediated natriuresis with CGP-42112A in the rat. Presented at the Council for High Blood Pressure Research, Washington, DC, 2005.
32. Xue C, **Carey RM**, Siragy HM. Reduced renal AT₂ receptor in diabetes is reversed by inhibition of AT₁ receptor or NADPH oxidase. Presented at the Council for High Blood Pressure Research, San Antonio, 2006.
33. Padia SH, Howell NJ, Siragy HM, **Carey RM**. Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in AT₁ receptor-blocked rats. Presented at the Council for High Blood Pressure Research, San Antonio, 2006.
34. Ahmed, F, Howell NL, Siragy HM, **Carey RM**. Extracellular renal cyclic GMP is required for nitric oxide-induced natriuresis in the rat. Presented at the Council for High Blood Pressure Research, San Antonio, 2006.
35. Park J, Kemp BA, Howell NL, Gildea JJ, **Carey RM**. Nitric oxide-induced natriuresis requires extracellular transport of cyclic GMP via an intact microtubulin network in the rat kidney. Presented at the Council of High Blood Pressure Research, Tucson, AZ, 2007.
36. Kemp BA, Ahmed F, Howell NL, Gildea JJ, **Carey RM**. Extracellular cyclic GMP restores nitric oxide-induced natriuresis abolished by organic anion transport inhibition. Presented at the Council for High Blood Pressure Research, Tucson, AZ, 2007.
37. Padia SH, Gildea JJ, Keller S, Howell NL, Kemp BA, McGrath HE, **Carey RM**. Intrarenal dopamine D₁-like receptor activation induces natriuresis and angiotensin type-2 receptor translocation from cytosol to apical plasma membranes of renal proximal tubule cells. Presented at the Council for High Blood Pressure Research, Tucson, AZ, 2007.
38. Padia SH, Kemp BA, Howell NL, Fournie-Zaluski M-C, Roques BP, **Carey RM**. Intrarenal aminopeptidase N inhibition unmasks natriuretic responses to angiotensin II in AT₁ receptor-blocked rats. Presented at the Council for High Blood Pressure Research, Tucson, AZ, 2007.
39. Gildea JJ, McGrath HE, **Carey RM**, Jose PA, Felder RA. A novel dopamine D₅ receptor

selective antagonist (PM 436) reveals that the dopamine D₅ receptor negatively regulates the fenoldopam-dependent D₁ receptor brush border translocation. Presented at the Council for High Blood Pressure Research, Tucson, AZ, 2007.

40. Chai W, Liu J, Barrett EJ, **Carey RM**, Liu Z. Losartan enhances muscle microvascular blood volume via AT₂R-dependent mechanism. Presented at the Annual Meeting of the American Diabetes Association, 2009.
41. **Carey RM**, Schoeffel CD, Gildea JJ, Jones JE, McGrath HE, Gordon LN, Park MJ, Williams SM, Jose PA, Felder RA. Salt-sensitivity of blood pressure is strongly associated with polymorphisms in the sodium-bicarbonate symporter. Presented at the Council for High Blood Pressure Research, Orlando, FL, 2011.
42. Padia SH, Enayat S, Founrie-Zaluski M-C, Roques BP, Howell NL, Kemp BA, **Carey RM**. Angiotensin III-induces natriuresis via a renal AT₂ receptor-soluble guanylyl cyclase-cyclic GMP signaling pathway. Presented at the Council for High Blood Pressure Research, Orlando, FL, 2011.
43. Abadir PM, Foster DB, Crow MT, Burks TN, Cohn RD, Fedarko NS, **Carey RM**, O'Rourke B, Walston JD. Identification and characterization of a mitochondrial angiotensin system. Accepted at the Council for High Blood Pressure Research, Orlando, FL, 2011.
44. Kemp BA, Gildea JJ, Howell NL, **Carey RM**, Padia SH. Renal cAMP recruits D1Rs and AT₂R to apical plasma membranes of proximal tubule cells. Presented at the Council for High Blood Pressure Research, Orlando, FL, 2011.
45. Gildea JJ, Lahiff DT, Van Sciver RE, Schoeffel CD, **Carey RM**, Felder RA. Urine-Derived Living Renal Proximal Tubule Cells Differentially Respond to Ang II in Patients from a Salt Sensitivity Study. Presented at the Council for High Blood Pressure Research, Orlando, FL, 2011.
46. Kemp BA, Howell NL, Shao W, Navar LG, **Carey RM**. Aminopeptidase regulation of intrarenal angiotensin II and III levels in the rat. Presented at the Council for High Blood Pressure Research, Washington, DC, 2012.
47. Gherghe C, Demp BA, Howell NL, **Carey RM**. Mechanism of pressure-natriuresis: evidence that Na⁺/K⁺ATPase is a renal extracellular cyclic guanosine 3',5'-monophosphate receptor. Presented at the Council for High Blood Pressure Research, Washington, DC, 2012
48. Tweeden KS, Knudson MB, Shikora S, **Carey RM**. Intermittent neural transmission block of the intra-abdominal vagus induces sustained blood pressure reduction in obese subjects. Presented at the Scientific Sessions of the American Heart Association, 2012.
49. **Carey RM**. Discussant on the EnlightNTM trial. Presented at the Scientific Sessions of the American Heart Association, 2012.
50. Artamonov M, Good M, Momotani K, Isakson B, **Carey RM**, Le TH, Somlyo A. Role of

ribosomal S6 kinase 2 (RSK2) in vascular myogenic tone and blood pressure regulation. Presented at the Council on Hypertension, American Heart Association, Orlando, FL, 2016

51. Kemp BA, Gildea JJ, Howell NL, Keller SR, **Carey RM**. Evidence that the extracellular domain of Na⁺/K⁺ATPase is the receptor for cyclic GMP-induced natriuresis. Presented at the Council on Hypertension, American Heart Association, Orlando, FL, 2016.
52. Erdbruegger U, Howell NL, Rudy C, **Carey RM**, Le TH. Distinct profiles of extracellular vesicles are elevated during evolution of hypertension. Presented at the Council on Hypertension, American Heart Association, Orlando, FL, 2016.
53. Peng X, Gildea JJ, Jose PA, **Carey RM**, Felder RA. Dopamine D2 receptor is associated with inverse salt sensitivity. Presented at the Council on Hypertension, American Heart Association, Orlando, FL, 2016.

XII. MAJOR LECTURES ON MEDICAL EDUCATION

1. **Carey RM**. Evaluation of clinical teaching: role of students, faculty and medical school administration. Presented at the annual meeting of Society of Surgical Chairmen, Washington, D.C. 1991.
2. **Carey RM**. Stimulating and Evaluating Excellence in Medical School Teaching, Society of Surgical Chairmen, Washington, D.C., 1991.
3. **Carey RM**. Health reform and medical education. Presented as the Graduation Speech for Housestaff Graduation Exercises, Ochsner Clinic Foundation, New Orleans, 1993.
4. **Carey RM**. Strategies for Augmenting the Culture for Generalist Medical Education. Presented at the Second National Primary Care Conference, Dallas, 1994.
5. **Carey RM**. Promotion, Tenure, Faculty Mentoring and Faculty Development, Presented at the AAMC Council of Deans Spring Meeting, Tucson, AZ, 1995.
6. **Carey RM**. Vision of institutions and health in the year 2020. Presented at the Institute of Medicine 25th Anniversary Symposium, National Academy of Sciences, Washington, DC, 1995.
7. **Carey RM**. Cost of Medical Education. Presented at the National Meeting of the Robert Wood Johnson Foundation, Key Biscayne, FL, 1997.

XIII. MAJOR LOCAL PRESENTATIONS (1986-PRESENT)

1. **Carey RM**. University of Virginia School of Medicine: Current Status and Vision for the

1990s, December, 1986.

2. **Carey RM.** State of the University of Virginia School of Medicine, December, 1987.
3. **Carey RM.** State of the University of Virginia School of Medicine, December, 1988.
4. **Carey RM.** Major Commencement Speaker, The University of Virginia School of Medicine, 1986, 1987, 1988.
5. **Carey RM.** The University of Virginia School of Medicine: Highlights of 1989-Hopes and Challenges for 1990, December, 1989.
6. **Carey RM.** Running with the Wind. The University of Virginia School of Medicine: 1990 and Beyond, December, 1990.
7. **Carey RM.** Baccalaureate Opening Remarks. The University of Virginia School of Medicine, 1991.
8. **Carey RM.** Mastering the Mountain. The University of Virginia School of Medicine: 1991 and Beyond, December, 1991.
9. **Carey RM.** Medicine and Health During the English Colonization of Virginia, History of Medicine Lecture, 1992.
10. **Carey RM.** Casting for Keepers. The University of Virginia School of Medicine: 1992 and Beyond, December, 1992.
11. **Carey RM.** The University of Virginia School of Medicine: Essentials for Success in the Age of Health Care Reform. November, 1993.
12. **Carey RM.** Innovation and Leadership: Signature of the University of Virginia School of Medicine. December, 1994.
13. **Carey RM.** Baccalaureate Address: Class of 1995. Knowledge Translates to Hope in the Physician-Patient Bond. May, 1995.
14. **Carey RM.** RISE and Shine: The Subtle Distinctions of Professionalism of the University of Virginia School of Medicine. December, 1995.
15. **Carey RM.** Chipping Away Towards Combustion: Principles for Synergism at the University of Virginia School of Medicine. December, 1996.
16. **Carey RM.** Clinical Investigation: History and Destiny. The Second Annual Kenneth R. Crispell Lecture, University of Virginia Health Sciences Center, October, 1997.
17. **Carey RM.** Vision for the 21st Century of the University of Virginia School of Medicine. January, 1998.

18. **Carey RM.** Dr. John Lederer and Early American Exploration. The Third Annual Kenneth R. Crispell Memorial History Lecture, April, 1999.
19. **Carey RM.** Initiating a Chain Reaction: Our responsibility to each other through personal engagement. January, 1999.
20. **Carey RM.** University of Virginia School of Medicine, 2000 Celebration and Call to Action, January, 2000.
21. **Carey RM.** Eleventh Edward W. Hook, Jr. Lecture, University of Virginia School of Medicine. High blood pressure, hormones and the kidney: the quest for understanding. July, 2000.
22. **Carey RM.** Progress towards excellence in the discovery, dissemination and application of knowledge: The University of Virginia School of Medicine 2000. January, 2001.
23. **Carey RM.** The University of Virginia School of Medicine: Providing Service for the Public Good. The 38th Medical Alumni Advisory Meeting, Norfolk, January, 2001.
24. **Carey RM.** University 2020 Vision. The 38th Medical Alumni Advisory Meeting, Norfolk, January, 2001.
25. **Carey RM.** Capitalizing on Our Contiguity: The School of Medicine within the Academical Village. February, 2002.
26. **Carey RM.** Cross-matrixing our strengths: School of Medicine collaboration with other schools of the University. The 39th Medical Alumni Advisory Meeting, The Homestead, February, 2002.
27. **Carey RM.** Academic and clinical medicine: achievement and promise. The Jefferson Literary and Debating Society, March, 2002.
28. **Carey RM.** Medical Grand Rounds: Adrenal insufficiency. University of Virginia, June, 2006.
29. **Carey RM.** Medical Grand Rounds: Carey-Marshall-Thorner Medical Research Day. The renin-angiotensin system: new discoveries and their clinical implications. University of Virginia, April, 2007.
30. **Carey RM.** Medical Grand Rounds: Predicting the JNC VIII Blood Pressure Guidelines: Will there be different targets and approaches? University of Virginia, August, 2011.
31. **Carey RM.** Medical Grand Rounds: Discovering and managing secondary hypertension. University of Virginia, August 2013.

XIV. OTHER PRESENTATIONS

1. **Carey RM.** Keynote Address, Hooding Ceremony, Medical College of Georgia School of Medicine, Augusta, GA; May, 2003.
2. **Carey RM.** Effective Practices and Tools, Second National Summit on Patient Safety, Arlington, VA, November, 2003.
3. **Carey RM.** Transformation of ideas into testable hypotheses and beyond. Introduction to Clinical Investigation for the University of Virginia Multidisciplinary Training Program in Clinical Investigation, 2006 and 2007.
4. **Carey RM.** State-of -The Endocrine Society Address, ENDO-09, Washington Convention Center, Washington, D.C., 2009
5. **Carey RM.** Four astounding medical discoveries this year. University of Virginia President's Development Event. Palm Beach, FL. 2016